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ABSTRACT
In the present study, passive immunoneutralization was used as a means of 
neutralizing circulating thyroid hormones in vivo to study the response of the thyroid 
gland to such a physiological challenge. The mechanisms involved in the regulation 
of serum thyroid hormone levels and the effect of immunoneutralis ation on lipid and 
carbohydrate metabolism, as reflected in serum glucose, cholesterol and triglyceride 
concentrations, were investigated.
Murine monoclonal antibodies to thyroid hormones were produced in order to 
provide the required quantities of specific high-affinity antibodies for in vivo studies. 
Spleen cells of Balb/c mice immunized with either Tg or T4  were fused with Sp2 
mouse myeloma cells. Enzyme-linked immunosorbent assays (ELISA) and the dot 
immunobinding assays were chosen for screening of the hybridoma cultures. Thirty 
clones secreting specific monoclonal antibodies to Tg and seven clones secreting T4  
monoclonal antibodies were obtained. Monoclonal antibodies from two ceU lines, 
MMT3.1 and MMT4.1, were isolated from ascitic fluid, purified and characterized 
with regard to titre, affinity, specificity and class.
Sheep Tg and T4  polyclonal antibodies were also purified and characterized 
and proved to have high affinities and specificities. Binding characteristics of both 
monoclonal and polyclonal antibodies were investigated in vitro and polyclonal 
antisera were chosen for immunoneutralization study.
In vivo immunoneutralisation studies were performed in male Wistar rats. 
Antibodies to Tg, T4  or both were administered intraperitoneaUy and blood samples 
were collected at several time intervals. The affinity of the Tg polyclonal antisemm 
(8.0 X lO'^^mol/L) used in this study exceeded that of the binding capacity of Tg 
receptors of liver, kidney and heart; ranging between 1.8 x lO'^mol/L and 5 x 
lO'^^mol/L depending on the experimental conditions, and the binding capacity of the 
amount of antibodies used amounted to more than 2500 times the total Tg and 20 
times the total T4  in the rat serum.
Since the antibodies administered interfered with the measurement of Tg and 
T4  by radioimmunoassay, serum samples collected from antiserum-treated animals
were extracted with acid/ethanol. Serum Tg and T4 , measured by a second antibody 
radioimmunoassay, were elevated in all experimental groups. TSH levels, on the 
other hand, remained at basal levels. This treatment with antibodies 
had no effect on total cholesterol concentrations whereas serum triglycerides were 
decreased and glucose levels were increased in all experimental groups.
Long-term administration of Tg and/or T4  antiserum was also investigated. 
Animals were treated with a weekly dose of 0.5ml antiserum and blood samples 
obtained, beginning from one day prior to antibody injection. Hormone levels as 
well as glucose, cholesterol and triglyceride showed no significant change throughout 
the study. Finally, the effect of long-term administration of thyroid hormones 
antibodies on several rat tissues including brain, pituitaries, thyroid, liver, kidneys 
and pancreas, all known sites of thyroid hormone action, was also investigated. The 
microscopic examination of sections of these tissues showed no abnormality 
compared with those from control rats.
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CHAPTER ONE
GENERAL INTRODUCTION
THE THYROID
1.1 Anatomy and Development
The thyroid is the largest endocrine gland in the human, weighing about 
25-30g in adults. It originates during embryological development from endodermal 
tissue of the pharynx at the base of the tongue. This area evaginates to form the 
thyroglossal duct which is responsible for the transfer of the embryonic thyroid 
tissue to its position where the development of the lobes and isthmus occurs. The 
thyroid gland consists of two lobes, one on each side of the trachea joined by a 
bridge of tissue, the thyroid isthmus (Fig. 1.1). The thyroid is made up of spherical 
groups of cells called follicles. Each follicle is composed of a single layer of 
epithelial cells surrounding a lumen filled with a viscous material called colloid.
Thyroid follicular size and shape generally varies over a wide range, and there is no
discernible pattern in the distribution of follicle sizes within the gland. The 
histologic appearance of the follicular cells is influenced by the circulating level of 
thyroid-stimulating hormone (TSH). In the absence of TSH, the follicles are large, 
the follicular cells are flat and the luminal colloid is abundant. When the gland is 
stimulated, depending on the intensity of TSH stimulation, the follicular cells vary in 
height between squamous and tall columnar and the lumens become narrow 
(Fig. 1.2) (Williams and Goodbum, 1983; Halmi, 1986).
1.2 • Hormone Synthesis and Scretion
The thyroid gland produces three major hormones, thyroxine (T4 ), 
triiodothyronine (T3 ) and reverse triiodothyronine (rTg). The structure of these 
hormones are shown in Fig. 1.3. Thyroid hormones are synthesized in the colloid 
by iodination and condensation of tyrosine molecules bound in peptide linkage in 
thyroglobulin, the main protein component of the thyroid colloid. This protein is 
synthesized in large amounts by the thyroid gland and may represent up to 7 5 % of 
the thyroid protein content (Van Herle et al, 1979). Because of its important role in 
the biosynthesis of thyroid hormones, thyroglobulin has long been and remains the 
subject of numerous studies. Thyroglobulin is an iodinated glycoprotein with a 
molecular weight of about 660,000 and a sedimentation coefficient of 19s (Marriq et 
al, 1977; Van Herle et al, 1979). Due to its exceptional size, numerous efforts have 
been made to study thyroglobulin’s basic characteristic, such as the number and size 
of the. subunits. There is a general agreement that thyroglobulin is composed of two
Fig. 1.1. The human thyroid (Ganong, 1983)
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identical 12s subunits containing a 300,000 dalton polypeptide translated from a 33s 
in RNA (Vassart et al, 1977). Recent developments in recombinant DNA techniques 
has permitted the isolation of thyroglobulin messenger RNA (Lissitzky, 1984). This 
made it possible to determine the primary stmcture of the subunit and the analysis 
of thyroglobulin processing and its hormonosynthetic mechanism (Malthiery et al, 
1989).
Thyroid hormone formation takes place in several successive but independent
stages:
1. Active transport of iodide.
2. Protein synthesis and iodination, the synthesis of thyroid hormones and their
storage in thyroglobulin.
3. The secretion of the thyroid hormones.
1.2.1 Iodide Transport
. The first step in the synthesis and storage of thyroid hormone is the uptake 
of iodide by the thyroid gland from the circulating blood. The basic mechanism of 
iodide transport in the thyroid has not yet been fully explained despite much
research. The thyroid uptake of iodine is regarded as active transport, a process 
linked with Na'^ -K'*' ATPase (Wolff and Halmi, 1963; Bagchi and Fawcett, 1973). 
Inorganic iodide from the diet is actively transported into the thyroid gland against 
an electrical gradient and is then diffused to the folhcular lumen, where it is 
concentrated. This process is blocked by the addition of oxidation inhibitors, such 
as cyanide and by the action of inhibitors of oxidative phosphorylation, e.g.,
dinitrophenol. Ouabain also blocks this process, indicating that the uptake is ATPase 
dependent (Wolff and Halmi, 1963). Bagchi and Fawcett (1973) have also 
concluded from studies with infused thyroid cells that Na"^  plays a key dual role in 
iodide transport by increasing iodide influx and inhibiting iodide efflux. A number 
of anions such as perchlorate, thiocyanate and bromide also decrease iodide transport 
by competitive inhibition. TSH appears to be the most important factor regulating
iodide transport. The effect of TSH on iodide transport appears to be mediated by
cyclic adenosine monophosphate (cAMP) (Tong, 1974).
1.2.2 Thyroid Hormone Synthesis
Iodide, the form in which iodine enters the thyroid gland, must first be 
oxidized to iodine before it can act as an effective iodinating agent. Because H2 O2  
and O2  are the only known biological oxidizing agents which are sufficiently potent 
to oxidize iodide, it was thought, that iodination in the thyroid involves a peroxidase 
(Taurdg, 1970). The existence of a thyroid peroxidase, the enzyme responsible for 
the oxidation and binding of iodide, has now been confirmed by several groups of 
workers (Taurog, 1970). However, thyroid peroxidase is active only in the presence 
of H2 O2 .
Several lines of studies for obtaining information on the site of iodination in 
the thyroid have indicated that iodination of thyroglobulin occurs in the follicle 
lumen, probably at the apical surface of the follicle cells. These include 
autoradiographic evidence obtained with the hght microscope (Nadler and Leblond,
1955), or with the electron microscope (Ekholm and WoUman, 1975). Information 
provided by histochemical locahsation of thyroid peroxidase within the thyroid 
foUicle has also supported the view that the apical membrane with its associated 
microvilli is the site for iodination of thyroglobulin (Tice and WoUman, 1974). 
Nevertheless, evidence based on autoradiography of rat thyroid glands (Croft and 
Pitt-Rivers, 1970), has pointed out an intraceUular site for iodination in the thyroid. 
However, the majority of the evidence at present favours the view that iodination 
occurs at the ceU coUoid interface.
Harington and Barger (1927) were the first to suggest that diiodotyrosine 
(DIT) is the biologic precursor of T4 . A mechanism for the coupling of two 
molecules of DIT to form T4  was originally proposed by Johnson and Tewkesbury 
in 1942 and further developed by Harington in 1944. This mechanism suggested 
that two DIT are coupled to form T4  after oxidation to DIT free radicals. Later 
studies indicated that tyrosine residues in peptide linkage within the thyroglobulin 
molecule are most likely the precursor of T4  and that the coupling of two molecules 
of DIT occurs within the thryoglobulin molecule. This mechanism is now referred 
to as intramolecular coupling. Although a possible intermolecular mechanism has 
also been proposed (Ogawara and Cahnmann, 1972), most studies in recent years 
have been based on the intramolecular model.
In 1951, Harington initially suggested that the coupling reaction of DIT to 
form T4  does not require any special enzyme, only an oxidized form of iodine. 
However, studies performed in various laboratories have provided evidence that 
thyroid peroxidase (TPO) does not only catalyze the formation of the precursors of 
T4  and T3  but also plays a direct catalytic role in the coupling reaction (Deme et al, 
1978).
lodination of tyrosine molecules attached to thyroglobulin appears to occur 
first in position 3 to form monoiodotyrosine (MIT). MIT is next iodinated in the 
5-position to form DIT. The coupling of two molecules of DIT, stiU in peptide 
linkage to thyroglobulin, then occurs to form T4 . Proof that the reactions occur in 
this sequence was demonstrated by administrating ^^ *1 to intact animals (Roche et al,
1956), and was confirmed by studying the time course of protein iodination and of 
DIT, MET, T4  and Tg formation in the model iodination system (Deme et al, 1976).
1.2.3 Release and Secretion of Thyroid Hormones
Thyroid hormones are stored in the colloid of the thyroid foUicle incorporated 
in thyroglobulin. Therefore, their secretion requires the hydrolysis of thyroglobulin 
to free the hormones from the gland into the bloodstream.
Although De Robertis claimed the discovery of a proteolytic enzyme in the 
colloid (De Robertis, 1941), no conclusive evidence for thyroglobulin hydrolysis in 
the colloid has ever been presented. In recent years the secretory process have been 
thoroughly investigated by cytologic and cytochemical techniques (Ericson, 1983). It 
is now largely accepted that hydrolysis of thyroglobulin occurs exclusively within the 
thyroid follicular cell. The thyroglobulin colloid is ingested by the apical pole of 
the follicular cells via the process of endocytosis and appears in the cytoplasm as 
colloid droplets. TSH plays a cmcial role in the secretion of thyroid hormone; 
endocytosis occurs only under high TSH stimulation (WoUman, 1969). The 
sequence of events in the secretory process can be evidenced within 1 0  minutes after 
administration of TSH (WoUman, 1965). The first event to take place is the 
formation of pseudopods at the apical membrane. These pseudopods pinch off smaU 
volume of the coUoid by endocytosis. The vacuoles formed are then drawn into the 
cells and appear as coUoid droplets. The droplets migrate toward the basal end of
the cell and fuse with lysosomes which contain hydrolytic enzymes including 
peptidase and protease (WoUman, 1969). The resulting bodies, known as 
phagolysosomes, migrate toward the basal end of the cell and the coUoid graduaUy 
disappears, indicating that proteolysis of the thyroglobolin has occurred. The 
products of the hydrolytic process, free amino acids including the iodinated tyrosine 
and thyronine are then released into the circulation by a secretion process involving 
microtubules and microfilaments. WoUf and WUUams studied the role of 
microtubules and microfUaments in thyroid secretion (Wolff and WiUiams, 1973) and 
suggested possible mechanisms by which microtubules might participate in the 
release of thyroid hormone.
The main iodinated compounds bound in the thyroid venous blood in man 
are T4 , Tg, iodide, and smaU amounts of iodotyrosines. Free amino acids are 
recycled for protein synthesis, most of the free iodotyrosine residues are rapidly 
deiodinated by the iodotyrosine deiodinase (Stanbury and Morris, 1958) and the 
iodide liberated is largely reutUized in situ.
1.3 Transport of Thyroid Hormones
Thyroid hormones are present in the blood almost completely bound to 
carrier proteins (Robbins et al, 1978). The major proteins involved in binding the 
thyroid hormones are thyroxine-binding globulin (TBG), thyroxine-binding 
prealbumin (TBPA) and albumin.
1.3.1 Thyroxine-Binding Globulin (TBG)
In 1952, Gordon and co-workers were the first to discover that a major 
proportion of the circulating thyroxine is bound to an alpha globulin (Gordon et al, 
1952). A number of early attempts to purify TBG were unsuccessful (Tata, 1961), 
because of its low concentration in plasma (about 15 mg/L) and its relative 
instabihty to changes in pH. In 1969, Pensky and Marshall first reported the 
isolation of TBG by affinity chromatography on T4 -agarose. It was then possible to 
proceed with detailed characterisation of the molecule. TBG is a glycoprotein 
consisting of a single polypeptide chain of molecular weight between 54,000 and 
64,000 daltons (Robbins et al, 1978), with about one half of the residues forming
short a-hehces and one fifth in 6 -structure (Johnson et al, 1980). Several reports on 
the amino acid and carbohydrate composition have shown major discrepancies 
(Robbins et al, 1978). TBG contains between 13 and 23% carbohydrate with four 
complex polysaccharide units (Zinn et al, 1978) and 6  to 10 terminal sialic acid 
residues. TBG appears to possess a single high-affinity binding site for T4  which is 
shared by Tg and other thyronine analogues. Approximately two-thirds of the 
plasma T4  is carried by TBG whereas small amounts of T4  are bound to TBPA and 
albumin.
1.3.2 Thyroxine-Binding Prealbumin (TBPA)
Prealbumin was identified as a distinct thyroxine-binding protein in 1958 
(Ingbar, 1958). Its purification was accomphshed some years ago by conventional 
methods (Purdy et al, 1965) because of its relative high concentration in semm 
(about 250 mg/L). TBPA consists of four identical polypeptide chains containing no 
carbohydrate (Kanda et al, 1974; Blake and Oatley, 1977). It is an extraordinarily 
stable molecule with a molecular weight of 55,000 daltons and 127 amino acid 
residues of known sequence (Kanda et al, 1974). The four subunits are arranged 
tetrahedrally to form a nearly cyhndrical channel that traverses the entire molecule 
(Blake et al, 1974). TBPA has two identical binding sites for thyroid hormones 
located within the wide open ends of this channel (Blake and Oatley, 1977). One of 
these sites has higher affinity for T4  while the association constant of the other is 
much lower (Cheng et al, 1977). Although both sites are apparently identical, the 
binding of T4 to one inhibits the binding to the second (negative cooperativity). 
The exact mechanism of this negative cooperativity is still incompletely understood.
TBPA transport only about 15% of the T4  in the blood. Originally TBPA 
was not thought to bind Tg. However, Davis et al, have shown that Tg is also 
bound by the blood proteins although rather less strongly (Davis et al, 1972). The 
affinity constant of Tg for TBPA is about tenfold lower than that of T4 , however, 
the amount of plasma Tg bound to TBPA is stiU uncertain (Blake et al, 1974).
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13.3 Albumin
Albumin is the most abundant protein in human plasma. It has a relatively 
low affinity for the thyroid hormones, but their high concentration results in binding 
approximately 15% of circulating T4  and possibly more of the Tg. The molecule 
consists of three major stmctural domains with repeating amino acid sequences 
probably formed by gene duplication (Brown et al, 1979). Albumin has one 
relatively strong binding site for thyroid hormones and at least four weaker sites.
Normally 99.98% of the T4  in plasma is bound to plasma proteins while Tg 
is not bound to quite as great an extent (99.8%). However, numerous studies over 
the past two decades have shown that it is the free hormone fraction in blood which 
is active for both endocrine and metabohc effects including the important feedback 
effects on the hypothalamus and pituitary gland (Reichhn and Utiger, 1967), and 
hepatic and renal clearance of Tg and T4  (Oppenheimer et al, 1967).
1.4 Metabolism of Thyroid Hormones
Many early studies have shown that because of the chemical nature of the 
iodothyronine, the major metabolic reactions would include deiodination, conjugation 
at the phenohc hydroxyl group, and deamination/decarboxylation of the alanine side 
chain. In peripheral tissues, especially the liver and kidney, about 80% of 
circulating T4  undergoes monodeiodination to produce Tg and rTg (Schimmel and 
Utiger, 1977). This accounts for more than two-thirds of the Tg produced in the 
body and almost all of the rTg (Adlkofer et al, 1980). The two enzymes responsible 
for these reactions, 3’-deiodinase catalyzing the formation of Tg and 3-deiodinase 
catalyzing the formation of rTg, have different pH optima which has been a major 
reason for considering them as separate enzymes. Deiodination can occur at either 
the phenolic (3’ deiodination) or the non-phenolic ring (3 deiodination) of the 
iodotyrosines.
The conversion of T4  to Tg was first described by Pitt-Rivers and associates 
in 1955, but the authors had doubts about their results and withdrew them. It was 
only in 1970 that this view was confirmed by two separate studies (Braverman et al, 
1970; Sterling et al, 1970). Except for T4  which originates solely from the thyroid.
11
the quantitative contribution of various tissues to the total production of Tg and other 
iodothyronines from T4  is unknown. The thyroid accounts for only a minor portion 
of the iodothyronine deiodination. The hver and kidney are quantitatively important 
in terms of total production of Tg from T4  because of their size and high 
3’-deiodinase level, however, their contribution to whole body T4  monodeiodination 
is not clear (Distefano et al, 1982). The monodeiodination of T4  to Tg in the 
pituitary is of special importance. About one half of the nuclear Tg is derived from 
circulating free Tg while the other half of intrapituitary Tg comes from local T4  
monodeiodination. It is this Tg which is responsible for the saturation of 80% of 
nuclear Tg receptors in the pituitary gland (Larsen et al, 1981). This contrasts with 
other tissues such as the hver where only 50% of the nuclear Tg receptors are 
saturated by Tg derived from endogenous T4  to Tg conversion (Larsen et al, 1981). 
In comparison with anterior pituitary, T4  to Tg conversion in rat brain homogenates 
is 40 to 80 times smaller, which would suggest that the contribution of brain to total 
body Tg production is negligible (Crantz and Larsen, 1980). Monodeiodination of T4  
in the central nervous system, produces Tg mainly for local demands of nuclear 
receptors. Studies of the conversion of T4  to Tg in distinct regions of the central 
nervous system revealed a wide distribution of locally generated Tg in main brain 
structure; 65% in cerebral cortex, 50% in cerebehum and 22% in the spinal cord 
(Van Dooren et al, 1985). This study concluded that monodeiodination of T4  to Tg 
does riot only vary from one organ to another but also within one organ. The effect 
of certain antithyroidal dmgs on the deiodination of T4  has been known for a 
number of years. Propylthiouracil (PTU), the most studied representative, inhibits T4  
to Tg conversion, an effect accompanied by an abmpt decrease in semm Tg level, an 
increase in rTg and an increase in TSH secretion (Geffner et al, 1975). A number 
of unrelated dmgs including propranolol, amiodarone and X-ray contrast agents have 
been shown to cause similar effects (Burger et al, 1976; Burgi et al, 1976; Lumholz 
et al, 1978). A wide variety of nonthyroidal illnesses and dietary restrictions also 
depress T 4  monodeiodination. These conditions, however, are quickly reversed with 
recovery or refeeding (Chopra and Smith, 1975; Moshang et al, 1975).
Phenohc conjugations are significant reactions in iodothyronine metabohsm. 
The conjugation reactions take place mainly in the hver. The two major phenohc 
pathways are with glucuronide and sulphate. T4  preferentiaUy forms glucuronide 
(Taurog, 1954; Flock et al, 1965), whereas much less Tg glucuronide is formed. On
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the other hand, Tg as well as 3,3’-diiodo- and 3’-monoiodothyronine are 
preferentially conjugated to sulphate (Sorimachi and Robbins, 1977). Sato and 
Robbins have indicated that iodothyronines which contain a single iodine on the 
phenolic ring (Tg, 3,3’-T2  and 3-Tj) are by preference sulphated, whereas 
iodothyronines with two iodine atoms at the phenohc ring are preferentiaUy 
conjugated with glucuronic acid (Sato and Robbin, 1981). The products of this 
route, hormone glucuronide or suphate, are excreted in the bile and then hydrolyzed 
to the parent compound in the lower intestine, most likely by bacterial enzymes 
(Taurog, 1954), which are then reabsorbed into the bloodstream, thus forming the 
enterohepatic cycle. However, the existence of this cycle in mammals is open to 
doubt.
Deamination and decarboxylation are the major metabohc reactions affecting 
the alanine side chain of the thyroid hormones. In vivo and in vitro studies in 
human tissues and experimental animals have shown that iodothyronines are
metabohzed to propionic acid, pymvic acid, and acetic and formic acid derivatives by 
oxidative deamination or decarboxylation. Oxidative deamination or transamination 
leads initiaUy to the formation of pyruvic acid analogues of T4  and Tg and 
subsequent decarboxylation produces the acetic acid analogue. The iodinated 
intermediates of acetic derivatives of T4  [tetraiodothyroacetic acid (tetrac)] and Tg 
[triiodothyroacetic acid (triac)] are detected in the blood (Nakamura et al, 1978; 
Burger, 1981). These compounds exhibit thyroid hormone-like activity, which is 
lower than that of their precursors T4  and Tg. Although these acetic acid derivatives 
of iodothyronine have high affinity for p/g albumin and for the nuclear Tg receptors 
(Cody, 1980), they play a quantitatively insignificant role in physiologic and
pathologic states in which thyroid hormone economy and n%etabolism are altered 
(Pittman et al, 1980). On the other hand, the role of the pymvic acid analogues of
T4  and Tg in hormone metabolism has not yet been defined. Decarboxylation
resulting in formation of decarboxylated metabolites of T4  and Tg, 3,3’,5,5’ 
tetraiodothyroethylamine (Tetram), and 3,3’,5-triiodothyroethylamine (Triam), has not 
yet been demonstrated. However, these derivatives could be of biological 
importance because of their chemical similarity to biogenic amines, but their 
significance remains uncertain (Meyer and Hesch, 1982).
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1.5 Effects of Thyroid Hormones
The thyroid gland has a powerful influence over the activities of the whole 
body. The diversity of effects of thyroid hormones on growth and development, on 
metabolic processes, on physiological functions and on various enzyme activities in 
the body as a whole and in tissue preparations have been known for a long time.
The effect of thyroid hormones on growth and development is clearly 
manifested in amphibian metamorphosis. Metamorphosis, under thyroid control, is 
accompanied by extensive alterations, including tail resorption, leg growth, changes 
in haemoglobin stmcture, formation of the urea cycle, shortening of the 
gastrointestinal tract and the appearance of new digestive enzymes (Cohen, 1970).
In mammals, including human, thyroid hormones are essential for normal 
growth and development. Disturbances of growth, occuring after thyroidectomy, are 
best manifested in young animals. As a result these animals are greatly retarded in 
growth, the development of their gonads is stopped and their metabolic rate falls 
sharply. Furthermore, the absence of thyroid hormones during the neonatal stages of 
hfe results in severe and irreversible nervous system damage (Ford and Cramer,
1977).
The relationship between thyroid hormones and oxygen consumption has been 
known for many years. The effects whereby thyroid hormones cause an increase in 
the basal metabolic rate, oxygen consumption and heat production are observed not 
only in experiments in vivo but also after the addition of thyroid hormones in vitro 
to organs and to tissue slices, homogenates and subceUular fractions. These effects 
were initially thought to be related to an uncoupling of oxidative phosphorylation. 
However, such uncoupling only occurs in the presence of non physiological levels of 
thyroid hormone.
Edelman and colleague examined the calorigenic effect of thyroid hormones 
and related them to the activity of the membrane enzyme Na-K-ATPase (Edelman 
and Ismail-Beigi, 1974). This enzyme is responsible for the calorigenic sodium 
pump, the active sodium transport through the cell membrane, and is regulated by 
intra- and extracellular Na and K fluctuations. The energy required for this action is
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provided from hydrolysis of ATP to ADP, a heat producing action. In many normal 
mammahan tissues, about 35 to 40% of the oxygen consumption is dependent on the 
activity of the sodium pump. Edelman has observed, moreover, that the increment 
in oxygen consumption in various tissues in vitro after the administration of thyroid 
hormones to intact animals is blocked by the cardiac glycoside ouabain, an inhibitor 
of the sodium pump. These finding suggest that the stimulation of the enzyme 
induced by thyroid hormone appears to be the result of an increased number of 
pump units rather than to an alteration of pre-existing enzyme molecules.
Many investigators have critically examined the mechanisms whereby thyroid 
hormones enhance Na-K-ATPase. In many of these reports, T3  administration to 
euthyroid or hypothyroid rats did not change the activation energy of ATPase 
(Rahimifar and Ismail-Beigi, 1977). Furthermore, Primack and Buchanan have 
shown that the inhibition of Na-K-ATPase by ouabain does not interfere with the Tg 
stimulation of oxygen consumption when succinate is used as substrate (Primack and 
Buchanan, 1974). Although it is generally agreed that thyroid hormones stimulate 
sodium and potassium transport, the relative importance of this action in contributing 
to calorigenesis remains uncertain.
The relationship between thyroid status and lipid metabohsm has been 
recognised for many years. Different thyroid states are characterized by various 
alterations in lipid metabolism. Although many investigations have demonstrated an 
acceleration of hpid synthesis by the action of thyroid hormones, hyperthyroidism is 
associated with decreased levels of total and low-density hpoprotein (LDL) 
cholesterol in the semm (Abrams and Grundy, 1981). However, the concomitant 
increase in LDL catabolism, the elimination of cholesterol from the body by bile and 
a reduced enterohepatic bile acid circulation provide an explanation for these 
observations. These effects are reversed in hypothyroidism which exibits a reduction 
in cholesterol synthesis (Abrams and Grundy, 1981). In addition, fatty acid 
oxidation, ketogenesis and hepatic lipogensis capacity are increased in 
hyperthyroidism and reduced in hypothyroidism.
Alterations in the semm and tissue levels of thyroid hormones have a 
profound influence on carbohydrate metabolism. In the hypothyroid state, glucose 
oxidation, glucose utihzation and glucose turnover rate were found to increase
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markedly while the reverse effects were observed in hypothyroid state (Müller and 
Seitz, 1980). Thyroid hormones evidently influence glucose production by 
stimulating gluconeogenesis from amino acids (Müller and Seitz, 1980, 1984a), and 
also its utilization in the tissues. They also increase the rate of carbohydrate
absorption from the gastrointestinal tract (Marechaud et al, 1980). There is an 
increased evidence of the coexistence and interaction of diabetes meUitus with 
thyroid disease (Riley et al, 1981). Despite these observations, the exact mechanism 
of thyroid hormone action on glucose homeostasis is not yet clear.
1.6 Mechanism of Action of Thyroid Hormones
A number of different theories have been put forward to explain the actions 
of thyroid hormones. However, much attention has recently been centered on 
nuclear binding of thyroid hormones. Evidence for specific binding of both T4  and 
T3  to receptors at the level of the cell nucleus has been provided by several 
laboratories (Latham et al, 1976).
■ The nuclear receptor; a chromatin protein of the nonhistone class, exhibits 
high-affinity, saturable binding sites for thyroid hormones. The affinity of the 
nuclear sites for T3  obtained by most workers is 1 0  times higher than that for T4  
with an association constant of about 2 x 10  ^ M'^ (Oppenheimer et al, 1976). The 
number of the binding sites in tissues is dependent on the responsiveness of the 
tissue to thyroid hormones. There are 5000 to 10000 sites per cell in rat liver 
nuclei whereas the number of sites in tissues such as the spleen and testis which are 
unresponsive to thyroid hormones is very low (Oppenheimer et al, 1974).
Although T3  binding to the nuclear receptors is well documented, very little 
is known about the events following this initial interaction. However, it is thought 
that the binding of T3  to the nuclear receptors increase the transcription of the DNA 
message, leading to an enhanced synthesis of mRNA which direct the formation of 
inducible proteins in the ribosomes (Towle et al, 1981). A variety of different 
proteins are probably involved. However, three inducible proteins including growth 
hormone, O2 u“globulin (a protein of unknown function synthesized in the livers of 
male rats) and malic enzyme (an enzyme of the hexose monophosphate shunt, 
lipogenesis and cholesterol synthesis) have been the subject of particular attention
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because of their association with increased specific messenger RNA formation and 
thus the synthesis of inducible protein (Kurtz et al, 1976; Seo et al, 1977; Towle et 
al, 1981).
Binding of thyroid hormone to mitochondrial component of the inner 
membrane was first reported by Sterling and Milch and confirmed by other 
investigators (Sterling amd Milch, 1975; Hashizume and Ichikawa, 1982). These 
reports have described a saturable site of high affinity for Tg in the inner 
mitochondrial membrane with an association constant that exceeds 10^  ^ M '\ The 
inner mitochondrial membrane has long been known as the site of oxidative 
phosphorylation. The interaction of thyroid hormones with the mitochondria 
resulting in uncoupling of oxidative phosphorylation in hyperthyroid patient or 
experimental animal has been known for many years (Tapley et al, 1955). More 
recently, the concept of direct action of thyroid hormones on the mitochandria has 
been considered (Sterling et al, 1978). These investigators have reported the 
presence of a specific binding component in the mitochondrial membranes of various 
tissues in the body including kidney, myocardium, skeletal muscle, lung, liver, 
intestine and adipose tissue but not in tissues unresponsive to thyroid hormone. 
However, the precise physico-chemical alterations that T3  might initiate in the 
mitochondrial membrance remain to be elucidated.
Direct action of thyroid hormones on the cell membrance has also been 
suggested (Pliam and Golfine, 1977). These investigators reported the presence of 
saturable binding sites in rat liver plasma membranes with an association constant of 
about 0.3 X 10^M'\ Conclusive evidence of this direct action has been provided by 
in vitro studies of Ca^^-ATPase activity in human and plasma erthyrocytes (Davis et 
al, 1983). Cell surface receptors mediate entry of free hormone into cells either by 
passive diffusion or by promoting energy-dependent carrier mediated entry of T3  into 
cells (Maxfield et al, 1981). The relative importance of these two modes of entry 
under various physiologic circumstances remains to be clearly established.
1.7 The Hypothalamic-Pituitary Thyroid Axis
The thyroid gland is controlled by the pituitary hormone thyroid stimulating 
hormcMie (TSH) which is mainly regulated by the trophic action of thyrotrophin
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releasing hormone (TRH) secreted by the hypothalamus, and the negative feedback 
action of thyroid hormone (Fig. 1.4).
Thyroid-stimulating hormone or thyrotrophin (TSH) is a glycoprotein of 
molecular weight 28000 daltons secreted by thyrotrophs in the anterior pituitary. 
The TSH molecule consists of two noncovalently linked subunits, a  and B (ComeU 
and Pierce, 1973). The a-subunits contains 96 amino acid residues and is identical 
to the a-subunits of luteinizing hormone (LH), follicle stimulating hormone (FSH) 
and human chorionic gonadotrophin (HCG), but is synthesized by different genes. 
The 6 -subunit of 110 amino acid residues, is specific for TSH and confers specific 
binding to the thyroid by interaction with specific cell membrane receptors (Brabant 
et al, 1989).
It is well known that TSH secretion is primarily regulated by the negative 
feedback control of thyroid hormone specifically their free fractions at the level of 
the thyrotroph. However, the relative importance of T4  and T3  in inhibiting TSH 
secretion is far from settled. Both T3  and T4  bind to high-affinity soluble nuclear 
receptors in the thyrotroph. However, the affinity of T3  for the receptor is much 
higher than that of T4  (Gershengom et al, 1979). Furthermore, in experiments with 
thyroidectomized rats have shown that approximately 50% of intrapituitary T3  is 
derived from T4  monodeiodination and 50% from circulating T3 , whereas most of 
the nuclear T3  in other tissues, e.g. liver and kidney, is derived from circulating T 3  
(Larsen et al, 1981; Silva et al, 1987). Following these findings, a number of 
studies have suggested that circulating T4  may be a more important regulator of TSH 
secretion than circulating T3 . Other findings in man and rats, however, were not in 
accordance with this view (Bergengard et al, 1987; Emerson et al, 1989).
Evidence of direct inhibitory effect of thyroid hormones on pituitary TSH 
secretion is substantial (Larsen et al, 1981). However, the effect of these hormones 
on TSH synthesis has not been clearly defined. Long term and short term 
administration of thyroid hormones have different effects on the suppression of 
pituitary secretion of TSH. Long term administration suppresses TSH synthesis 
resulting in pituitary TSH depletion (Harada et al, 1975). This result is presumably 
due to inhibition of the thyroid hormones at the nuclear level. Acute administration 
of T3  or T4  , on the other hand, suppresses the release of TSH leading to increased
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Fig. 1.4. Diagram of the hypothalamic-pituitary-thyroid axis 
(modified from Reichlin, 1986)
Hypothalamus^
Pituitary
TSH
Free T4 and Tc
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pituitary TSH concentration and decreased serum TSH level (Silva and Larsen,
1978).
The hypothalamic thyrotrophin releasing hormone (TRH) is the most 
important positive stimulator of TSH secretion. The identification of TRH was first 
achieved by Guillemin’s and Schally’s groups (Schally et al, 1968; Guillemin et al, 
1971) after the extraction of hundreds of thousands of ovine and porcine 
hypothalami and monumental chemical purification work, but the tripeptide was 
finally isolated, its structure established and a synthetic duplicate with identical 
physiologic effects prepared.
The tripeptide is Pyro-Glutamyl-Histidyl-Proline amide (pGlu-His-Pro-NH2 ) of 
molecular weight 362. Both the cyclic N-terminal (PGlu) and the NH2  terminal are 
essential for full activity, except when histidine is methylated in position 3, which 
increased potency eightfold (Vale et al, 1971).
TRH stimulatory effects are initiated by binding to specific receptors on the 
plasma membrane of the pituitary thyrotroph (Labrie et al, 1978). Its action was 
initially attributed to activation of adenyl cyclase leading to formation of cyclic AMP 
which in turn resulted in the secretion of TSH. More studies, however, have shown 
that increased intracellular cyclic AMP is not always associated with increased TSH 
secretion (Gershengom et al, 1980a). It has now been shown that TRH binding to 
receptor stimulates extracellular calcium uptake into cells, release of intracellular 
stores of calcium into the cytoplasma and the formation of calcium-calmodulin 
complexes resulting in the activation of protein kinases in the cell membrane which 
translocate into the cytoplasm (Geras and Gershengom, 1982). Phosphorylations of 
cellular proteins including those of the secretory granules and plasma membrane, by 
these protein kinases are thought to facilitate fusion of TSH-containing vesicles with 
the p l^m a membrane and hence exocytosis of the hormone (Scharff, 1981). Apart 
from the well know effects of TRH on synthesis and secretion of TSH, TRH seems 
to have important regulatory influence on the glycosylation of the hormone 
(Weintraub et al, 1983). In vitro studies suggest that TRH increases glycosylation of 
thyrotrophin and that this mechanism in tum leads to increased biological activity of 
the hormone.
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Although it is well established that the thyrotrophic cells are regulated by 
thyroid hormones directly, the effects of thyroid hormone at the level of the 
hypothalamus are unclear. Some investigations point towards a direct negative 
feedback of thyroid hormones at the hypothalamic levels on TRH synthesis or 
secretion (Belchetz et al, 1978). Recent studies have shown that thyroid hormones 
exert an inhibitory action on hypothalamic synthesis of TRH (Brabant et al, 1989).
In addition to the dominant negative regulation of the serum thyroid 
hormones and the positive stimulation of TRH, it has become increasingly clear that 
TSH secretion is also modulated by a number of other hormones and 
neurotransmitters such as somatostatin, dopamine, noradrenaline and corticosteriods 
(Abrahamson and Millar, 1986). However, the effects of these factors are generally 
less marked than those of TRH or thyroid hormone and their exact role in the 
normal physiological regulation of TSH secretion remains unclear.
1.8 Thyroid Function Tests
1.8.1 Thyroid Hormone Measurement
In recent years serum T4 , T3  and TSH assays together with TRH test have 
become the most important laboratory tests for the evaluation of thyroid function.
Although T3  is the major active form of the thyroid hormone, thyroxine 
measurement is still the most used in the clinical assessment of thyroid function. 
One fundamental reason is that 80% of circulating T3  is derived from 
monodeiodination of T4  in peripheral tissues, a process inhibited by various factors
such as stress, starvation, nonthyroidal illnesses and drugs, which make
measurements of serum T3  only an indirect reflection of thyroid secretion. The
measurement of thyroxine levels only on the other hand, will not pick up
hyperthyroid patient suffering from T3 -toxicosis and in whom the thyroxine 
concentration is in the normal range.
Circulating thyroid hormones are almost completely bound to plasma proteins 
where bound and free hormones are in rapid equilibration. Changes in these 
proteins cause alterations in serum total T4  and T3  concentrations. Several
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conditions and agents have been shown to alter the amount of binding proteins or 
interfere with the thyroid hormones binding to them. Amongst these are pregnancy 
which was known for many years to increase TBG (Robbins and Nelson, 1958) and 
contraceptive pills containing oestrogen (Burr et al, 1977). A wide variety of 
diseases including liver, kidney, thyroidal and nonthyroidal endocrine diseases are 
also associated with alterations in the levels of thyroid hormone-binding proteins.
In order to overcome these problems a variety of methods have been 
investigated to make free serum T4  and T3  measurements possible. However, 
because of their exceedingly low concentrations the free hormones are not yet truly 
amenable to direct measurement. The most widely used methods for measuring free 
T4  and T 3  are based on equilibrium dialysis or ultrafiltration (Lee et al, 1964; 
Sterling and Brenner, 1966). These techniques depend on the ability of free, but not 
bound, T4  and T3  to pass a dialysis membrane.
1.8.2 TSH Measurements and TRH Tests
Due to the clinical significance of TSH and TRH, based on present 
knowledge of the regulatory mechanisms of thyroid secretion, serum TSH assay and 
TRH test are now used as routine tests for assessing thyroid function.
TSH radioimmunoassays are the most convenient and reliable methods used 
for determining serum TSH. These assays require the use of highly specific
anti-TSH serum which react primarily with the 6 -subunit of the TSH molecule.
Many anti-TSH sera, however, react to some degree with the a-subunit which is
common to other glycoprotein hormones and require special treatment (Binoux et al,
1974). TSH, on the other hand, has a considerable degree of species specificity ^ d  
sensitive assays require the use of anti-TSH sera of the same species of whom TSH 
levels to be measured. In most TSH radioimmunoassays the detection limit range 
from 0.5 to l|iU  TSH/ml serum, however, assays capable of detecting 0.1|xU/ml 
have been described (Spencer and Nicoloff, 1980). Normal values for the 
concentrations of TSH in euthyroid subjects are still controversial mainly because 
TSH is detectable in the serum of most, but not all, normal individuals. These 
values vary from undetectable ((<0.5 to l|xU/ml) to 6  to 8 |xU/ml) (Utiger, 1986) and 
thus differentiation between a pathologically low TSH concentration such as that
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associated with hyperthyroidism and one which is suppressed by adequate circulating 
thyroid hormone concentrations, is difficult. However, measurement of basal TSH is 
of prime importance in the diagnosis of primary hypothyroidism in which serum 
TSH concentrations are invariably high. It also provides crucial information in 
differentiating primary from the very rare cases of secondary hypothyroidism in 
which the TSH concentration will be unmeasurably low. In mild cases of primary 
hypothyroidism, TSH level may not be greatly elevated and it may be necessary to 
carry out a TRH test to assess the thyroid status.
The TRH test provides an extremely useful information of the 
pituitary-thyroid axis in thyroid disorders. It is classically carried out by injecting a 
small amount of TRH intravenously with serum TSH levels measured before and 
after TRH administration. In normal subjects, intravenous administration of TRH 
(200-500|ig) elicits a rapid increase in serum TSH within 15-30 minutes (Hershman, 
1974). The TSH response to TRH is flat in thyrotoxicosis even in very mild forms 
of hyperthyroidism such as ophthalmic Graves’ disease or autonomous thyroid 
nodules where most of the clinical signs are lacking. An excessive response to 
TRH, on the other hand, is observed in primary hypothyroidism because of the lack 
of negative feedback at pituitary level (Abrahamson and Millar, 1986). The TRH 
test is also used in cases of secondary or tertiary hypothyroidism to differentiate the 
origin of the pathological process, i.e. to differentiate hypothalamic from pituitary 
destruction. In most cases of pituitary disease, the TSH response is impaired or 
absent. In contrast, hypothalamic hypothyroidism results in either a classic TSH 
response or, more frequently, a normal but delayed response where the peak may be 
delayed for up to 60 minutes (Snyder et al, 1974).
1.9 Auto-Immune Thyroid Disease
The ability of the immune system to differentiate between self and non-self 
is of great importance because failure in this system to recognise host antigens can 
result in autoimmune diseases. Although all endocrine organs are susceptible to 
autoimmune diseases, the thyroid and pancreas are the most frequent targets of an 
autoimmune attack.
23
The origin of autoantibodies is still unknown. Several theories have been 
suggested to explain the origin of autoantibodies. The first theory of Burnet 
postulated that self-reactive clones of lymphocytes are deleted during ontogency and 
autoimmunity occurs as a consequence of somatic mutation of the variable regions of 
immunoglobulin genes to generate self-reactive lymphocytes (Forbidden clones) 
(Burnet, 1959). Jeme modified the hypothesis and suggested that all normal 
individuals have self-reactive B-lymphocytes with their network of 
idiotype-anti-idiotype interaction and autoantibodies may arise from pertubation of 
the idiotypic network (Jeme, 1971). The third theory postualted that helper T and 
suppressor T lymphocytes are in balance and when this balance is shifted towards a 
relative decrease of suppressor T, the ability to elicit an immune response to "self' 
is enhanced resulting in the destructive autoimmune manifestations (Rose et al, 
1981).
Although very high levels of antibodies are classically detected in the serum 
of patients with autoimmune disease, only few have been proven to cause tissue 
damage whereas the majority appears to have no harmful effects. The latter type of 
antibodies cause functional abnormalities either by stimulating or inhibiting cell 
surface membrane receptors whüe most harmful antibodies action lead to target cell 
death (Salvi et al, 1988).
Autoimmune thyroid diseaes are associated with a variety of antibody types 
(Table 1.1) including thyroglobulin antibodies (TgAb), thyroid peroxidase antibodies 
(TPOAb) (antimicrosomal antibodies) and TSH receptor antibodies (TRAb). 
Autoantibodies to thyroglobulin were the first antibodies described in autoimmune 
thyroiditis (Roitt et al, 1956) and are directed against the main consitutent of the 
thyroid colloid, thyroglobulin (Tg). Although human TgAb react with two or three 
antigenic sites on the Tg molecule, they cross-react with various human tissues and 
other foreign antigens (Salvi et al, 1988). However, these antibodies are not 
cytotoxic wherease antimicrosomal antibodies fix complement and have a cytotoxic 
effect on thyroid tissue. The antimicrosomal antibody has recently been shown to be 
largely directed against cell-membrane antigens; peroxidase appears to be the main 
component (Davies et al, 1988). There is a clear association of high titre of TgAb 
with Hashimoto’s thyroiditis but TgAb are rarely present when TPOAb are not 
detected. TPOAb, on the other hand, are detected in nearly aU patients with
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Table 1.1 Thyroid autoantibodies identified in human subjects (Fisher et al, 
1987; Fisher, 1988; Amino, 1988).
TgAb Thyroglobulin antibody
TPOAb - Thyroid peroxidase antibody
TSA TSH receptor stimulating antibody or thyroid stimulating 
antibody
TEA - TSH (cAMP) blocking antibody
TBIA - TSH binding-inhibiting antibody
CSA - Collagen stimulating antibody
TGBA - Thyroid growth stimulating antibody
TGBA - Thyroid growth blocking antibody
TSI - Thyroid stimulating immunoglobulin
LATS - Long acting thyroid stimulator
LATS-P - Long acting thyroid stimulator protector
HTS - Human thyroid stimulator
HTACS - Human thyroid adenylcyclase stimulator
25
Hashimoto’s thyroiditis and seem to play a major pathogenic role in the destruction 
of thyroid cell (Flynn et al, 1988).
Adams and Purves were the first workers who gave evidence for the 
presence of a non-TSH humoral factor which stimulated the thyroid in Graves’ 
disease (Adams and Purves, 1956). This factor was then called long acting thyroid 
stimulator (LATS). Since that time a variety of antibodies directed against the 
thyroid TSH receptors have been reported. The classical TSH receptor antibodies 
remain the thyroid stimulating antibodies (TSA) of Graves’ disease. These 
antibodies interact with the same thyroid cellular sites as does TSH and stimulate the 
thyroid cell through an increase in cAMP. Other antibodies that inhibit the binding 
of TSH to its receptor referred to as TSH-binding inhibiting antibody TBIA, receptor 
blocking antibodies (TBA) which block TSH-stimulated cAMP production by thyroid 
follicular cells and thyroid growth stimulating antibodies (TGSA) which appear to 
act through a cAMP-independent mechanism have also been detected in patients with 
Graves’ disease (Fisher et al, 1987; Davies et al, 1988; Fisher, 1988; Amino, 1988; 
Flynn et al, 1988; Salvi et al, 1988; De Baets, 1989).
1.10 Thyroid Diseases
1.10.1 Hyperthyroidism
Hyperthyroidism is a condition characterized by an increased secretion rate of 
thyroid hormones, with a sustained rise in their free plasma level. The term 
thyrotoxicosis is generally preferred because it covers the complete list of causes of 
increased thyroid hormone activity whereas the term hyperthyroidism is reserved by 
some authorities to those diseases giving rise to increased activity of the thyroid 
gland itself, but not including increased thyroid hormone production from 
extra-thyroidal tissues (Roth and McAuliffe, 1989). The clinical signs and symptoms 
of hyperthyroidism are well and fully documented in most general medical textbooks. 
For the purpose of this chapter, they are summarized in Table 1.2.
Hyperthyroidism may result from several causes (Table 1.3), however. 
Graves’disease is the most common cause accounting for 70 to 85 percent of all 
cases (AUen and Braverman, 1987). It usually occurs in young adults 20 to 50
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Table 1.2 Signs and symptoms of hyperthyroidism (in approximate order of
incidence) (Williams and Goodburn, 1983).
Signs
Tachycardia (occasionally progressing to atrial fibrillation).
Enlarged, palpable thyroid gland.
Warm, smooth, moist, skin.
Fine finger tremor.
Hyper-active movements.
Thyroid bruit (rushing sound of blood circulating through the thyroid heard on 
auscultation).
Eye signs (ranging from wide-eyed stare, mild proptosis and lid-lag to gross
ophthalmophathy involving damage to eyelids, cornea and extra-ocular muscles). 
Gynaecomastia in male subjects, breast enlargement in women.
Symptoms
Nervousness and irritability.
Increased sweating, especially palmar and facial.
Intolerance to heat, preference for cool weather.
Intermittent palpitations and an awareness of increased pulse rate.
Weight loss, usually associated with increased appetite.
Fatigue and weakness.
Menstrual irregularity (usually oligomenorrhoea, occasionally dysfunctional uterine 
bleeding, reduced fertility).
Diarrhoea and hyper-active bowel.
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Table 1.3 Varieties of hyperthyroidism (Williams and Goodburn, 1983).
Graves’ disease (toxic diffuse goitre).
Toxic nodular goitre.
Uni-nodular.
Multi-nodular.
Thyroidits
Sub-acute (de (^ervain’s) thyroiditis.
Chronic thyroiditis with transient hyperthyroidism.
Nodular hyperthyroid goitre due to excess exogenous iodine 
(Jod-Basedow disease).
Excess exogenous thyroid hormone.
Iatrogenic.
Self-administered.
Neoplasia
Follicular adenoma of thyroid.
Follicular carcinoma of thyroid.
TSH-secreting tumours.
Choriocarcinoma.
Hydatidiform mole.
Ectopic TSH-secreting tumours.
Pituitary TSH-secreting tumour.
(Secondary hyperthyroidism)
Metastatic thyroid tumours.
Thyroxine-secreting teratoma (Stmma ovarii).
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years of age and affects women five times more frequently than men. Graves’ 
disease is the most prominent of the autoimmune thyroid diseases. It is 
characterised by the presence of TSH receptor antibodies: receptor stimulating 
antibodies (TSA) (Fisher et al, 1987) which are identified by their capacity to 
stimulate cAMP production in thyroid follicular cells in culture. There is now 
evidence that TSH receptor antibodies exhibit IgG light chain and subclass 
restriction, indicative of these antibodies being the cause at least in part of Graves’ 
disease (Davies et al, 1988). Studies in patients with Graves’ disease have identified 
TSA in 70 to 90% of patients. Patients with Graves’ disease usually also have 
significant levels of TgAb or TPOAb and many have detectable levels of 
growth-stimulation IgG (TGSA). Approximately 70% of these patients have been 
shown to have TSH-binding inhibitors (TBIA). All patients with Graves’ disease 
studies produced mainly unifunctional antibodies of either TSA or TBIA. These 
functional differences are mainly due to the heterogeneity and differences in fine 
specificities of TSH receptor antibodies. In some patients TBIA titres increased 
when they developed hypothyroidism, and this coincided with the appearance of 
receptor blocking antibodies (TBA) (De Bates, 1989).
Ophthalmopathy and dermopathy are often manifested in patients with 
Graves’ disease, however, the pathogenesis of these manifestations is not yet clear 
(Fisher et al, 1987).
The onset of Graves’ disease shortly after unusual emotional stress such as 
the loss of a loved one, or after physical stress such as trauma or a major illness is 
a common clinical finding. However, the mechanism behind this phenomenon is 
still unknown.
1.10.2 Hypothyroidism
Deficiency of thyroid hormones produces characteristic clinical changes 
depending upon the degree of deficiency, the mechanism underlying the disorder and 
the age at which it occurs. The main clinical features of hypothyroidism are listed 
in Table 1.4.
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Table 1.4 Signs and symptoms of adult-onset hypothyroidism (in
approximate order of incidence) (Williams and Goodburn, 1983).
Dry, coarse, cool skin.
Myxoedemic features (coarse skin and lips, puffy eyelids, thick tongue).
Slow, hoarse speech.
Thin dry, brittle hair.
Undue sensitivity to cold (wearing warm clothes even in warm weather).
Impaired cerebration, poor memory, slow reactions (both mental and physical). 
Apathy, listlessness, decreased libido.
Slow ankle reflex (both on contraction and especially on relaxation).
Constipation.
Weight gain (often associated with decreased appetite).
Peripheral oedema.
Slow pulse.
Menstrual irregularity (esp. menorrhagia but occasionally amenorrhoea and resulting 
in impaired fertility).
Deafness.
Hyperlipidaemia (giving rise to xanthomata, occlusive vascular disease and its 
complications, cardiac enlargement and hypertension).
Myxoedema coma (rare, usually in elderly women, associated with hypothermia, poor 
prognosis).
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The causes of hypothyroidism, based on the etiology of the syndrome, are 
classified into three types: Primary (thyroprivic). Secondary (Pituitary) and tertiary 
(hypothalamic). In the first type (thyroprivic hypothyroidism), the origin of the 
disorder is the gland itself which is unable to produce enough hormones. In 
pituitary hypothyroidism decreased hormone secretion results from lack of TSH 
stimulation due to pituitary disorders whereas hypothalamic hypothyroidism results 
from inadequate TSH secretion caused by TRH insufficiency as a consequence of 
hypothalamic disease (De Visscher and Ingenbleek, 1980).
Thyroprivic hypothyroidism is the most common type presented in 95% of 
hypothyroidism cases in adults in which approximately 70% of cases are caused by 
Hashimoto’s disease or chronic thyroiditis and up to 20% are Graves’ disease 
patients after treatment (Amino, 1988).
This disorder occurs at all ages but there is a large number of evidence 
indicating that the peak incidence of the disease occurs between the ages of 50 and 
60 years (Horton et al, 1976). In this disease, like hyperthyroidism, women are 
much more frequently affected than men with a female:male ratio between 4:1 and 
25:1 according to different reports (Horton et al, 1976; Irvine et al, 1979).
Hashimoto’s thyroiditis is a chronic autoimmune disorder of the thyroid gland 
that is characterised by a painless small or moderate-size goitre in which lymphotic 
infiltration is prominant. Most patients with Hashimoto’s thyroiditis progress to 
hypothyroidism after a long period of euthyroidism, some 5 to 10% have an 
associated destructive thyrotoxicosis, often with ophthalmopathy (Fisher et al, 1987; 
De Baets, 1988; Amino, 1988; Fisher, 1988). The majority of Hashimoto patients 
manifest significant levels of TgAb and/or TPOAb. In addition TGSA has been 
detected in 40-60% of these patients which presumably mediates thyroid growth via 
a thyroid TSH receptor (Fisher et al, 1987). Low titres of other TSH receptor 
antibodies (TBIA and TBA) have also been found in patients with Hashimoto’s 
thyroiditis, although, the prevalence of these antibodies vary considerably in different 
studies.
HLA may play a role in the development of autoimmune diseases. The 
major histocompatibility complex (MHC), also called human leukocyte antigen
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(HLA) is encoded on the short arm of the sixth chromosome in human. This area 
contains genes for three major classes of molecules: Class I genes code for the 
transplantation antigens (HLA-A, B and C), Class II genes representing the HLA-D 
region which is subdivided into three major Loci, DP, DQ and DR and finally Class 
m  genes code for complement molecules (Davies et al, 1988). The association 
between HLA and Hoshimoto’s thyroiditis is not as well documented as in Graves’ 
disease. Patients with Graves’ disease have an increased frequency of certain HLAs; 
HLA-B8 , HLA-DR3, HLA-DR5 and HLA-B8-D3 combination in Caucasians, 
HLA-BW35 in Japanese and HLA-BW46 in Chinese. Several studies have also 
clearly demonstrated an increased incidence of HLA-DR5 in patients with goitrous 
Hashimoto’s thyroidits (Flynn et al, 1988).
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CHAPTER TWO 
PRODUCTION OF MURINE MONOCLONAL 
ANTIBODIES TO THYROID HORMONES
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2.1 INTRODUCTION
2.1.1 Antibodies: Past and Present
The search for the mechanism of antibody formation began late in the 19th 
century. Several groups began to study the relationship between bacterial infections 
and the presence of natural antitoxins in the blood stream. These substances were 
the subject of very intensive studies (1889-1901) by the German bacteriologist Emil 
Behring who called them antibodies. In his studies, Behring had discovered that 
animals which survived diphtheria infection had developed a natural antitoxin to 
diphtheria in their blood. In 1890, Paul Ehrlich joined Behring in his studies in 
which they found that antibodies could also be produced in the blood serum by 
injecting foreign material into animals. Ehrlich then developed his side-chain theory 
of antibody formation in order to explain the reaction which is induced by foreign 
substances. His theory postulated that foreign substances are chemically linked with 
side chains present on a white blood cell’s surface receptors. Copies of the bound 
receptor were then produced in great excess and antibodies were shed into the blood.
In 1906 studies by Landsteiner on antigenic proteins coupled with different 
chemical groups, showed that unlimited amounts of antibodies can be produced by 
one animal. These discoveries concluded that the information used in response to 
such a wide spectrum of antigens could not possibly be inherently possessed by a 
host animal, this led to the rejection of Ehrlich’s "side-chain theory".
The "template theory" of antigen formation was then introduced in the 1930s 
to accommodate Lansteiner’s observations. A number of studies suggested that 
antibodies were produced in direct contact with their antigens where they develop a 
"shape" and a chemical affinity complementary to those of the antigen. These 
studies also suggested that antibodies differ in their protein composition and binding 
specificities which are determined by the antigen template. Collectively these 
suppositions were known as the "template theory" of antigen formations which was 
widely believed prior to the 1950’s.
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In 1957 Maefarlane Bumet announced the "clonal selection theory" which 
suggested that each lymphocyte had a unique receptor specificity, and that one cell 
produced just one kind of antibody. Nossal and Lederberg (1958) conducted several 
studies in which they provided evidence in support of the clonal selection theory. 
They showed that single antibody forming cells from rats immunized with two 
different antigens made antibody against one type of antigen, but no cell made 
antibody against both. However, the "clonal selection theory" remained controversial 
until the mid-1960s when it became generally accepted (Ada and Nossal, 1987).
It is now well established that antibodies are, in fact, proteins belonging to a 
specific class of serum proteins called immunoglobulins. Immunoglobulin G, 
abbreviated IgG, is the best known and most fully studied of the immunoglobulins 
(Fig. 2.1). An antibody molecule is a glycoprotein made up of two identical high 
molecular weight polypeptides (heavy (H) chains) and two identical low molecular 
weight polypeptides (Light (L) chains) joined together by a variable number of 
disulphide bonds (Brodsky, 1988). The N-terminal portions of both H- and L-chains 
contain variable amino acid sequences (V regions) which create unique binding sites 
for the antigen to which the antibody is directed. The remaining parts of the chains 
(C regions) contain relatively constant amino acid sequences which allow their 
classification into five classes and a number of sub-classes (Table 2.1). There are 
only two types of light chain. Kappa (K) and Lambda (X), and only one of them 
present in any one antibody molecule.
2.1.2 The Immune System
The essential function of the immune system is protection against foreign 
invaders such as disease causing pathogenic organisms (viruses, bacteria, parasites). 
Vertebrates have a specific immune mechanism in addition to the non-adaptive 
defence system possessed by lower animals. The three major characteristics of 
immune response: specificity, memory and non-self recognition provide a flexible 
and more effective response to antigenic challenge (Roitt, 1984). The body has two 
principle immune defence systems: cellular immunity which is provided by certain 
cells of the lymphoid system, particularly T cells and humoral immunity which is 
immunity due to circulating antibodies (the products of B cells).
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Fig. 2.1. Schematic diagram of immunoglobulin molecule (Price, 1987)
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During fetal development, lymphocyte precursors are derived from 
lymphoblasts in bone marrow and are dispersed into the blood which carries them 
through many organs. Those lymphocytes which populate the bursa fabricius in 
birds or the foetal liver, the foetal spleen and bone marrow in mammals (Weissman 
et al,. 1974) become transformed into B lymphocytes responsible for humoral 
immunity and lymphocytes which populate the thymus become transformed into the 
T lymphocytes responsible for cellular immunity. They then migrate from the 
primary lymphoid organs to the lymph nodes and bone marrow (Sprent, 1973).
There are four different types of T cells: helper, suppressor, activator and 
effector T cells which are also called cytotoxic, or killer T cells.
The stimulation of the body’s immune response involves cooperation of T 
and B cells. When a foreign substance (antigen) first enters the body, it binds to 
the appropriate B lymphocytes. Individual B cells, when activated by recognition of 
a foreign invader, divide forming a clone of plasma cells that secrete antibodies. 
These antibodies bind specifically to the foreign substance and initiate a variety of 
elimination responses. Helper T cells facilitate this process and suppressor T cells 
inhibit it while activator T cells regulate suppressor and helper T cells. During an 
immune response, T and B cells must first proliferate and differentiate before they or 
their products are capable of eliminating a foreign invader. The proliferation of T 
cells depends on their coming into physical content with macrophages that have 
taken up the antigen to which they are reacting. B cell activation, on the other 
hand, occur by either Major Histocompatibility Complex (MHC) unrestricted or 
MHC-restricted B cell activation pathway (Weigle, 1987). In the case of 
MHC-unrestricted B cell activation, the cross-linking of Ig receptors by antigen is 
assumed to be the initial triggering signal. This signal accompanied by 
MHC-restricted presentation of antigen to T cells by macrophages results in the 
release of lymphokines which drive the antigen-activated B cells to proliferate and 
differentiate and secrete specific antibodies. In MHC-restricted B-cell activation 
pathway, helper T cell recognise both antigen and Class II MHC molecules leading 
to antibody synthesis. The activation of MHC-restricted pathway seems to be the 
major route responsible for a significant part of the total antibody response, and 
different sub-population of B-cells dictate the response of each pathway.
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2.1.3 Monoclonal Antibodies
In 1975 Kohler and Milstein reported the first successful in vitro production 
of monoclonal antibodies using somatic cell hybridization technology. In their study, 
Kohler and Milstein fused antibody-forming spleen cells isolated from an immunized 
mouse with sheep red blood cells (SRBC) with cultured murine malignant cells 
which confer immortality on the spleen cells making it possible to grow the spleen 
cell hybrids in culture outside of the animal. Since then the technology has been 
developed as a research tool and has gained wide spread use.
Monoclonal antibody is defined as a uniform homogeneous antibody derived 
from one clone of cells which are all directed at a single epitope or antigenic 
determinant.
In the past several years monoclonal technology has progressed from 
producing animal and human monoclonal antibodies by fusing spleen cells or 
lymphocytes with myelomas to producing T cell factors by fusing T cells with T 
cell thymomas (Thurlow and McKenzie, 1983). Monoclonal antibodies have become 
increasingly important in diagnosis in both laboratory and clinical medicine.
2.1.4 Comparison of Monoclonal Antibodies to Conventional Polyclonal 
Antibodies.
The fundamental differences between monoclonal and polyclonal antibodies 
and their advantages and disadvantages have been extensively reviewed (Nakamura, 
1983; Thurlow and McKenzie, 1983; Campbell, 1984; Grossman 1986; Coding, 
1986). The production of a polyclonal antibody usually requires a very pure antigen 
preparation. After the animal is suitably immunized, serum obtained from the animal 
will contain the antibodies of interest, but it will also contain antibodies against a 
variety of other antigens which the animal has been exposed to. Polyclonal 
antibodies are heterogeneous mixtures produced by multiple clones of 
antibody-forming (B) cells. Polyclonal antibodies suffer from certain disadvantages 
including lack of precise specificity, affinity, class and subclass. They also suffer 
from lack of uniform characteristics even when drawn from the same animal. In 
addition, there will always be the threat of a limited supply of this antibody which
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is restricted by the volume of the animal’s serum. On the other hand, monoclonal 
antibodies are monospecific antibodies produced by an isolated clone. The potential 
benefits of this technology are enormous. The use of nonpurified and even 
unknown antigens such as crude tumour cells to produce a pure homogenous 
antibody preparation is one of the major advantages of the hybridoma technology. 
Furthermore, unlimited quantities of a homogenous antibody of a defined isotype can 
be prepared. Because monoclonal antibodies have the ability to bind to a 
determinant unique to the required antigen, their specificities can be far more 
precisely defined. Thus, antibodies suited for a particular task can now be 
generated.
In spite of the benefits of this technique, there are certain disadvantages that 
may arise from the use of monoclonal antibodies. Unlike polyclonal antisera where 
mixed population of antibodies are present in the antisera, monoclonal antibodies are 
preparations containing a single antibody. Whereas, the affinity of the polyclonal 
antisera lies in the cooperative effects between multiple types of antibody, that of 
monoclonal antibodies is fixed and thus if low may make the antibody unsuitable for 
use. Furthermore, the belief that a monoclonal antibody is monospecific is not 
entirely correct; Lane and Koprowski (1982) cited several examples of unexpected 
cross-reactions of monoclonal antibodies. On the other hand, monoclonal antibodies 
may sometimes be too specific. This is because they usually bind to one single 
unique site on the antigen molecule and therefore if for any reason this site is 
altered, the antibody may not continue to bind. In addition, monoclonal antibodies 
may have highly individual physical or chemical properties such as euglobulin or 
cryoglobulin properties which may greatly diminish their usefulness in many 
immunological procedures. The lack of precipitatory or agglutinating properties is 
another limitation which often accompanies the use of monoclonal antibodies.
2.1.5 Applications of Monoclonal Antibodies
2.1.5.1 Diagnostic Application
Because of their homogeneity, specificity and availability of limitless supply, 
monoclonal antibodies can be used to improve and standardise currently available 
clinical tests. A range of monoclonal antibodies to hormones such as LH, HCG and
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TSH have been produced with improved affinities and specificities. In addition, 
monoclonal antibodies to drugs such as digoxin have provided greater specificity 
than polyclonal antibodies raised in the sheep (Thurlow and McKenzie, 1983).
A number of monoclonal antibodies to bacterial, viral, parasitic and 
mycoplasmal antigens have also been described. These reagents were used for 
identifying and classifying organisms such as pneumococcus, measles and malarial 
parasite antigens (Price, 1987). In addition, with the aid of monoclonal antibodies, 
interferon (Milstein, 1980), a cellular product responsible for viral activity has been 
isolated and purified to a high degree.
Tissue diagnosis is another major area in which monoclonal antibodies have
been used for the characterisation of biopsy specimens. There is now a long list of
monoclonal antibodies produced against different components of normal tissue. 
These include anti-renal monoclonal antibodies that react to different portions of the 
renal tubules, glomeruli, endothelium or to the interstitium, monoclonal antibodies to 
prostate antigen and to a plasma membrane antigen of neurons (Thurlow and 
McKenzie, 1983; Grossman, 1986).
At the present time, tumour diagnosis is certainly the field in which there has
been most interest in monoclonal antibodies. A number of monoclonal antibodies to
solid tumours such as carcinoma of the colon , breast, lung, bone, neuroblastoma, 
and to melanomas have been described (Embleton et al, 1981; Kennet et al, 1981; 
Tjandra and McKenzie, 1988). The initial reports of these antibodies (to colon and 
melanomas) were promising. However, many of these anti-human tumour 
monoclonal antibodies appeared to react with carcinoma tissue as weU as normal 
tissue. Nevertheless, these antibodies are still extremely useful particularly in 
detecting the tissue of origin of tumour métastasés. Monoclonal antibodies are not 
only used for detection of the primary tumour but also for monitoring of the 
progress of the disease. Monoclonal antibodies that can separate lymphocytes into 
different functional groups are now commercially available. The most interesting are 
those defining functional T cells such as T helper cells (0KT4^, 0KT8 ) and T 
suppressor/cytotoxic cells (0KT4', 0KT8^). Many diseases have now been 
examined for their helper (T4) and suppressor (T8 ) T-lymphocyte ratios in blood. 
Rheumatoid arthritis, primary biliary cirrhosis, multiple sclerosis and many other
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diseases are currently being monitored for T4/T8 ratios using OKT monoclonal 
antibodies. OKT4/OKT8 ratios have also been helpful in the diagnosis of the 
acquired immunodeficiency syndrome (AIDS) and in monitoring the immune status 
of patients after organ transplants (Brodsky, 1988).
Monoclonal antibodies have also been used to define many of the subgroups 
of Leukaemia. Monoclonal antibodies to other blood components such as 
monocytes, neutrophils, or platelets (McMichael et al, 1981) have also been 
produced. The last, for example, has proved to be useful in clarifying the role of 
surface receptor antigen in platelet aggregation.
The use of monoclonal antibodies for radio-localisation of tumours and their 
métastasés is another area of interest. Because of their high specificity, monoclonal 
antibodies can be radiolabelled and used as imaging agents (Grossman, 1986).
2.1.5.2 Therapeutic Applications
Although monoclonal antibody technology is relatively new, it has already 
had a great impact on both basic science and clinical medicine. However, 
monoclonal antibodies are likely to make their most significant impact in the 
therapeutic area.
At present, the major clinical research efforts are being put into anti-tumour 
antibody research and development. Monoclonal antibodies can be used for therapy 
in native or conjugated form. There have already been several reports of using 
native monoclonal antibody in patients with Sezary cell leukaemias, CALL‘D 
leukaemia and lymphosarcoma but several problems were encountered including the 
production of human antimouse antibodies and antigenic modulation of the tumour 
so that it is no longer recognised by the antibody (Thurlow and McKenzie, 1983).
' Renal and bone marrow transplantation is another area of interest in which 
monoclonal antibody serotherapy has been applied. In one report 0KT3 monoclonal 
antibody has been successfully used to treat a group of patients suffering from acute 
cellular rejection (Cosimi et al, 1981; Ortho Multicenter Transplant Study Group, 
1985). In bone marrow transplantation. Graft Versus Host Disease (GVHD), is a
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major cause of morbidity and mortality. However, acute leukaemia patients who 
received a marrow graft treated with 0KT3 monoclonal antibody before infusion 
have demonstrated significant reduction of GVHD.
. Theoretically, monoclonal antibody could be coupled to almost any substance 
of interest and thereby be directed for treatment of a malignant neoplasm. Several 
groups have studied the possibility of coupling monoclonal antibodies to drugs, 
toxins, radioisotopes and enzymes. Monoclonal antibodies conjugated to cytotoxic 
agents such as conventional chemotherapeutic drugs has been used in animal and 
tissue culture. In the first clinical trial, monoclonal antibody (termed KS 114) 
conjugated to methotrexate, a cell cycle-specific cytotoxic compound, was used to 
treat adenocarcinomas. In aU 12 patients that were treated, binding to the tumour 
was saturated at a total dosage of Ig antibody (Broomby et al, 1986).
Conjugating monoclonal antibodies to toxins is another approach used to kiU 
target tumour cells. Pastan and colleagues (1986) have shown that toxin monoclonal 
antibody conjugates were successful in prolonging survival and actually inhibiting 
tumour growth in animal models. Monoclonal antibodies can also be radiolabeUed 
and used as vehicles to deliver therapeutic doses of radiation. Larson et al (1985) 
reported the treatment of human melanoma with ^^ I^ Fab monoclonal antibody to a 
high-molecular-weight antigen of malignant melanoma. In this report, an objective 
response occurred with therapy in one of these patients in which more that 50% 
reduction in the size of metastatic deposits was achieved.
It is important to note that murine monoclonal antibodies were used in most 
of the studies reported above. Despite the fact that data from clinical trials showed 
that murine monoclonal antibody can be administered safely, continuous 
administration of murine antibodies can lead to the production of human anti-mouse 
antibodies that recognise the therapeutic "foreign" monoclonal antibody and that 
neutralise its effect rendering the therapy ineffective. On the other hand, the use of 
human monoclonal antibody for therapy wül not elicit a host immune response and 
will avoid the risk of anaphylactic reactions including serum sickness. Although a 
few human monoclonal antibodies have been described to measles virus (Croce et al, 
1980), carcinoma of the lung (Embleton et al, 1981) and malignant glioma (Schnegg 
et al, 1981), this area is still largely unexplored mainly because of the unavailability
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of suitable human myeloma-hke fusion partners. Several attempts have been made 
to produce human monoclonal antibodies either by using Epstein-Barr virus or by 
making mouse/human hybrids. However, the use of mouse-human monoclonal 
antibodies for in vivo therapy did not eliminate the sensitisation problems. 
Furthermore, mouse/human hybrids were either very poor producers or proved to be 
chromosomally unstable (Price, 1987). More recently, mouse/human heteromyeloma 
(Ostberg and Pursch, 1983; De Silva et al, 1991) fusion partners have been produced 
and used with limited success. Nonetheless, the unabated research no doubt wiU 
result in better myeloma ceU lines which wiU be stable and produce large amounts 
of specific human antibodies.
2.1.6 Production of Monoclonal Antibodies
Monoclonal antibodies can be produced by several different methods. 
However, the method initiated by Kohler and Milstein (1975) is the one that is most 
commonly used. In this method, spleen cells are isolated from an immunized animal 
and fused with a suitable tumour cell line in order to produce hybridomas which 
exhibit the properties of both the normal antibody-forming cell and the myeloma 
fusion partner (Fig. 2.2). In most situations, mouse spleen cells are used for this 
purpose because mice can easily be immunized and thus are an excellent source of 
B-lymphocytes. Most importantly is that several murine cell lines are available for 
the production of hybridomas. At the conclusion of the fusion, fusion mixture wiU 
not only contain the hybridoma cells of interest, but will also contain a variety of 
cells including unfused myeloma and spleen cells, spleen cells fused with spleen 
cells and myeloma cells fused with myeloma cells. Spleen cells present no problems 
since they are not adapted to tissue culture and therefore die after a very short time. 
Myeloma cells, on the other hand, have an infinite life expectancy under optimum 
growth conditions. Therefore, it is necessary to select out the hybridoma cells and 
to eliminate the unfused myeloma cells and myeloma-myeloma hybrids from the 
fusion mixture. This is achieved by growing the myeloma cells in either 
8 -azaguanine or 6 -thioguanine. The cells that survive in this selection media lack 
the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT). This 
enzyme is important for the synthesis of purine and pyrimidine nucleotides by the 
salvage pathway. If the main biosynthetic pathway for nucleotides is blocked with 
folic acid analogue aminopterin, the salvage pathway is used instead in which
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Fig. 2.2. The production of mouse monoclonal antibodies (Zuckier et al, 1989)
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exogenous hypoxanthine or guanine is utilized via the enzyme HGPRT. The 
myeloma cells made deficient in the enzyme HGPRT cannot grow in medium 
containing hypoxanthine, aminopterin and thymidine (HAT) because the main 
pathway is absent because of the presence of aminopterin and the salvage pathway is 
blocked by the lack of HGPRT (Littlefield, 1964). The hybridomas, however, 
possess the enzyme HGPRT from the normal spleen cells and can therefore use the 
hypoxanthine in the HAT medium in the salvage pathway.
Although the first hybridomas were produced using Sendai virus (Kohler and 
Milstein, 1975), polyethylene glycol (PEG) first introduced in 1975 by Pontecorvo, is 
the most commonly used fusogen. This is because of the relative ease of handing 
of PEG as well as the difficulty of removing sendai virus from the cell culture. The 
use of PEG has also resulted in a higher fusion frequency and greater reproducibility 
(Goding, 1986). Clones of hybrid cells that produce a desired antibody can then be 
identified by a suitable assay. Various techniques are used in screening for antibody 
production such as resetting, radioimmunoassay (RIA), enzyme-linked immunosorbent 
assay (ELISA), flow cytometry, and cytotoxicity depending upon the availability of 
the technique within the laboratory. Since there may be more than one clone of 
hybridoma in the original well, cloning is a necessary step to separate the desired 
hybridoma line from irrelevant coexisting clones to ensure that the monoclonal 
antibody produced is truly monoclonal. Cloning by limiting dilution is usually the 
method of choice. In this method, hybridoma suspension is diluted so that there is 
an average of one hybridoma per microtitre well. The addition of a feeder layer is 
recommended for fusion steps and the cloning of hybridomas. Hybrid cells are 
often intolerant of dilution but the ability of cultured cells to grow at very low 
densities is usually increased if they are seeded onto feeder cells. Feeders are a 
group of slow-growing or non-growing cells. Although they are needed for cell 
growth, the mechanism is still poorly understood. The most used feeders are 
thymocytes, peritoneal macrophages, and spleen cells which are the easiest and 
quickest to prepare. More recently, a number of soluble growth factors given in the 
form of conditioned medium that would substitute for feeder cells have been 
described. Several studies have demonstrated growth factors such as human 
endothelial culture supernatant, endothelial cell growth supplement and extract of 
bovine neural tissue promote the growth of hybrid cells (Astaldi et al, 1980; Pintus 
et al, 1983). In other studies, murine macrophage-conditioned medium, has been
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shown to promote cloning, efficiency of growth and stability of hybridomas 
(Sugasawara et al, 1985). Walker et al (1986) have reported that the use of murine 
fibroblast conditioned media is effective in potentiating all phases of monoclonal 
antibody production. As soon as cloned lines become visible, they should be 
screened and the positive cell line expanded and frozen. Recloning should always 
be carried out to ensure true monoclonality of the antibody.
Large amounts of hybridoma antibody can either be obtained by growing 
hybridoma cells into larger cultures (in vitro) or they can be injected into appropriate 
mice and carried as solid tumour which secrete large quantities of homogenous 
antibody (in vivo).
The following study describes the production of murine monoclonal 
antibodies to thyroid hormones and the characterisation of these antibodies in terms 
of antibody specificity, cross-reactivity, titre, affinity and class. The antibodies 
produced as a result of this work were intended for the use in passive 
immunoneutralization study.
2.2 Materials and Methods
2.2.1 Preparation of T3  and T4  Conjugates
Following the method of Burke and Shakespear (1975), the antigen 
3,3’,5-triiodothyronine (T3 ) (Sigma Chemicals Ltd.) was conjugated to chicken 
gamma globulin (Guildhay Ltd. Guildford, England) using
1-ethyl-3 (3-dimethyl-amino-propyl)-carbodiimide hydrochloride 
(CDI) (Sigma), as follows: 30mg of T3  were dissolved in 5ml ethanokNH^OH (25:1, 
V/V), spiked with ^^ I^-T3  and cooled to 4°C. Solutions of chicken gamma globulin 
(50mg) and CDI (200mg) were made in 5ml and 10ml of distilled water 
respectively. Both solutions were cooled to 4°C and two thirds of the CDI solution 
was slowly mixed with the chicken gamma globulin solution. The T3  solution was 
then added dropwise with continuous stirring. The pH of the solution was 
maintained at 7.0 by dropwise addition of 0.25M HCL. The reaction mixture was 
stirred for a further 10 minutes and the remaining CDI solution was then added 
dropwise, maintaining pH with HCL as before. The mixture was stirred on a
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magnetic stirrer overnight at 4°C. It was then applied to a sephadex G-25 column 
(50-100ml bed volume) and eluted with 0.05M sodium phosphate pH 7.4. 
Approximately 50 x 0.5ml fractions were collected in a fraction collector and the 
position of the purified conjugate peak was determined by counting 1 0 |il aliquots of 
each fraction in a gamma counter.
The T4  conjugate was supplied by (Guildhay Ltd.). The antigen 
N-formy 1-L-thyroxine gratefully prepared by Dr George Frost, The Robens Institute, 
University of Surrey, Guildford; was conjugated to bovine gamma globulin using the 
carbodiimide method of O’Sullivan et al (1979).
2.2.2 Immunization
4-6 Week old female Balb/c mice were immunized with either T 3  conjugated 
to chicken gamma globulin or with thyroxine conjugated to bovine gamma globulin. 
The immunogen was dissolved in sterile normal saline and mixed with an equal 
volume of Freunds complete adjuvant and 0.2ml (100jig of conjugate) was given as 
an intraperitoneal injection (i.p.). At four weekly intervals, three booster injections 
of 0.2ml (lOOjig of conjugate) were given i.p. but using incomplete Freunds 
adjuvant. After each immunization, the animals were tail-bled after a further period 
of 6  days. Blood was collected in small Eppendrof polyethylene tubes, centrifuged 
for 10 minutes and the serum was kept frozen at -20°C until assayed. Antibody 
titre was checked using the same assay which was used for screening. A final boost 
was given 4 days prior to fusion. One day before fusion, mice were bled and 
antibody titre was checked. A fusion experiment was performed when a positive 
titre in excess of 1 : 1 0 0 0  was obtained.
2.2.3 Cell Fusions
2,23,1 Preparation of Feeder Cells
The spleen of a normal mouse which did not receive any immunogen was 
used. The mouse was sacrificed by cervical dislocation, drenched in 70% ethanol 
and the spleen was aseptically removed and immersed in 10ml serum free RPMI 
medium (GIBCO, Paisley, Scotland). The spleen was then placed in a sterile Petri
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dish containing 5ml RPMI. A single-cell suspension of splenocytes was then 
prepared by gently teasing the spleen cells apart from the capsule using fine forceps. 
The cells were then transferred to 10ml centrifuge tubes (Sterilin Ltd. UK) and 
harvested by centrifugation (300g for 5 minutes), washed twice in RPMI, and 
counted in haemocytometer. Feeder cells were then diluted in RPMI supplemented 
with 10% fetal calf serum (FCS), 2 mM glutamine, ImM Pyruvate, 100 lU/ml 
penicillin, 100|ig/ml streptomycin and HAT solution (hypoxanthine, aminopterin and 
thymidine) (GIBCO), and 0.1ml (1 x 10^  ceUs)/well were seeded in 96-weU plates 
and incubated at 37°C in humidified atmosphere of C0 2 . Spleen feeder ceUs were 
usually prepared one day prior to fusion.
2.2.3.2 Preparation of Myeloma Cells
The myeloma cell line used for fusion was the murine myeloma cell line 
Sp2/0-Ag-14 (abbreviated Sp2). It is a non-immunoglobulin-secreting 8 -azaguanine 
resistant Balb/c MOPC-21 myeloma and is therefore susceptible to HAT selection.
Seven days before fusion, the Sp2 cell line was grown in RPMI medium 
supplemented with 10% FCS, 2mM glutamine, ImM Pyruvate, 100 lU/ml penicillin 
and lOOjiglml streptomycin (GIBCO) at 37°C in humified 5% C0 2  95% air 
incubator. The growth rate was maintained in the region of 2-5 x 10  ^ ceU/ml.
2.2.3.3 Fusion Protocol
The Sp2 myeloma cells were pelleted in a sterile universal tube (Sterilin Ltd. 
UK) by centrifugation at 300g for 5 minutes using a bench top centrifuge (MSE 
Scientific Instruments, Sussex,^ UK). The supernatant was decanted and the cells 
were washed 2-3 times in serum free RPMI medium. The cells were then counted 
and the volume needed was transferred into 50ml sterile centrifuge tube (GIBCO). 
The spleen from an immunized mouse was processed in the same way as for the 
feeder cells. Spleen cells were mixed with myeloma cells at 5:1 ratio and 
centrifuged for 5 minutes at 300g to form a pellet. The pellet was drained from the 
supernatant and the cells loosened by tapping the bottom of the tube. The cells 
were fused using 50% (W/V) Polyethylene glycol (PEG) 1500 (BDH Chemicals 
Ltd.), made up in serum free RPMI medium. The PEG solution was kept at 37°C
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in a water bath. One ml of 50% PEG was added over a period of 20 seconds with 
continuous shaking for a further 1 minute. 20ml of serum free RPMI medium were 
slowly added over a period of 10 minutes, to dilute out the PEG. The cells were 
centrifuged at 300g for 5 minutes and resuspended in HAT medium (RPMI
supplemented with 20% fetal calf serum, 2mM glutamine, ImM pyruvate, 100 lU/ml 
penicillin, 100 |ig/ml Streptomycin and HAT solution). One hundred microlitres of 
the cell suspension was dispensed into each well of 96-well tissue culture plates 
(Nunc, Rosküde, Denmark). These wells also contained 0.1ml of feeder cells 
(1 X 10  ^ ceUs)/well in HAT medium. Five days after the fusion, aU wells were fed 
with HAT medium for a further period of 7 days. The aminopterin was then diluted 
out from the cultures by feeding of the cultures with HT medium [RPMI
supplemented with 20% FCS, 2mM glutamine, ImM pyruvate, 100 lU/ml penicillin,
lOOjig/ml streptomycin and HT solution (hypoxanthine and thymidine)]. The
medium was removed every 2-3 days and replaced with fresh HT medium. Cultures 
were inspected daily to monitor the progress of hybridoma growth. Screening for 
antibody production began when colonies attain a reasonable size.
2.2.4 Screening Methods
It is almost impossible to produce monoclonal antibodies of a required 
specificity without taking into consideration the importance of a good screening 
system. Screening should be started as soon as clones are visible to the eye. 
Newly formed hybridoma clones secrete small amounts of antibody, therefore a 
rapid, sensitive, specific and reliable assay becomes an essential requirement. 
Allowing three to four days after the last medium change for antibody to 
accumulate, culture supernatant was harvested and tested for immunoglobulin as well 
as specific antibody secretion.
2.2.4.1 The Dot Immunobinding Assay
During the production of monoclonal antibodies, it is frequently necessary to 
assay large numbers of hybridoma supernatants for the presence of specific antibody. 
The dot immunobinding method of Hawkes et al (1982) in which the antigen is 
directly applied to the nitrocellulose as a dot provides a considerable simplification 
and simultaneous screening of a large number of samples. This method provides
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several advantages over conventional immunoassays (Bennett and Yeoman, 1983), 
including its simplicity, the great number of antigen-antibody combinations it can test 
and it could be used as a first qualitative screen (Alric et al, 1986).
Protocol one was used to screen hybridoma clones for a specific antibody 
production while protocol two was used to spot any antibody secreting clones.
a) Protocol I
A nitrocellulose membrane (Anderman & Co. Ltd.) was divided into 3-4mm square. 
SmaU amount l-2 |il (1 mg/ml) of the antigen (Tg ovalbumin or T4  ovalbumin) 
prepared following the method of Burke and Shakespear (1975) mentioned before in 
Section 2.2.1 was applied, left to dry before incubating with 200|il of culture 
supernatant for 2 hours at room temperature. After washing with tap water, the 
membrane was incubated for 30 minutes with donkey anti mouse horseradish 
peroxidase (Guildhay) at 1:2000 dilution at room temperature. The membrane was 
then washed with tap water and incubated with the substrate solution. To prepare 
the substrate solution, lOmg of 3-amino-9-ethyl carbazole (Sigma) was dissolved in 
6 ml dimethylsulphoxide (Aldrich Chemical Co. Ltd.). 45ml distilled water, 5ml 0.2 
M acetate buffer and 50|il of 30% V/V H2 O2  were added. The substrate solution 
was used immediately. Positive primary antibodies gave pink spots. After the 
colour was completely developed (20-30 minutes) the nitrocellulose membrane was 
washed in several changes of distilled water and air-dried.
b) Protocol n
Small amounts of culture supernatant (l-5|il) was spotted on two nitrocellulose 
membranes (Anderman & Co. Ltd.) which were divided into small squares, each was 
used for a single test. One membrane was incubated with donkey anti mouse 
IGg-peroxidase while the other was incubated with donkey anti mouse 
IGM-peroxidase (ICN Biomedicals Ltd.) at 1:1000 dilution for 30 minutes at room 
temperature. After washing with tap water, membranes were incubated with the 
substrate solution prepared as before until the colour was developed for 20-30 
minutes. Membranes were washed with tap water and left to dry.
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2.2A 2 ELISA
In recent years, several sensitive methods have become available for detecting 
monoclonal antibodies. Enzyme-linked immunosorbent assay (ELISA) has been the 
favourite technique because it offers several advantages of which the elimination of 
health hazards associated with the use of radioactive material is the most important 
one (Schuurs and Van Weemen, 1977). It is rapid to perform, uses reagents with 
long shelf life and capable of handling a large number of samples.
A wide variety of assay principles can be used in ELISA techniques (Bauke 
and Weemen, 1985). The various assays have been classified as either competitive 
or non-competitive. In competitive assays unlabeUed and labelled antigen compete 
for a limited number of antibody sites while in non-competitive assays the antigen 
(or antibody) to be measured is first allowed to react with antibody (antigen) on a 
solid phase followed by measurement of the binding of enzyme-labelled immune 
reactant.
Reagents
All chemicals were supplied by BDH except for the NaCl which was obtained from 
May and Baker Ltd.
Coating buffer
Sodium phosphate buffer 0.05M, pH 7.4: buffer A and B were prepared by 
dissolving 7.1g of Na2 HP0 4  and 7.8g of NaH2 P0 4  respectively per litre of distilled 
water. These were mixed in the ratio of 70.5:9.5 (A:B) and the pH was adjusted to
7.4.
Diluting buffer (PBS)
Phosphate buffered saline pH 7.4 was prepared by dissolving 8 g of NaCL, 0.2g of 
KCL, 2.9g of NaH2 P0 4  and 0.2g of KH2 PO4  per litre of distilled water and the pH 
was adjusted to 7.4.
Washing buffer (PBSG)
Phosphate buffer containing 0.1% gelatine (Sigma)
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PBSGT buffer
Phosphate buffer containing 0.1% gelatine and 0.05% Tween 20 (Sigma). 
Carbonate/bicarbonate buffer
This buffer O.IM pH 9.6 was prepared by dissolving 1.59g of Na2 Cog and 2.93g of 
NaHCOg in one litre distilled water and the pH was adjusted to 9.6.
Substrate buffer
Phosphate citrate buffer pH 4.9 was prepared by dissolving 7.1 g of Na2 HP0 4  and 
5.22g of citric acid per litre of distilled water and the pH was adjusted to 4.9.
Substrate solution
30mg of 0-phenylenediamine (Sigma) was dissolved in 75ml of substrate buffer. 
Just before use 30jil of H2 O2  solution (30%) were added.
Procedure
The screening ELISA assay was set up as follows:
1) 96-well microtitre plates (Dynatech Laboratories Ltd., Billingshurst, UK) were 
coated with 2 0 0 |il of conjugated antigen of 1 : 1 0 0  dilution using coating buffer and 
plates were incubated overnight at 4°C or for 2 hours at 37°C in a humidified 
container.
2) Plates were washed using PBSG buffer and 200|il of culture supernatant was 
added. The plates were incubated for 2 hours at 37°C and then washed.
3) Donkey anti mouse horseradish peroxidase conjugate was diluted at 1:2000 and 
2 0 0 |xl were added to the plates.
4) After 2 hours incubation at 37°C, plates were washed and then incubated for 30 
minutes with 2 0 0 jil of substrate solution.
5) The reaction was stopped by adding 50|xl of H2 SO4  at 2.5M and the optical 
density of the weUs was read at 492nm using a Titertek Multiskan Plus (Flow 
Laboratories, UK) connected to an Amstrad PC1640 personal computer for data 
processing.
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2.2.5 Cloning
As soon as positive wells were identified, the hybrid cells were cloned using 
the limiting dilution method.
The number of cells in the original well were counted, diluted to the
concentration of 50, 5 and 0.5 cells/ml in medium containing 20% FCS and grown 
in 96-well tissue culture plates containing a feeder layer of splenocytes from normal 
non-immunized Balb/c mouse. Several vials of the original positive wells were 
expanded and stored frozen in liquid nitrogen. Culture supernatant from wells 
containing subclones were assayed for antibody secretion and wells with single 
clones which were positive for antibody secretion were expanded and frozen.
Hybridoma lines were cloned 2-3 times to make absolutely certain that each is a true 
clone.
2.2.6 Freezing and Recovery of Cells
The following procedure is used for both fusion partner and hybridoma cells. 
Cells that were in log phase of growth were gently spun down and resuspended at 
1-2 X 10  ^ cells/ml in freezing medium, a mixture of 90% (V/V) FCS and 10% 
(V/V) Dimethyl Sulphoxide (DMSO) (Sigma). They were then aliquoted into 2ml 
cryotubes (Nunc, Denmark) and placed in a polystyrene box and immediately placed 
into a -70°C freezer for at least 24 hours before transferring to a liquid nitrogen 
container for long term storage.
At least one vial from each ceU line is thawed down to check cell recovery.
The vial was thawed rapidly at 37°C water bath and cells were resuspended in
medium containing 20% FCS, centrifuged for 5 minutes at 300g. The washing step 
was repeated 2-3 times to remove the DMSO completely. The cells were 
resuspended with the same medium and cultured in a tissue culture flask at 37°C, in 
humidified atmosphere of 5% CO2 .
54
2.2.7 Antibody Production
Once stable hybrid clones secreting antibody were isolated, they were 
expanded slowly in vitro by transferring to 24-well plates followed by 25-cm^ flasks, 
80 cm^ flasks and 175-cm^ flasks (GIBCO).
For in vivo production, about 10^-10  ^ viable hybridoma ceUs were injected 
intraperitoneally (i.p.) into pristaned mice. Mice were primed 7 days prior to 
hybridoma injection by i.p. injection of 0.5ml Pristane (2,6,10,14- 
tetramethylpentadecane supplied by Sigma). 2-5 weeks later the mice were killed 
and ascitic fluid was collected, centrifuged for 15 minutes at 2000rpm and stored at 
4°C.
2.2.8 Characterisation of Antibody
2.2.8.1 Determination of Antibody Class
It is often important to know the immunoglobulin class of the monoclonal 
antibody in order to select methods for its purification. Antibody class was most 
readily determined by the use of class specific antibodies in the dot immunobinding 
assay which was used for screening. Two methods were used in the determination 
of immunoglobulin class.
a) ELISA
The screening ELISA method described in Section 2.2.4.2 was used except for the 
labelled second antibody. Donkey anti mouse IGg-peroxidase and donkey anti 
mouse IGM-peroxidase (ICN Biomedicals Ltd.) were used instead. They were 
diluted at 1:2000 and 2(X)p.l were added to the plates. The plates were incubated for 
2 hours at 37°C and the assay was then completed as in Section 2.2.4.2.
b) Isotyping of Mouse Monoclonal Antibodies.
Serotec isotyping kit for mouse monoclonal antibodies specifically designed to 
identify the class and subclass of monoclonal antibodies in tissue culture supemant 
was used. The principle of this test system is based on red ceU agglutination. A 
positive agglutinated result is produced when highly specific antibody (which is
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coupled onto sheep red blood cells) recognises and binds to the particular isotype to 
which it is directed. This binding forms a lattice on the bottom of the microtitre 
plate well-termed agglutination.
Culture supernatant was diluted at 1:10, 1:100 and 1:1000 in phosphate buffered 
saline (PBS) and 30|il of each dilution was dispensed into each of seven wells 
across a microtitre plate. 30pl of each specific isotyping reagent was added to the 
wells of the microtitre plate. Each isotyping reagent consists of a purified, rat 
monoclonal antibody specific for a single class/subclass of immunoglobulin (IgGI, 
IgG2a, IgG2b, IgA and IgM), coupled to sheep red blood cells. The coupled rat 
antibodies recognize the heavy chain portion of the mouse immunoglobulin. The 
plate was covered with a lid and placed on a plate shaker for six seconds. It was 
then left on a flat surface for one hour for results to develop. Positive and negative 
controls were supplied with the kit.
2.2.S.2 Antibody Purification
a) Ammonium Sulphate Precipitation
Ascitic fluid containing anti-Tg or anti-T^ monoclonal antibody was subjected to a 
stepwise ammonium sulphate precipitation. Ascitic fluid was placed in a beaker on 
a magnetic stirrer. Saturated ammonium sulphate was added dropwise at a 
concentration of 33%. The mixture was stirred for 15-30 minutes and centrifuged 
for 30 minutes at 3000rpm. The pellet was resuspended in phosphate buffer O.OIM 
pH 7.4. Ammonium sulphate was removed by dialysing for three days at 4°C 
against 2 litres of phosphate buffer O.OIM pH 7.4. The dialysis buffer was changed 
twice every day.
b) Gel Filtration
This method provides rapid purification of immunoglobulins in a single step. A 
28 X 1cm column was packed with Sphacryl S-300 ready to use pre-swoUen beads 
(Pharmacia). The column was washed with phosphate buffer O.OIM pH 7.4. Ascitic 
fluid was applied and washed with the same buffer. Small aliquots of the collected 
fractions were diluted at 1:10 and optical density (OD) was measured at 280nm. A 
1 mg/ml solution will have an OD of -1.2. The total amount of protein was then 
calculated.
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2.2.S.3 Titre and Standard Curves
Preparation of Tg and T4  Standards
A stock solution of Tg and T4  were prepared and the concentration checked 
spectrophotometrically. Working solutions were then prepared by appropriate 
dilution. Approximately, 15mg of 3,3’,5-Triiodothyronine or L-thyroxine, free acid 
(Sigma) were dissolved by the addition of 4ml 0.04M NaOH. This solution was 
then diluted 1:100 in 0.04M NaOH and its optical density was read at 325nm. The 
exact concentration was calculated using the following formula:-
Tg : MW = 651 T4 : MW = 777
Eg25 = 4660 Eg25 = 6200
Cone. = OD X 10^
molar extinction (E)
This stock solution was then further diluted in assay buffer to produce working 
standard solution of 16nmol/L (for Tg top standard) and 480nmol/L (for T4  top 
standard). One millilitre aliquots of working solution were ffeeze-dried and stored at 
-20°C. For use, the content of each vial was reconstituted with 1ml of assay buffer 
to produce the top standard of either 16nmol/L for Tg or 480nmol/L for T4 . Tg and 
T4  top standards were then double diluted to produce the concentrations of 8,4,2,1 
and 0.5nmol/L and 240,120,60,30 and 15nmol/L respectively.
Preparation of Tg and T4  Enzyme-Labelled Conjugates
Tg and T4  (20mg) was dissolved in 3ml of Dimethylformamide (DMF) 
(BDH). 3 mg of N-hydroxysuccinimide (Sigma) and 16mg of
N-N’-Dicyclohexylcarbodiimide (Sigma) each dissolved in lOOpl redistilled DMF 
were added consecutively and the mixture was incubated overnight at room 
temperature in the dark. After the addition of 25mg of horseradish peroxidase 
dissolved in 1 ml distilled water, the mixture was left to incubate overnight at 4°C in 
the dark. The conjugate was dialysed against distilled water overnight at 4°C and 
was then purified on sephadex G 100-120 column using O.OIM phosphate buffer pH
7.4 as eluent. Fractions were pooled and tested using competitive ELISA.
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Competitive Enzyme Immunoassay
96-well microtitre hard plates (Dynatech) were coated in carbonate/ 
bicarbonate buffer pH 9.6 with purified ascites containing either Tg or T4  monoclonal 
antibodies at dilutions of 1:10, 1:50, 1:100, 1:500, 1:1000, 1:5000 and 1:10000 plates 
were incubated overnight at 4°C or for 2 hours at 37°C in a humidified container. 
Plates were washed with PBSGT buffer.
Pooled fractions of Tg or T4  horseradish peroxidase conjugate were diluted at 
1:100, 1:500, 1:1000 and 1:5000 and 200|xl were added to the wells. Plates were 
incubated for 2 hours at 37°C and then washed. After the addition of substrate 
solution prepared as in Section 2.2.4.2, plates were incubated for 30 minutes at 
37°C. The enzyme was inactivated by the addition of 50fxl of H2 SO4  2.5M and the 
absorbance was measured at 492nm.
As soon as this method was optimized, it was used to construct standard 
curves in which lOOjil of standard incubated with lOOpl of antigen-labelled 
conjugate competed for the coated antibody.
2.2.5.4 Cross-reactivity Study
The specificity of the antibody was assessed using the following analogues: 
3-lodo-L-tyrosine, 3,5-diiodo-L-tyrosine, 3,5-Diiodo-DL-thyronine, 3,3’,5- 
triiodothyroacetic acid, 3,3 ’ ,5 ’ -triiodothyronine (reverse Tg) and 
3,3’,5-triiodothyronine (Tg) or 3,3%5,5’-tetraiodothyronine (T4 ). Competitive ELISA 
system was used in which a fixed amount of antigen labelled conjugate was 
incubated in the presence of increasing amounts of cross-reactants (0.5-16|imol/L). 
The cross-reactivity of the antibody was calculated as the ratio (expressed as a 
percentage) of the mass of the specific antigen (Tg or T4 ) to that of the cross 
reacting compound required to reduce binding of the label by 50%.
2.2.8.5 Affinity Constant
Antibody affinity was measured using a non-competitive ELISA method. 
The affinity constant (K ^) of antigen-antibody reactions was determined utilizing the 
OD-50 of sigmoid serial dilution ELISA curves. This method measures the total
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antibody concentration added per well rather than the bound to free ratio (Beatty et 
al, 1987).
Serial dilutions of conjugate in 0.05M phosphate buffer pH 7.4 were coated 
on 96-well plates overnight at 4°C. The concentrations of the conjugate were 5.0, 
2.8, 0.56 and 0.28|ig/ml. For each coating dilution, serial dilutions of Tg 
monoclonal antibody 50, 16.7, 8.3 and 4.2|ig/ml were added. Plates were incubated 
for 2 hours at 37°C and then washed with PBSGT buffer. Donkey anti mouse 
horseradish peroxidase (1:2000) was incubated for 2 hours at 37°C. After washing, 
200|il of substrate solution was incubated for 30 minutes at 37°C. 50|il of 2.5M 
H2 SO4  were added and OD was measured at 492nm. The affinity constant was 
calculated using the following equation:
K n - 1aff -
where
n =
2 (nlAb’l, - [AblJ
[Agit
[Ag’lt
Same method was followed to calculate the K f^f of the T4  monoclonal antibody. 
The concentrations of the antibody were 0.5, 0.25, 0.125 and 0.0625|ig/ml.
2.3 RESULTS
2.3.1 Preparation of Tg Conjugate
Tg was conjugated to chicken gamma globulin using the carbodiimide 
method. The reaction mixture was purified using sephadex G-25 column. The 
elution profile is shown in Fig. 2.3. Because gel filtration separates proteins 
according to their size and because the gel itself occupies about 70% of the volume 
of the column; very small molecules are freely permeable into the beads and thus 
are removed by gel absorption while very large molecules are totally excluded and 
dissociated from the beads. Therefore, as the sample proceeded down the column
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Fig.2.3 Elution profile of the Tg-chicken gamma 
globulin conjugate on Sephadex G-25 column.
Other fractions
I
Conjugate fractions
0 1 0 20 30 40 6050
Fraction Number
6 0
the first protein fractions emerge contain T3  non reversibly bound to protein (purified 
conjugate). As elution proceeds, reversibly protein-bound Tg, carbodiimide and 
unbound Tg were eluted. The fractions from 12-24 (Fig. 2.3) were pooled, 
lyophilized and kept at -20°C. Calculated molar ratio in purified conjugate was Tg: 
chicken gamma globulin 6 : 1 .
2.3.2 Immunization
The results of Balb/c mice immunized with either Tg or T4  conjugates and 
the polyclonal response monitored using sandwich ELISA are shown in Figs. 2.4 and
2.5. The results show that the antibody response in immunized mice increased 
steadily during immunization. The titre of Tg and T4  polyclonal antisera after the 
final boost was 1:1000 and 1:1500 respectively.
2.3.3 Cell Fusions
The fusion protocol followed was the same in aU fusions. For the 
production of Tg monoclonal antibodies, six separate fusion experiments were 
performed. Hybridization between spleen cells and Sp2 myeloma cells was carried 
out at 5-10:1 ratio and mixed cells were seeded into 96-well plates. Plates were 
screened using the dot immunobinding assay and a sandwich ELISA system. Thirty 
positive colonies were obtained from these fusions of which seven colonies were 
chosen and cloned by limiting dilution and positive clones from these cells were 
expanded and recloned. Of the resulting clones, seven cell lines were expanded for 
characterization studies. Preliminary studies (titre and displacement) were carried out 
and hybridomas MMT3.1 and MMT3.2 were finally chosen for further 
characterisation and for the production of ascites fluid.
In the production of T4  monoclonal antibodies, one fusion was performed in 
which seven cell lines were established. Spleen cells from an immunized mouse 
were fused with myeloma cells at 5:1 ratio and cells were plated into 96-weU plates. 
The dot immunobinding assay was used for initial screening of supernatant. A 
number of culture supernatants positive on the dot immunobinding assay were also 
screened by ELISA. 79% of wells contained hybridoma colonies of which seven 
were positive when analyzed for antibody. From these, the best three were chosen
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for cloning by limiting dilution. Three positive hybridoma cultures were selected for 
cloning and further characterisation, of which hybridoma MMT4.1 was expanded and 
injected into mice to produce ascites fluid.
2.3.4 Screening Methods
The dot immunobinding assay was used for initial screening of supernatant.
An example of the results obtained from initial screening of hybrid cell cultures is 
shown in Table 2.2. Positive hybridoma cultures producing specific antibodies were 
mainly selected using the non-competitive ELISA system. Positive result was 
defined as that gave OD at 492nm higher than twice the negative control. Table 2.3 
gives an example of the results.
2.3.5 Characterisation of Antibody
2.3.5.1 Antibody Class
The immunoglobulin class of Tg and T4  fusion supernatants were determined 
by ELISA method and results were confirmed using Serotec isotyping kit for mouse 
monoclonal antibodies. An example of the results are presented in Table 2.2. The 
typing of both cell lines MMT3.1 and MMT4.1 revealed them to be IgM type.
23.5.2 Antibody Purification
Ascites fluid of cell lines MMT3.1 and MMT4.1 were semipurified by 33% 
saturated ammonium sulphate precipitation followed by chromatography on sephacryl 
S-300. The recovered antibodies in the ammonium sulphate precipitated globulin 
were assessed by constmcting antisera dilution curves. These curves were compared 
with those obtained from the neat ascites (Figs. 2.6 and 2.7). The results show that 
complete recovery of T3  and T4  antibodies in the Ig preparation was obtained.
The elution profile from the sephacryl S-300 column is illustrated in Figs.
2.8 and 2.9. In the literature 3-15mg/ml antibody in ascites fluid was reported 
(Nakamura, 1983; Goding, 1986). The T4  monoclonal antibody produced exceeded
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Table 2.2 Immunoglobulin class and subclass of T 3  and T4  fusion 
supernatants
Supernatant Dot Immunobing ELISA Serotec Isotvping
T3  Fusions:
1B6 IgG IgG IgG2b
3A6 IgG IgG IgGI
4E2 IgG IgG IgG2a
5A7 IgM IgM IgM
T4  Fusion:
1A12 IgM IgM IgM
4É12 IgM IgM IgM
5C3 IgG IgG IgGI
6H2 IgG IgG IgG2a
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Table 2.3 Screening ELISA results of some T3  and T4  monoclonal antibodies
T, MAb T. MAb
Clone OD at 
492nm
Clone OD at 
492nm
2G4
3A6
4F7
4G5
5A7
RPMI 20% PCS 
Normal mouse serum IK 
Mouse T3  Polyclonal 
antiserum IK 
Second antibody 
Substrate
1.011 1A12
0.983 2G5
1.692 3G5
1.199 4E12
1.785 4G2
0.078 RPMI 20% PCS
0.218 Normal mouse serum
IK
2.001 Mouse T4  Polyclonal
0.052 antiserum IK
0.031 Second Antibody
Substrate
2.042
1.287
1.167
2.376
2.435
0.067
0.221
2.583
0.061
0.053
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Fig.2,6 Antibody dilution curves o f T 3  MAb (MMT3.1)
in neat and ammonium sulphate puriSed ascites.
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Fig.2.7 Antibody dilution curves o f T 4  MAb (MMT4.1)
in neat and ammonium sulphate purihed ascites.
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Fig.2.8 Elution profile of Tg M Ab (MMT3.1) 
on Sephacryl S-300 column.
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Fig.2.9 Elution profile of T 4  M Ab (M M T4.1) 
on Sephacryl S-300 column.
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that range (17.2mg/nil) and the T3  monoclonal antibody produced was within that 
range (9.2mg/ml).
2.3.S.3 Antibody Characteristics
The characteristics of the monoclonal antibodies were studied using purified 
ascites fluid. An antibody titre of 1:500 and 1:8000 were obtained from cell lines 
MMT3.1 and MMT4.1 respectively (Figs. 2.6 and 2.7). The ELISA titre was taken 
as the dilution of the antibody preparation which gave optical density (OD) of 
1.0-1.5. Standard curves were contructed using competitive ELISA assay. Results 
are presented in Figs. 2.10 and 2.11. The cross-reactivity of T3  and T4  monoclonal 
antibodies was tested using the competitive ELISA system. The degree of 
specificity is demonstrated in Figs. 2.12 and 2.13. Cross reactivity studies revealed 
no interference with any of the cross reactant studied as shown in Table 2.4.
CeU lines MMT3.1 and MMT4.1 were also used for affinity constant 
determination. Serial antibody dilution curves for the different antigen-coating 
concentrations are shown in Fig. 2.14 and 2.15. Calculated values of K f^f for cell 
lines MMT3.1 and MMT4.1 based upon the curves in Figs. 2.14 and 2.15 were 
11 X 10  ^ L/mol and 3.8 x 10  ^ L/mol respectively.
2.4 Discussion
To prepare murine monoclonal antibody, the spleen cells of immunized 
mouse are fused with cells from a myeloma cell line using a surface active agent 
such as polyethylene glycol. Mixed cell culture after fusion are grown in selective 
medium (HAT). Of the resulting hybridoma only a few are likely to be producing 
antibodies against the antigen of interest. The culture medium firom these growing 
hybridoma cultures are then assayed for specific antibody, and those few hybridomas 
are isolated and cloned.
In the production of T3  monoclonal antibodies, six separate fusions were 
performed in which 30 ceU lines producing T3  antibodies were obtained. Seven of 
these clones were further cloned by the limiting diluting technique and positive cells 
from these wells were used for recloning. Of the resulting clones, two cell lines 
MMT3.1 and MMT3.2 were expanded and grown in mice to produce ascites fluid.
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Fig.2.10 Standard curves for Tg, using MAb
(MMT3.1) in competitive ELISA assay.
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Fig.2.11 Standard curves for T4 , using MAb
(MMT4.1) in competitive ELISA assay.
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Table 2.4 Specificity of T3  and T4  monoclonal antibodies
% Cross reaction
Cross reactant T3  MAb 
(MMT3.1)
T4  MAb 
(MMT4.1)
3-lodo-L-tyrosine 
3,5-Diiodo-L-tyrosine
3,5 -Diiodo-DL-thyronine 
3,3%5-Tniodothyroacetic acid 
3,3’,5’-Triiodothyronine (reverse T3 ) 
3,3’,5-Triiodothyronine (T3 )
3,3 ’,5,5’-Tetraiodothyronine (T4 )
0.036
<0.01
0.069
0.090
0.060
100
0.067
0.18
<0.01
<0.01
0.73
0.69
0.48
100
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The ascites produced were partially purified by ammonium sulphate precipitation and 
chromatography on Sephacryl S-300. Both of these antibodies belong to IgM class 
as indicated by sandwich ELISA method and confirmed by the serotec isotyping kit. 
Further characterisation studies were carried out on cell line MMT3.1. The affinity 
constant obtained by the Beatty et al (1987) method was revealed to be 11 x 10  ^
L/mol. An important requirement of a T3  antibody in terms of specificity is a low 
cross-reactivity with T4 . In these terms the T3  monoclonal antibody produced 
appears to be adequate with cross-reactivity of less than 0 . 1 % with T4 .
The fusion process for the production of T 4  monoclonal antibody was 
successful in that a large number of colonies were produced, that resulted in the 
production of seven independently derived monoclonal antibodies to T 4 . After 
cloning and recloning of these hybridomas, cell line MMT4.1 was grown into ascites 
and used for further characterisation. The antibody proved to be of relatively high 
affinity with an association constant of 3.8 x 10  ^ L/mol. The degree of specificity 
of the T4  monoclonal antibody was analyzed, cross-reactivity with T3  <0.5%.
Both methods used for screening were satisfactory. The dot immunobinding 
assay was used for initial screening of supernatant and proved to be rapid, 
reproducible and economical. At least 1000 assays could be performed in a day, if 
necessary. However, specific antibody secretion was mainly detected by a sandwich 
ELISA system. The screening ELISA was a rapid and reproducible system 
specifically detecting T3  or T4  antibodies.
There have been two previous reports in which monoclonal antibodies to 
thyroid hormone was produced. Wang et al (1981) reported the production of 
murine monoclonal antibodies to T3  and T4  by fusing murine splenocytes from an 
immunized mouse (BSA-T4  or BSA-T3 ) with NSl myeloma cells. After cloning by 
limiting dilution and recloning on soft agar, two clones were selected for further 
characterisation; clone 16-A for the production of monoclonal anti-T4  and clone 1 2 -A 
for the production of monoclonal anti-T3 .
Mpoko et al (1985) produced a monoclonal antibody to thyroxine. In their 
study, the spleen cells of a Balb/c mouse immunized with thyroxine methyl ester 
conjugated to human serum albumin were fused with NSl myeloma cells. The
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limiting dilution method was used for cloning and recloning of positive clones and 
cell line D5 was established. In both reports radioimmunoassay was used for 
screening.
In comparison with our results, the T3  monoclonal antibody produced by 
Wang et al (1981) had a significantly higher association constant 1.4 x 10  ^ L/mol 
while the T4  monoclonal antibody had a significantly lower association constant 
1.5 X 10  ^ L/mol. However, the association constant of the T4  monoclonal antibody 
(1.83 X 10  ^ L/mol) produced by Mpoko et al (1985) was similar to that of our T4  
monoclonal.
The success of a fusion is judged by its cloning efficiency and the maximal 
survival of hybridomas secreting specific antibodies. Cloning efficiency depends on 
the number of binucleated hybridoma produce; trinucleated or multinucleated cells do 
not give rise to continuously growing daughter cells (Ege, 1984). Therefore, even in 
successful fusions only one in every 2 0 ,0 (X) antibody-forming cells is converted into 
a functioning hybridoma that will grow in culture and continue to produce antibody. 
Furthermore, fusion should be carried out between populations of cells which have 
been synchronized in the same phase of the cell cycle in order to ensure maximal 
survival of the hybrids (Coon, 1967). Olsson and co-workers (1983) have also 
suggested that for successful hybridization, B lymphocytes should be in a certain 
stage of differentiation.
The above results show that fusion experiments carried out for the production 
of T3  and T4  monoclonal antibodies were successful in that a considerable number of 
antibody-producing cells were obtained. However, none of the antibodies produced 
were of high affinity. The reasons behind this can probably be related to the choice 
of animal donor. There have been previous reports which have shown that some 
immunogens such as human parathyroid hormone (Nussbaum et al, 1985) and Group 
A Streptococcus (Raybould and Takahashi, 1988) stimulate poor antibody response in 
m ice, and consequently high-affinity murine monoclonal antibodies can be difficult to 
obtain. A logical solution to this problem may lie in the use of other species such 
as rabbits and sheep which have been successfully used to produce high titres of 
high-affinity antibody when hyperimmunized with most immunogens, including T3  
and T4  (Ratcliffe et al, 1974; Seth et al, 1975). However, the production of a
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thriving, functional hybridoma is dependent on a close phylogenetic relationship 
between the two parent cell lines, mice and rats are so far the only species to have 
provided suitable cell lines. Thus, the main reason for the difficulty in preparing 
rabbit and bovine monoclonal antibodies is the lack of suitable myeloma parental 
cells. As no rabbit and bovine myeloma lines are readily available, murine myeloma 
cells have been mainly used in the production of rabbit and bovine monoclonal 
antibodies. Such hybridomas are easy to produce and have the same excellent in 
vitro growth characteristic as conventional mouse x mouse hybridomas. Most of 
these hybridomas, however, tend to cease immunoglobulin production due to 
preferential loss of chromosomes of the non-myeloma species or to disturbance of 
gene expression (Teng et al, 1983; Groves et al, 1987). Several reports have 
described the production of rabbit monoclonal antibodies either by fusing spleen cells 
with mouse myeloma lines or by transformation of rabbit B cells in vitro (Raybould 
and Takahashi, 1988). However, both methods proved to be unsuccessful because of 
genetic instability or difficulty in transforming rabbit B cells. The use of viruses in 
interspecies fusions have been reported (Boylston et al, 1980; Furuya et al, 1982). 
However, it was found that viral fusions suffered from low cloning efficiency and 
unstable transformed cell lines secreting small amounts of specific antibody were 
mainly produced (De Silva, 1988). In recent years the introduction of 
heteromyeloma lines which are produced by fusing human or bovine lymphocytes 
respectively with a mouse myeloma line appear to have a great impact on the 
stability of hybridomas obtained by interspecies fusions (Teng et al, 1983; Tucker et 
al, 1984). Nevertheless, unlike murine hybridomas technology, no bovine or rabbit 
fusion partners has yet been established for bovine or rabbit monoclonal antibodies.
Although hybridoma technology has now reached a level where it is possible 
to produce monoclonal antibodies against most antigens; the important fact is that it 
remains very difficult to generate monoclonal antibodies that react with weak 
immunogens (Zuckier et al, 1989). In general, weak immunogens do not have the 
ability to stimulate a large number of antibody-forming cells to proliferate and 
differentiate, therefore, they cannot produce many cells that can be used in the 
fusion process. Because the fusion process is highly inefficient and only a small 
number of antibody producing-cells secrete high-affinity antibodies, this would 
probably result in the production of relatively low affinity antibodies.
8 1
Immunization of animals for the production of Tg or polyclonal antisera 
results in the production of endogenous T3  or T4  as well as T3  or T4  antibodies 
which would limit the availability of antibody binding sites in the resultant antisera. 
Because the binding sites with the higher association constants will first be occupied, 
antisera with a majority of low avidity binding sites will be produced (Mpoko et al, 
1985). Attempts to improve such antisera have not generally been successful (Oliver 
and Cano, 1977).
The result of this study demonstrate that Balb/c mice are poor responders to 
thyroid hormones and thus low affinity monoclonal antibodies are produced. Rabbits 
(Ratcliffe et al, 1974) and sheep (Seth et al, 1975) on the other hand have been 
successfully used for the production of high affinity T3  and T4  polyclonal antisera. 
However the unavailability of established bovine or rabbit fusion partners make the 
option of producing bovine or rabbit monoclonal antibodies to T3  and T4  difficult.
8 2
CHAPTER THREE 
DEVELOPMENT OF ASSAYS
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3.1 Introduction
Radioimmunoassay was first used by Yalow and Berson in 1959 for the 
measurement of plasma insulin levels. The method depends upon competition 
between an unlabelled antigen and the same antigen, labelled with a radioactive 
isotope, in the formation of immune complexes in the presence of a limited quantity 
of specific antibody which will only bind 50% of the antigen. A variety of 
techniques are available for the separation of antibody-bound antigen from the free 
form. Since the early reports of Morgan and Lazarow (1962) and Utiger et al 
(1962), most radioimmunoassays utilized double-antibody methods to separate bound 
from the free antigen. Several workers (Peterson and Swerdloff, 1979; Chad, 1980) 
have shown that the incorporation of a small amount of ammonium sulphate or 
polyethylene glycol has many advantages in separation involving a second antibody. 
The incubation time can be shortened, the concentration of second antibody can be 
reduced and antibodies previously rejected because of their poor precipitation 
characteristic can be used successfully. Another popular method for separating 
antibody complexes from free ligand is the use of dextran-coated charcoal. This was 
originally described by Herbert et al in 1964. Dextran acts as a molecular sieve that 
allows only the smaller-molecular-weight particles (i.e. the unbound antigen) to 
penetrate into, and be absorbed by, the inner core of charcoal, whilst excluding the 
much larger antigen-antibody complex. In view of its specificity, sensitivity and 
technical simplicity, radioimmunoassay has gained widespread use especially in the 
field of endocrinology.
3.1.1 Tg Radioimmunoassay
Triiodothyronine (Tg) was first identified in blood by Gross and Pitt-Rivers in 
1952. However, its role in clinical thyroid disease was not fuUy appreciated for a 
good many years. Since 1957, several papers have documented a clinical syndrome 
characterized by thyrotoxicosis attributable to increased serum levels of Tg. The 
work of Hollander (1968) in which serum concentrations of Tg and T4  were 
measured by gas chromatographic methods was especially convincing. Sterling 
(1971) and later Wahner and Gorman (1971) reported simpler methods for estimating 
Tg in semm using competitive protein-binding assays (CPB). Although such 
methods represented considerable improvements over the techniques previously
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available such as paper chromatography (Nauman et al, 1967; Sterling et al, 1969) 
and gas chromatography (Hollander, 1968) they required prior processing of serum 
to release Tg from its binding proteins. This initial step is not only tedious and time 
consuming but also subject to artifacts (Burke and Eastman, 1974). CPB assays 
have since been replaced by specific radioimmunoassay that allows the measurement 
of thyroid hormones in unextracted serum.
Many workers have successfully introduced radioimmunoassay for Tg which 
made routine analysis of Tg in serum feasible (Gharib et al, 1970; Gharib et al, 
1972). Specific antiserum for Tg were first produced by Brown et al, in 1970. 
Antiserum used in radioimmunoassay have been successfully raised in a number of 
animals, for example, sheep (Seth et al, 1975), rabbits (Ratcliffe et al, 1974) 
guinea-pigs, (Burke and Shakespear, 1975) and goats (Chan, 1974) by immunization 
with either Tg or T4  conjugated to human or bovine semm albumin by toluene 
diisolyanate or carbodiimide procedures. The use of these antisemm in 
radioimmunoassay enabled the direct measurement of total Tg and T4  in semm. 
Because more than 99% of circulating thyroid hormones are bound to semm proteins 
such as thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA) and 
albumin, their direct measurement requires the addition of a blocking agent that 
prevent their binding to these proteins without interfering, to any major extent, with 
the antigen-antibody reaction. Various blocking agents have been employed for this 
purpose including, tetrachlorothyronine (Mitsuma et al, 1971), Merthiolate (Hiifher 
and Hesch, 1973), diphenylhydantion (Lieblich and Utiger, 1972), and salicylate 
(Larsen et al, 1973). However, 8 -anilino-l-naphthalene sulphonic acid has proven to 
be the most efficient compound for this purpose (Evans et al, 1977). These agents 
block the binding of T4  and Tg to semm proteins and therefore allow direct 
measurement of these hormones.
3.1.2 T4  Radioimmunoassay
Although T4  was first isolated by Kendall in 1915, its measurement in body 
fluids is a recent development, starting with competitive protein-binding (CPB) assay 
developed by Ekins (1960). In 1964 Murphy and Pattee reported an ingenious 
method for measuring semm T4  which for the first time did not depend on iodide 
analysis. Their method, an extension of Ekins’ studies (1960) of competitive
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protein-binding (CPB), is based on a specific property of T 4  i.e., its capacity to 
displace radioactive T4  from a complex of radio-labelled T4  and thyroxine-binding 
globulin. These methods, however, were too cumbersome for routine analysis and 
they have been superseded by specific radioimmunoassay. In general the production 
of high-affinity antibodies to T4  is difficult (Kruse, 1976). This is generally agreed 
to be due to relatively high levels of circulating T4  in the semm of animals used for 
antisera production. This result in the saturation of high-affinity binding sites on 
antibodies produced and thus antisera with a preponderance of low avidity binding 
sites. Recently monoclonal antibodies to T4  have been reported (Wang et al, 1981; 
Mpoko et al, 1985). However, the antibodies produced by Wang et al (1981) did 
not offer any advantages over existing polyclonal antisera whereas in the case of 
Mpoko et al Study (1985) the antibody produced appears to offer significant 
advantages over the polyclonal antisera tested.
3.1.3 TSH Radioimmunoassay
A large variety of bioassay methods were used for the early measurement of 
semm TSH levels. These assays, however, were time-consuming and difficult to 
perform. They also suffered from serious limitation including insensitivity and 
nonspecificity (Ridgway, 1988). TSH measurements by radioimmunoassay began in 
the early 1960s. Radioimmunoassay of TSH offered several advantages over the 
tedious bioassay methods such as good precision and the capacity of handling a 
large number of samples simultaneously. The early TSH radioimmunoassays (Odell 
et al, 1965) were able to detect TSH in 50% of euthyroid subjects and also in aU 
patients with primary hypothyroidism. The inability of these assays to distinguish 
normal from hyperthyroid subjects promoted several modifications of TSH 
radioimmunoassays to increase sensitivity (Wehmann et al, 1979; Wehmann et al, 
1985). Monoclonal antibody to human TSH was first reported by Ridgway and 
colleagues in 1982. Subsequently, other investigators produced TSH MAbs with 
improved affinities and specificities (Odell et al, 1986; Klee and Hay, 1987). These 
antibodies had a great impact on classic TSH radioimmunoassays in terms of 
sensitivity and specificity. They were also used to develop highly specific sensitive 
immunoradiometric TSH assays capable of detecting approximately 1 to 0.1|J.U 
TSH/ml, and some assays sufficiently sensitive to detect 0.05|iU/ml. The use of 
immunoradiometric TSH assays has resulted in TSH measurements approaching
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100% specificity and in 100% detection of euthyroid subjects. Immunoradiometric 
assays also enhanced the ability to distinguish between euthyroid and hyperthyroid 
patients and therefore predict normalcy from either enhanced or suppressed TSH 
secretion (Ridgway, 1988). TSH has also been measured by other methods such as 
ELISA in which polyclonal antisera (Tshikawa et al, 1982) and monoclonal antibody 
(Denyer, 1984) were employed.
The development of radioimmunoassays for the hormones involved in the 
investigation of thyroid function, have broadened the understanding of thyroid 
physiology. These advances have also led to a greater understanding of the nature 
of thyroid diseases.
The following sections describe the development of assays required to 
monitor several biological responses which may be affected by in vivo administration 
of T3  and/or T4  antibodies. In addition, a comparative study between the rate of 
binding of Tg and T4  to monoclonal and polyclonal antibodies to thyroid hormones 
was also performed.
3.2 MATERIALS AND METHODS
3.2.1 Tg and T4  Radioimmunoassay
3.2.1.1 Chemicals and Reagents 
Assay Buffer
Barbitone buffer 0.05M pH 8 . 6  was made up by dissolving 1.27g of 
barbitone (BDH) and 8.89g of sodium barbitone (BDH) in a litre of distilled water. 
This buffer containing 0.1% bovine serum albumin (BSA) (Sigma) was used in the 
assays.
Antiserum
Sheep anti-Tg serum 510/15.11.84 was obtained from Guildhay Ltd. The 
antiserum was raised against 3,3’,5 - triiodothyronine (Sigma) conjugated to BSA 
with carbodiimide (Sigma).
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Sheep anti-T^ serum HP/S/1046 supplied by Guildhay Ltd was raised against 
3,3’,5,5’ - tetraiodothyronine conjugated to bovine gamma globulin (Sigma) using 
carbodiimide.
Label
and (Amersham International pic) were diluted in assay buffer
containing 4mg/ml 8 -anüino-l-naphthalene sulphonate (ANS) (Sigma), so that lOOjil 
of this solution contained approximately 400pg of ^^I-Tg or ^^I-T^.
Rat Hormone Free Serum (RHFS)
This was prepared by mixing a pooled rat serum with dextran-coated charcoal 
(lOOg charcoal per htre serum) overnight at 4°C. The mixture was centrifuged for 
30 minutes at 3000 rpm, filtered 2-3 times and checked by radioimmunoassay (RIA) 
to ensure the stripping of T4  and Tg. One millilitre aliquots were stored at -20°C.
Standard
The preparation of Tg and T4  standards have been previously described in 
Section 2.2.8.3. RHFS was used to reconstitute Tg and T4  top standard vials 
(1 ml/vial) to give the concentrations of 16nmol/L and 480nmol/L respectively. 
These solutions were then double-diluted to give the concentrations of 8,4,2,1 and 
0.5nmol/L and 240,120,60,30 and 15nmol/L respectively.
. Second Antibody
Donkey anti-sheep D48 pool 11/12 obtained from Guildhay Ltd was used 
throughout at an initial dilution of 1:50 in assay buffer. Normal sheep serum (NSS) 
was also added at an initial dilution of 1 :1 0 0 0 .
Polyethylene Glycol Solution (PEG)
Polyethylene glycol 6000 (BDH) was dissolved in distiUed water giving a 
2 0 % solution.
Dextran-coated Charcoal
This was prepared by mixing overnight at 4°C a 2.5% suspension of Norit A 
activated charcoal (Sigma) in water which contained a 0.25% suspension of dextran 
T-70 (Sigma). The fines were removed by centrifugation and the charcoal was
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resuspended in phosphate buffer 0.05M pH 7.4, and stored at 4°C. For use, 
dextran-coated charcoal was mixed on a magnetic stirrer for 15-30 minutes at 4°C 
before addition.
3.2.1.2 Assessment of Antisera
Antibody Titre and Standard Curves
Sheep anti-Tg serum was diluted to give the following dilutions: 1:1000,
1:2000, 1:4000, 1:8000 and 1:16000 dilutions, sheep anti-T^ was diluted to give
1:500, 1:1000, 1:2000, 1:4000 and 1:8000 dilutions. Aliquots of diluted antiserum 
(100|il) and label solution (lOOpl) were incubated with lOOjil of assay buffer. In 
addition, total (T) and nonspecific binding tubes (NSB) were prepared by adding 
lOOjil of label solution to the totals, and 100|il of label solutions and 200|il of assay 
buffer to the NSBs. Second antibody (500|il) and lOOjil of 20% PEG solution were 
added to all tubes except totals, tubes were then vortex-mixed and incubated at room 
temperature for two hours. After centrifugation for 30 minutes at 3000 rpm, the 
supernatants were aspirated and radioactivity in the tubes were counted in a 
multigamma counter for 60 seconds.
As soon as antibody titre was assessed, standard curves were constructed
(Table 3.1) with and without the presence of RHFS.
Specificity
Cross-reactivity studies were carried out by preparing a series of standard 
curves. The assay protocols included one with increasing concentrations of the 
antigen (Tg or T4 ), whereas for the others increasing concentrations of possible 
cross-reactants were used. In this procedure, different concentrations of the 
cross-reactants were allowed to react with a fixed amount of antisemm (Tg or T4 ) 
and a fixed amount of labelled antigen (^^I-Tg or ^^I-T4 ). The antigen-antibody 
complex was precipitated with second antibody and PEG and pellets were counted 
for 60 seconds in a multigamma counter.
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Affinity Constant
The results collected for preparing the standard curves were used to produce 
Scatchard plots from which the affinity constants of T3  and T4  antiserum were 
calculated. For this purpose the concentration of labelled added per tube was
calculated. Bound/Free (B/F) ratios for each datum point was also calculated and 
plotted against the corresponding J antigen (labelled and unlabelled) concentration.
3.2.2 Measurement of Rat Serum Samples
In vivo experiments on unanesthetized, freely moving rats that require 
frequent blood sampling normally involve tail bleeding. As comparatively small 
volumes of blood can be collected from a rat in such experimental conditions, 
suitable T3  and T4  radioimmunoassays were developed to cope with such samples. 
In this study, lOOjil of antiserum, appropriately diluted, and 50jil of the 
radio-labelled solution were incubated with 2 0 |xl (T3  assay) or 25pi (T4  assay) of 
standard or serum samples. Second antibody (250pl) and PEG solution (50pl) were 
added, tubes were mixed and incubated for two hours at room temperature. 
Reagents were then centrifuged for 30 minutes at 3000 ipm, aspirated and the pellets 
were counted in a multigamma counter. T3  and T4  serum levels were measured in 
serum samples collected from twenty animals.
3.2.3 Measurement of Extracted Serum Samples
When samples are collected from an immunoneutralized animal they contain 
a relatively high concentration of the neutralizing antiserum. The interference of the 
antiserum used for immunoneutralization with the radioimmunoassay used to monitor 
the biological response is considered to be a serious problem. This problem was 
circumvented by extracting semm samples by an acid/ethanol procedure described by 
Daughaday et al (1980).
Extraction Method: The serum sample (200pl) was added, with thorough 
mixing, to SOOpl of a mixture of 87.5% ethanol and 12.5% 2 M hydrochloric acid 
(vol/vol) (May & Baker Laboratory products) in polystyrene tubes. After standing 
for 30 minutes at room temperature, the tubes were centrifuged at 2500 rpm for 30 
minutes at 4°C. Standing for various periods, up to 16 hours, gave similar results.
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Approximately 0.5ml of supernatant was collected and transferred to a fresh tube, 
and 0.2ml of 0.855 M Tris base (Sigma) was added and mixed. This concentration 
of Tris-base was determined by titration to neutralize the acid/ethanol extract of 
serum. After neutralization, the extracts were stored at 4°C for at least a week.
Tg and T4  radioimmunoassay were constructed to measure extracted samples 
as follows: A lOOpl aliquot of the extracted standard, control or sample was 
incubated with lOOpl of antiserum, 50pl of label solution, 500pl of second antibody 
and lOOpl of 20% PEG solution. After an incubation period of 2 hours at room 
temperature, tubes were centrifuged at 4°C for 30 minutes at 3000 rpm, aspirated 
and counted in a multigamma counter. The efficiency of the extraction was checked 
by setting up a series of tubes containing a) Tg antiserum diluted 1:2 in NRS b) T4  
antiserum diluted 1:2 in NRS c) NRS. All samples were extracted and the presence 
of the antibody was checked by incubating lOOpl of the extracts with 50pl of label. 
The extracts were also incubated in the presence of antiserum (lOOpl). The bound 
antigen-antibody was precipitated with second antibody and PEG. The pellet was 
counted in a multigamma counter.
3.2.4 Assay Validation
Recovery Studies
These studies were carried out by the measurement of rat hormone free 
serum to which different known amounts of either Tg or T4  was added. A pooled 
rat serum, which was measured previously was also used to determine the recovery 
after spiking with known amounts of Tg or T4  to give 1.5, 3, 7 and 14 nmol of Tg 
per litre and 45, 90, 170 and 380 nmol of T4  per litre. These spiked samples were 
analyzed by RIA using both small and large sample volumes. In each case the 
assay was also carried out on the neat sample as well as the organic extract.
Sensitivity
Sensitivity has been defined as the least amount of antigen that can be 
distinguished (with precision) from zero. From a series of standard curves 
constructed under similar conditions, the assay sensitivity was calculated using the
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following equation:
Assay sensitivity = 2 x Standard deviation of Bq
Where Bq is protein-bound radioactivity, as a percentage of the total, in the absence 
of added unlabelled antigen.
Intra- and Inter-assay Variations
A pooled rat serum was used in order to assess the reliability of the 
optimized assay. The intra- and inter-assay coefficient of variation were calculated 
according to the formula:
CV = ËE X 100%,
X
where SD = Standard deviation and X = mean of values.
3.2.5 Rat Thyrotrophin (TSH) Radioimmunoassay 
Reagents and Buffers 
Assay Buffer
Phosphate buffer O.OIM pH 7.4 was made up by dissolving 1.2g of Na2 HPo4  
anhydrous, 0.3g of NaH2 PO4 .2 H2 0  and 9g of NaCL in a litre of deionized water, 
0.25% of BSA was added to this buffer before use.
Rat TSH Immuno-reagents
These reagents were kindly supplied by Dr A.F. Parlow of the Department of 
the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases 
(NIADDK), Pituitary Hormones and Antisera Centre, California. These include: rat 
thyroid stimulating hormone (rTSH) antiserum (rabbit), rTSH antigen for iodination 
and rTSH reference preparation (r-TSH-RP-2) for use as cold standard.
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Preparation of rTSH Standards
The use of charcoal to strip hormones from serum results in removing small 
molecular weight hormones (e.g. Tg and T4) but not molecules with large molecular 
weight such as TSH (MW 28(X)0). RHFS, therefore cannot be used in rTSH assay. 
TSH, however, has a considerable degree of species specificity i.e., the use of rTSH 
assay may only allow the measurement of TSH in rat serum but not in serum from 
other species. TSH in bovine serum was found to be not measurable in rTSH assay 
and therefore, bovine serum was used in this assay as a source of TSH-free serum. 
The content of the r-TSH-RP-2 vial was reconstituted with 1ml distilled water. 
Aliquots of 25pi of this solution (5pg/ml) were stored at -20°C. For use each 
aliquot was diluted in bovine serum to produce the top standard (4.48mU/ml). This 
was then double diluted to give the concentrations of 2.24, 1.12, 0.56, 0.28, 0.14, 
0.07 and 0.035 mU/ml.
Second Antibody
Donkey anti-rabbit serum (Guildhay Ltd) was used at an initial dilution of 
1:16 in assay buffer containing normal rabbit serum at 1 : 2 0 0  dilution.
3.2.5.1 Iodination of rTSH
Radioimmunoassay of rTSH was performed by the chloramine-T method of 
Greenwood et al (1963). The reaction was performed in a V-shaped autoanalyzer 
cup. rTSH (20pg) was dissolved in 200pl phosphate buffer 0.5M pH 7.4, and 
placed in the cup. Chloramine-T dissolved in phosphate buffer and 0.5 mci of 
Nal^^^ were added respectively (5pg chloramine-T per Ipl of antigen). The reagents 
were mixed using a magnetic flea for 30 seconds. The reaction was stopped by the 
addition of lOOpl of sodium metabisulphite (lOOpg). The reaction mixture was 
immediately transferred to a Sphacryl S-300 column (30 x 1.5cm) equilibrated with 
0.05M phosphate buffer pH 7.4. Approximately, one hundred (0.5ml) fractions were 
collected in a fraction collector and the position of the antigen peak was determined 
by counting lOpl aliquots of each fraction in a gamma counter.
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3.2.S.2 Assay Optimization and Validation
Antibody Titre and Standard Curve
Day 1: rTSH antiserum was diluted at 1:100, 1:500, 1:1000, 1:5000 and 
1:10000. To duplicate LP3 tubes lOOpl of assay buffer, lOOpl of diluted serum and 
lOOpl of label solution (8000 cpm) were added. Total and NSB tubes were 
prepared as described before in Section 3.2.1.2. Tubes were mixed and incubated at 
room temperature overnight.
Day 2: The second antibody preparation (2(X)pl) and PEG solution (50pl) 
were added to all tubes except ’totals’. The reagents were mixed and incubated for 
two hours at room temperature. They were then centrifuged at 4°C for 30 minutes 
at 2500 rpm. Supernatants were aspirated and radioactivity in the tubes was counted 
for 1 0 0  seconds in a multigamma counter.
The standard curve was constructed using a sequential assay method (a 
disequilibrium assay). In this procedure, 200pl of unlabelled antigens (standard, 
control or sample) were pre-incubated with antiserum (lOOpl) overnight at room 
temperature. The label solution (lOOpl) was then added, tubes were mixed and 
incubated overnight at 4°C. Separation of the bound antigen-antibody was achieved 
by the addition of 200pl of second antibody and 50pl of PEG solution. Tubes were 
then incubated for two hours at room temperature, centrifuged for 30 minutes at 
2500 rpm at 4°C. Supernatants were aspirated and tubes were counted for 100 
seconds in a multigamma counter. This assay was also optimized to measure 
smaller sample volumes. In this procedure standard control and sample volumes 
were reduced to 100|il. An equilibrium assay, antiserum and label were added on 
the same day, was also set up to compare the effects of disequilibrium assay on 
sensitivity.
Recovery
Pooled rat serum spiked with known amounts of rTSH (1.0, 0.5, 0.16 and 
0.04mU of rTSH per miUitre) was used to determine the recovery.
95
Sensitivity
Data obtained from nine standard curves constructed under the same 
condition were used to calculate the assay sensitivity.
Intra- and Inter-assay Variations
The intra-assay coefficient of variation was calculated for 10 replicate 
samples of a pooled rat serum. For the inter-assay variation, a pooled rat serum 
was used with the determination repeated for nine batches of assays over a period of 
two weeks.
3.2.6 Determination of Glucose, Cholesterol and Triglyceride Levels in Rat
Serum
These measurements were carried out using a discrete centrifugal analyzer, 
Cobas Bio, ROCHE Diagnostica, Welwyn Garden City, GB.
3.2.6.1 Glucose Analysis
A glucose kit based on the use of the Hexokinase method (Mosca et al, 
1981) was obtained from ROCHE Diagnostica. Hexokinase is an enzyme that 
catalyses the phosphorylation of glucose by adenosine triphosphate (ATP) to form 
glucose-6 -phosphate and adenosine diphosphate (ADP). To follow the reaction, a 
second enzyme, glucose-6 -phosphate dehydrogenase (G-6 -PDH) is used in the 
presence of nicotinamide adenine dinucleotide (NAD), to catalyze the oxidation of 
glucose-6 -phosphate. In the process NAD is reduced to NADH in direct proportion 
to the amount of glucose originally present. The absorbance of NADH at 340nm 
provides a measure of glucose content. The reactions are as follows:
D-Glucose + ATP Hexokinase ^  D-glucose-6 -phosphate + ADP
D-Glucose-6 -phosphate + NAD^ G-6 -PDH ^
D-gluconate-6 -phosphate + NADH + H^
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3.2.6.2 Cholesterol Analysis
A cholesterol kit based on an enzymic oxidation of cholesterol (AUain et al, 
1974) was supplied by ROCHE Diagnostica. Cholesterol esters are hydrolysed by 
an esterase and ’total’ cholesterol is oxidised to a 3-oxo steroid and H2 O2 . In the 
presence of peroxidase, the hydrogen peroxide formed effects the oxidative coupling 
of phenol and 4-aminophenazone to form a red-coloured quinoneimine derivate. The 
colour intensity is proportional to the cholesterol concentration and is determined by 
monitoring the absorbance at 500nm. The reactions are as follows:
Cholesterol ester + H2 O Cholesterol esterase ^
cholesterol + fatty acids
Cholesterol + O2  Cholesterol oxidase ^
Cholestene-3-one + H2 O2
H2 O2  + 4-aminophenazone + phenol Peroxidase ^
Quinoneimine dye +2 H2 O
3.2.63 Triglyceride Analysis
A triglyceride kit based on the use of an enzymatic colorimetric method 
(EUefson and Caraway, 1982) was supplied by ROCHE Diagnostica. Triglycerides 
are hydrolysed by lipases to form glycerol, which in turn is phosphorylated and
oxidized to dihydroxyacetone phosphate. In the presence of peroxidase, the
hydrogen peroxide formed effects the oxidative coupling of 4-chIorophenol and
4-aminophenazone to form a red-coloured quinoneimine derivate. The colour 
intensity is proportional to the triglycerides concentration is determined by
monitoring the absorbance at 520run. The reactions are as follows:
Triglycerides Lipases ^ glycerol + fatty acids
Glycerol + ATP glycerol kinase ^  glycerol-3-phosphate + ADP
Glycerol-3-phosphate glvcerol phosphate oxidase ^
dihydroxyacetone phosphate + H2 O2  
H2 O2  + 4-chlorophenol + 4-aminophenazone
Peroxidase ^ quinoneimine dye + 2 H2 O
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3.2.6.4 Assay Precision and Accuracy
Quality control materials, some commercial and others obtained from St. 
Luke’s Hospital, Guildford, and a pooled rat serum were used in order to assess the 
reliability of the assays. These controls represented low, medium and high 
concentrations. The intra- and inter-assay coefficient of variation were calculated.
Quality control used:
Glucose assay: l)pooled human serum 1
2 )pooled human serum 2
3)pooled rat serum
Cholesterol assay: l)Lipid Control Serum LCS (Roche)
2)CIBA - Coming Lipids (Elevated Lipid Control) ELC
3)pooled rat semm
Triglyceride assay: l)Semm Lipid SNL (Nycomed)
2)ELC
3)pooled rat semm
3.2.7 Binding Study In Vitro
In this study the rate of binding of Tg and T4  in vitro to their corresponding 
monoclonal antibodies was investigated. The same study was also carried out with 
polyclonal antibodies. Results of these two studies were compared and those 
antisera showing the highest binding capacity chosen for immunoneutralization study 
in vivo.
3.2.7.1 Monoclonal Antibodies
Ascitic fluid containing anti-Tg (MMT3.1) or anti-T4  (MMT4.1) monoclonal 
antibodies purified by ammonium sulphate precipitation and fully characterized 
(Section 2.2.8) were used throughout this study. Equal volumes of anti-Tg or 
anti-T4  antibodies and hormone free rat semm containing 16nmol of Tg per litre or
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480nmol of T4  per litre were incubated at 37°C. The reaction was stopped at 
several time intervals (%, 1, 2 , 4, 6  and 24 hours) by the addition of cold 
dextran-coated charcoal. The mixture was further incubated for 10 minutes at 4°C 
and then centrifuged at 3000 rpm for 15 minutes. The supernatants containing 
antigen-antibody complex was collected and concentrations of Tg or T4  in the 
supernatant was measured by RIA after extraction of antibodies by an acid/ethanol 
procedure as described in Section 3.2.3.
3.2.7.2 Polyclonal Antibodies
The above method was also used in this study. Sheep anti-Tg serum
510/15.11.84 and sheep anti-T4  serum HP/S/1046 were subjected to ammonium
sulphate precipitation as described in Section 2.2.8.2. The avidity and binding 
capacity of the purified antibodies were assessed by Scatchard analysis. Tg 
antiserum was used at three different dilutions 1:100, 1:500 and 1:1000 in RHFS. 
The antiserum was used neat and diluted in RHFS at 1:5 and 1:10. The reaction 
was stopped at the following time intervals: 2, 4, 6 , 8 , 10, 15, 20, 25 and 30 
minutes.
3.3 RESULTS
3.3.1 Assessment of Antisera
Antibody Tire and Standard Curves
Sheep anti-Tg serum 510/15.11.84 and sheep anti-T4  serum HP/S/1046 were
used throughout this study. An antibody titre of 1:10000 for Tg antiserum and
1:2000 for T4  antiserum were determined (Figs. 3.1 and 3.2).
Standard curves were constructed under various conditions. They were first 
developed to measure lOOjil and 50|il serum samples in Tg and T4  assays 
respectively (Figs. 3.3 and 3.4). The assays were then modified so that smaller 
sample volumes can be measured (Figs. 3.3 and 3.4). The effects of serum on the 
assay standard curve were investigated by comparing standard curves carried out in 
assay buffer only with those performed in the presence of RHFS. The results are 
shown in Figs. 3.5 and 3.6.
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Fig.3,1 RIA antiserum dilution curve o f T 3  sheep
polyclonal Ab using neat and ammonium sulphate
purified antiserum.
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neat
ammonium sulphate purified
§
0 5 1 0 15 2 0
Antiserum dilution (xlOOO)
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Fig.3.2 RIA antiserum dilution curve o f T 4  sheep
polyclonal Ab using neat and ammonium sulphate
purified antiserum.
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Fig.3.3 RIA standard curve for Tg using sheep
polyclonal antibodies.
lOOpl assay70—
2 0 pl assay
§
10 2 050 15
Tg (nmol/L)
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Fig.3.4 RIA standard curve for T 4  using sheep
polyclonal antibodies.
25pl assay
50pl assay
§
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T4  (nmol/L)
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Fig.3.5 Effect o f serum on To RIA standard curve.
no serum 
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Fig.3.6 Effect of serum on T4  RIA standard curve.
no serum
25fjl serum
500200 300100 4000
T4  (nmol/L)
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specificity
Cross-reactivity studies revealed that T3  and T4  antiserum were highly 
specific (Table 3.2). Results of this study are shown in Figs. 3.7 and 3.8. The 
degree of cross-reaction was calculated using the method of Abraham (1969). The 
percent cross-reaction of specific antigen (Tg or T4 ) equals:
the amount of specific antigen required to displace 50% of label ^ ^QQ
the amount of cross-reacting compound required to displace 50% of label
Affinity Constant
The affinity constants of Tg and T4  polyclonal antibodies were found to be
12.5 X 10^° L/mol and 6.3 x 10  ^ L/mol respectively. The non-linear shape of the 
Scatchard plot indicated the presence of mixed populations of specific antibodies 
(Figs. 3.9 and 3.10).
3.3.2 Measurement of Tg and T4  in Rat Serum Samples
Tg and T4  levels were measured in serum from twenty rats. The Tg and T4
values obtained when lOOpl (Tg assay) or 50|il (T4  assay) sample was used showed 
very good agreement with those from assays where smaller size samples were taken. 
Normal rat serum T4  and Tg concentrations found in the present study were 
59.9±4.8nmol/L and 1.27±0.4nmol/L (mean ± SD) respectively.
3.3.3 Measurement of Tg and T4  in Extracted Serum Samples
Standard curves constructed using extracted standards are shown in Figs. 3.11 
and 3.12. Measurements of Tg and T4  in extracted normal rat serum samples (n=20)
gave satisfactory results when compared with those obtained from direct
measurements. The efficiency of the extraction method was also satisfactory; no 
binding activity was obtained when the extracts of a) Tg antiserum + NRS, b) T4  
antiserum + NRS, and c) NRS were incubate in the presence of radio-labelled 
antigen only.
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Table 3.2 Specificity of Tg and T4  Polyclonal Antibodies
Analogue
Tg Antibody T4  Antibody
Cross-Reactivitv( % ) Cross-Reactivitv( %)
3-Iodo-L-tyrosme
3,5 -Diiodo-DL-thyronine
3,5-Diiodo-L-tyrosine
3.3 ’ »5 -Triiodothyroacetic acid
3.3 ’ ,5 ’ -T riiodothyronine 
(reverse Tg)
3,3’,5,5’-Tetraiodothyronine (T4 )
3.3 ’ ,5 -Triiodothyronine(Tg)
0.2
<0.1
0.32
3.8
5.0
5.5
100
0.41
0.38
0.24
4.0
1.8
100
5.2
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Fig.3.9 Scatchard plot of Tg polyclonal antibodies.
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Fig.3.10 Scatchard plot of T 4  polyclonal antibodies.
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Fig.3.11 T 3  standard curve using extracted samples.
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Fig.3.12 T 4  standard curve using extracted samples.
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T4 (nmol/L)
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3.3.4 Assay Validation
Tables 3.3 and 3.4 summarize the results of the recovery studies. 
Comparison of results obtained by direct radioimmunoassay of serum (small and 
large sample volumes), and radioimmunoassay of T3  and T4  extracted from serum by 
an acid/ethanol method, showed excellent agreement between these three set of 
analyses. The mean percentage recovery of T3  and T4  was 94% and 95.1% 
respectively, indicating good accuracy of all procedures.
The sensitivity of the assays were calculated using 10 replicate tests of the 
zero standard. The sensitivity and the intra- and inter-assay coefficient of variation 
of the assays are presented in Tables 3.5 and 3.6. The precision and reproducibility 
of all assays were satisfactory.
3.3.5 Rat TSH Radioimmunoassay
3.3.5.1 Iodination of rTSH
The iodination of rTSH with chloramine T method resulted in the production 
of labelled product which gave a maximum binding ranging between 70 and 80%. 
The elution profile of the labelled hormone from the Sphacryl S-300 column is 
shown in Fig. 3.13. The eluate was stored at 4°C and was found to be stable for 
approximately four weeks.
3.3.5.2 Assay Optimization and Validation
Antiserum dilution curve was used to determine the titre of rTSH antiserum 
(Fig. 3.14). This was found to be 1:300, a value which conflicted with the 
recommended dilution factor of 1:10000 (final tube dilution) by NIADDK.
Characterisation studies of rTSH antiserum was carried out by NIADDK. 
These include cross-reactivity studies designed to evaluate the specificity of rTSH 
antiserum in terms of its reactivity with other glycoprotein hormones including rGH, 
rFSH, rLH and rPRL.
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Table 3.3 Recovery Studies of T3  from Rat Serum
Recovery (%)
T 3  added 
(nmol/L)
Direct Assay, 
Sample Volume 
100 III
Direct Assay, 
Sample Volume 
20 Lil
Assay C arried O ut on 
the Organic Extract 
of Samule
1.5 94 93 92
3 92 95 93
7 95 90 93
14 96 97 98
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Table 3.4 Recovery Studies of T4  from Rat Serum
Recovery (%)
T4  added 
(nmol/L)
Direct Assay, 
Sample Volume 
50 ul
Direct Assay, 
Sample Volume 
25 111
Assay Carried Out on 
the Organic Extract 
of Samnle
45 96 97 94
90 97 99 95
170 94 95 97
380 93 90 92
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Fig.3.13 Elution profile of radiolabelled rTSH 
on Sephacryl S-300 column.
700
Labelled hormone
600
500
o  400
o
9 300
Free iodine
200
100
702 0 30 40 501 0 600
Fraction number
119
Fig.3.14 rTSH antiserum dilution curve.
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Standard curves constructed using both equilibrium and disequilibrium assays 
are shown in Fig. 3.15. Greater sensitivity was obtained with disequilibrium assay 
system (8.75|iU/ml compared with 15.6|iU/ml) for the equilibrium assay. The use of 
disequilibrium assay also allowed the measurement of smaller serum volumes 
(100|ll1), without affecting the assay sensitivity. The intra- and inter-assay coefficient 
of variation were 2.7% and 5.3% respectively. The recovery studies showed 
satisfactory results, the mean recovery of exogenous rTSH being >90% in all assays 
(Table 3.7).
3.3.6 Determination of Glucose, Cholesterol and Triglyceride Levels in Rat 
Serum
The measurement of glucose, cholesterol and triglyceride m rat serum using 
Roche reagent kits and the Cobas Bio Analyzer were very simple, fast and required 
a very small sample volume. The precision of the assays expressed as the intra- and 
inter-assay coefficient of variation were calculated using commercial quality controls, 
pooled human sera as well as a pooled rat serum. The results obtained are 
presented in Table 3.8.
3.3.7 Binding Study In Vitro
3.3.7.1 Monoclonal Antibodies
Purified ascitic fluid containing T3  or T4  monoclonal antibodies incubated at 
37°C with T3  or T4  showed no significant binding during a period of incubation 
exceeded 24 hours. The experiment was repeated using crude ascites fluid 
preparation. The results obtained from this study have shown an increased 
percentage of binding of T3  and T4  to their corresponding antibodies reaching up to 
17.5% and 50% respectively after a long period of incubation, approximately 24 
hours (Table 3.9).
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Fig.3.15 Standard curves for rTSH.
equilibrium assay 
disequilibrium assay
30-=-
51 2 3 40
rTSH (mU/ml)
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Table 3.7 Recovery Studies of rTSH from Rat Serum
Recovery (%)
200jil Sample lOOpl Sample
rTSH added (mU/ml) Volume Assav Volume Assav
0.04 96 95
0.16 99 96
0.5 90 92
1.0 92 94
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Table 3.9 Study of the binding of T3  and T4  with T3  (MMT3.1) and T4
(MMT4.1) monoclonal antibodies in vitro
Time (hour) Binding of T3  (%) Binding of T4  (%)
V2  8.4 22.7
1 8.75 27.5
2 9.1 28.75
4 14.5 35.00
6 16.5 43.75
24 17.5 50.00
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3 3 ,1.2 Polyclonal Antibodies
The recovery of Tg and T4  antiserum in the ammonium sulphate precipitate 
preparations was assessed by constructing antiserum dilution curves. These curves 
were compared with those obtained for the neat antiserum in which they were found 
to be almost superimposed, indicating complete recovery of the antibodies in the 
purified preparation (Figs. 3.1 and 3.2). In addition, the supernatant obtained after 
the ammonium sulphate precipitation was also checked by incubating a serial 
dilutions of the supernatant with label solution in which no significant binding was 
shown. In vitro studies were carried out with three different dilutions of purified Tg 
antiserum 1:100, 1:500 and 1:1000. The percentage binding of the total Tg added 
(16nmol/L) was 100%, 90% and 67.1% respectively. Complete binding was only 
achieved by antiserum diluted 1:100 (Fig. 3.16).
Purified T4  antiserum used neat and diluted at 1:5 and 1:10 bound 100%, 
72% and 32% of the total T4  added (480nmol/L) in which complete binding was 
only accomplished by neat antiserum (Fig. 3.17).
3.4 DISCUSSION
In vivo experiments in rats that would require frequent sampling of blood 
and measurement of hormones by radioimmunoassay have one obvious limitation, 
that is the quantity of blood collected at any one time point is limited as would be 
the number of hormones measured. In the present study, the development, 
optimization and validation of radioimmunoassays that allow the measurement of Tg, 
T4  and TSH in small serum volume had minimized this problem. Data from these 
assays show precision to be well within acceptable immunoassay standard, with an 
intra- and inter-assay coefficient of variations of less than 5% and 15% respectively. 
These assays were sensitive enough to measure 0.5nmol Tg/L, 2 .4 nmolT4  /L and 
8.75|iU TSH/ml.
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Another problem that has been associated with passive immunoneutralization 
is when the antiserum used for immunoneutralization recognize (cross-react) with 
antigenic determinants on the radioimmunoassay reagents, particularly tracer 
preparation. In view of this problem a simplified, rapid acid/ethanol method was 
used to extract serum samples. The performance of the radioimmunoassays
constructed to measure extracted serum samples was compared with that of the direct 
radioimmunoassay. These two sets of results were in excellent agreement. 
Incorporation of an additional step of organic solvent extraction, removed the 
interference, from the antibodies present in the rat serum specimens, with the 
radioimmunoassay. For both T3  and T ,^ these modified assay procedures were found 
to meet the required standards of accuracy and precision.
Glucose, cholesterol and triglycerides were also measured in rat serum 
samples. The use of the Cobas Bio analyzer along with Roche Diagnostica
commercial kits allowed rapid and accurate measurement of these parameters. Data 
obtained from the analysis of commercially available lyophilized quality controls, 
pooled human and rat serum have shown good within-batch and between-batch 
precisions. The properties of this system: speed of analysis, simplicity of procedure, 
small sample volume requirement and the possibility of analyzing several hundred 
samples per day, have made it a useful adjunct to immunoneutralization studies.
Over the years, it has become firmly established that passive 
immunoneutralization requires a reasonably large quantity of high-titre antiserum 
(Tan et al, 1985; Groves et al, 1987). The production and characterization of
monoclonal antibodies to Tg and T4  (Section 2.2.8) were carried out in order to fulfil 
this requirement. However, the assessment studies on Tg monoclonal antibody 
(MMT3.1) and T4  monoclonal antibody (MMT4.1) have shown that both antibodies 
have low affinity constant of 11.0 x 10  ^ L/mol and 3.8 x 10  ^ L/mol
respectively. In addition, the results of the in vitro binding studies revealed that Tg 
and T4  MAbs exhibit low binding capacities since less than 50% binding was 
achieved after a long incubation period.
Since in vivo experiments require the use of high affinity antibodies to 
ensure complete neutralization and a high binding capacity at 37°C to avoid infusing 
excessively large volumes (Barling and Beloff-Chain, 1973; Tan et al, 1985), the Tg
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and T4  MAbs produced do not quite fulfil these requirement and thus are inadequate 
for this purpose.
On the other hand, polyclonal antibodies raised against Tg and T4  in sheep 
have proven to be of relatively high affinity with an association constant of 12.5 x 
10^ ® L/mol and 6.3 x 10  ^ L/mol respectively. In terms of specificity, both antisera 
showed no significant cross-reactivity with any of the thyroid hormone-analogues 
used in this study. In addition, the ability of these antibodies to neutralize thyroid 
hormones was shown by the results obtained from the in vitro binding studies in 
which complete binding was achieved within 2 minutes. In view of their binding 
capacity demonstrated by the results obtained from the in vitro studies and their 
avidity as determined by Scatchard analysis, the polyclonal antibodies used in this 
study appear to be adequate for the purpose of producing complete or virtually 
complete immunoneutralization.
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CHAPTER FOUR
PASSIVE IMMUNONEUTRALIZATION STUDIES
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4.1 Introduction
4.1.1 Immunoneutralization
During the last 30 years, immunoneutralization has become established as an 
important tool for studying the regulation of hormone secretion (CuUer and 
Negro-Villar, 1989). Immunoneutralization, designed, for example, with respect to 
an endogenous substance, should provide an effective way of probing into the 
physiological and biochemical function(s) of that substance, its interactions with 
other components and its response to various internal and external stimuli. 
Immunoneutralization can either be active where an animal is sensitized to produce 
antibodies against an endogenous factor (Joseph et al, 1987) or passive in which an 
antibody prepared in one animal is used to neutralize a specific factor in another 
(Taya and Sasamoto, 1988).
In contrast to active immunoneutralization, passive immunoneutralization 
offers several distinct advantages. These advantages include fuU characterisation and 
standardisation of the antiserum (Chretien et al, 1989), rapid elimination of the 
endogenous factor as well as controlling the onset of neutralization (Games et al, 
1989) and gradual removal of neutralization effect from the circulation (Clayton et 
al, 1990).
Despite the fact that passive immunoneutralization is one of the most 
important and useful approaches for removing an endogenous factor, it is not without 
its problems. In most studies employing passive immunoneutralization, large 
quantities of high-titre antibody is required to demonstrate complete neutralization, in 
other words, to prevent the endogenous substance from interacting with its biological 
receptors (Kaji et al, 1985). Another significant problem is that not aU antisera with 
high titre are usable for immunoneutralization (Fink et al, 1987). The reason behind 
that is still unclear. However, several possible explanations have been suggested 
(Culler and Negro-Vilar, 1989). In practice, the properties of antibodies (the binding 
capacity and avidity) can be mistakenly assessed by their titre, which is in most 
cases considered to be a good indicator of the antibody affinities. Nevertheless, 
some antibodies with high titre exhibit low affinities for the antigen which would 
favour the binding of circulating antigen to its biological receptors rather than to the
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antibody. On the other hand, antibodies can have high affinities for the antigen but 
they bind to it is such a way without blocking its active portion which allow the 
antigen to interact with its receptors. Another possible reason why certain antisera 
work poorly for immunoneutralization is the use of antiserum in which large 
amounts of the factor meant to be neutralized is present. This may occur when the 
antigen used to immunize the donor animal for the production of antiserum resemble 
the donor animal’s own endogenous factor. This would lead to antibody saturation 
as well as increased secretion of the factor itself to replace the deficiency which 
counteract the immunoneutralization properties of the antibodies. The production of 
anti-idiotypic antibodies is another possible interfering factor since they have the 
ability to bind to the antibody binding sites and prevent them from binding with 
their antigenic determinants.
When employing passive immunoneutralization, the presence of the antibody 
used for neutralization in high concentration in the sample collected is another major 
problem which should be dealt with in order to avoid a serious problem of 
interfering with immunoassays used to measure the required parameters (Tan et al, 
1985).
Since the early in vitro studies involving neutralization of endogenous insulin 
using insulin antiserum (Armin et al, 1960), immunoneutralization has become 
widely employed for studying the physiological regulation of hormone secretion. 
Antiserum to other pancreatic hormones such as glucagon (Tan et al, 1985), 
somatostatin (Seal et al, 1988) and pancreatic polypeptide (Fink et al, 1987) have 
been used to produce hormones deficiencies in order to study their physiological 
function and significance. These studies have proved to be most useful in defining 
the physiological role of pancreatic secretion.
In recent years, passive immunoneutralization technique has greatly facilitated 
our ability to study the basal and pulsatile secretion of the anterior pituitary 
hormones (Taya and Sasamoto, 1988; Culler and Negro-Vilar, 1989). Most studies 
have dealt with the hypothalamic factors that regulate the pituitary and the 
contribution of these factors to the secretion of hormones by the anterior pituitary. 
These studies included investigations related to the anterior pituitary hormones such 
as FSH, LH, GH, prolactin and ACTH.
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The hypothalamic-pituitary-gonadal axis is another major field in which the 
contribution of passive immunoneutralization technique has been of great value 
(Smith and Lee, 1989; Sanford, 1989). Several studies were reported in the 
literature where the effects of passive immunoneutralization of a number of gonadal 
steroid hormones were studied. The focus of a number of experiments (Morris et al, 
1988; Clayton et al, 1990) has been on the use of antisera to gonadal steroids in 
order to increase the ovulation rate and thus improve fecundity in the sheep and 
cattle.
Despite more than 30 years of study the precise roles played by the thyroid 
hormones are not fully understood. The effects of thyroid hormone excess and 
deficiencies on the body as a whole manifested in hyper- and hypo-thyroidism have 
been known for many years. Thus, it has been established over the years that 
thyroid hormones have profound effects on glucose homeostasis (Müller and Seitz, 
1984a) and lipid metabolism (Heimberg et al, 1985). They also have a role in the 
control of growth and development (Mattila et al, 1987). Although a number of 
effects of thyroid hormone on specific metabolic processes have been demonstrated, 
a unifying concept of the mechanism by which it produces acceleration of 
metabolism is not yet apparent. In several reports, studying of the physiological role 
of thyroid hormones have involved in vivo administration of exogenous hormones. 
In some of these studies thyroid hormones were administered as bolus injections 
(Silva and Larsen, 1977; Tonooka and Greer, 1980) which lead to transiently high 
concentrations of these hormones, whereas in other studies, euthyroid or 
experimentally hypothyroid animals (for example, thyroidectomized animals) were 
treated with a continuous infusion of thyroid hormones (Connors and Hedge et al, 
1981; Franklyn et al, 1988; Jones et al, 1988). Although a considerable amount of 
knowledge has been gained from these studies, further work remain to be done so 
that the role of thyroid hormones becomes more fully understood.
Active immunoneutralization approach has been employed in a limited 
number of studies (Nieschlag et al, 1973; Herrmann et al, 1975; Joseph et al, 1987). 
In these studies, investigations were carried out to study various parameters of 
thyroid function and serum TSH levels in animals immunized to produce antibodies 
against T4  and T3 . On the other hand, passive immunoneutralization techniques has 
been mainly used to study the physiological function of the hypothalamic peptide
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TRH (Strbak et al, 1986) and its role in the control of TSH secretion. Despite the 
considerable amount of knowledge gained from employing passive 
immunoneutralization to study the physiological roles of various hormone secretion, 
this experimental approach does not seem to have been applied to the field of 
thyroid hormones.
4.1.2 Glucose Metabolism in Altered Thyroid States
The exact mechanism of the action of thyroid hormones on glucose 
homeostasis is still unclear and yet to be elucidated. Thyroid hormones are known 
to increase glucose production and glucose utilization (Laville et al, 1984; 
Dimitriadis et al, 1985). Abnormalities of glucose tolerance are well recognised in 
hyperthyroidism, occurring in as many as 44-57% of hyperthyroid patients (MiiUer 
and Seitz, 1984a; Suthijumroon et al, 1988), with diabetes being present in only 3%. 
In this respect, several metabolic defects that occur in hyperthyroidism and
hypothyroidism are of interest. In hyperthyroidism, fasting plasma glucose levels are 
increased while in hypothyroidism it was significantly decreased. In clinical
hyperthyroidism or in thyroxine-treated animals, glucose oxidation by glycolytic 
pathway, glucose utilization and glucose turnover rate increased markedly while the 
reverse effects were observed in hypothyroid subjects (Okajima and Michio, 1979).
Thyroid hormones are generally considered to antagonize the action of insulin 
(Millier and Seitz, 1984a). There is an increased coincidence of insulin dependent 
diabetes mellitus and thyroid disease (Riley et al, 1981). Human hyperthyroidism
may be associated with hyperglycaemia with or without hyperinsulinemia, decreased
carbohydrate tolerance and enhanced risk of diabetic ketoacidosis (Miiller and Seitz, 
1984a; McKenzie et al, 1987). Thyrotoxicosis has been reported to induce hepatic 
and/or peripheral insulin resistance (Laville et al, 1984; Dimitriadis et al, 1985). By 
contrast other authors showed an increased hepatic insulin sensitivity in 
hyperthyroidism (Müller et al, 1986). More recently attention has shifted to the 
study of insulin receptors. Clinical or experimental hyperthyroidism increased, 
decreased or did not affect insulin receptor number, and it enhanced, did not change, 
or reduced the affinity of insulin receptor in different cell types (MüUer et al, 1986).
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Although a considerable amount of work on the effects of thyroid hormone 
on insulin action and glucose metabolism has been done, their underlying 
mechanisms are far from clear and further studies are still required.
4.13 Lipid Metabolism in Altered Thyroid States
Alterations in thyroid status result in changes in plasma concentrations of 
triglyceride (TG) and cholesterol and in the metabolism of plasma lipids and
lipoproteins.
Serum free fatty acid (FFA) concentration and turnover is increased in 
hyperthyroidism while hypothyroidism is accompanied by a normal or slightly
reduced content and turnover of FFA (Miiller and Seitz, 1984b). The increase in the 
turnover of FFA was accompanied by increased oxygen consumption in hyperthyroid 
patients, while the normal turnover in hypothyroidism was associated with decreased 
oxygen consumption. The increase of FFA turnover was also accompanied by
increased ketogenesis and C0 2  production and frequent elevation in the concentration 
of serum ketone bodies in hyperthyroid patients, without any changes reported in the 
hypothyroid state (Heimberg et al, 1985).
The relationship of plasma TG concentration to thyroid status is extremely 
variable. Plasma TG concentration may be normal, reduced or increased in 
hypothyroidism. However, a majority of investigators observed that the plasma 
concentration of TG was elevated in the hypothyroid state, particularly in
myxoedema. Similar discrepancies were observed for the hyperthyroid state also: 
unchanged, reduced and slightly raised plasma TG values being reported (Miiller and 
Seitz, 1984b). The plasma TG concentrations clearly is the net result of several 
metabolic processes, including absorption of dietary fat (chylomicrons), endogenous 
synthesis of the VLDL by the liver and secretion into plasma and clearance of 
chylomicrons and VLDL from the plasma. Chylomicron clearance rate is unchanged 
in hypothyroid normotriglyceridaemic patients, whereas it is reduced in 
hypothyroidism accompanied by elevated TG levels (Abrams et al, 1981). The 
effects of altered thyroid status on synthesis of TG in vivo has been examined in 
humans (Sandhoefer et al, 1966; Nikkila and Kikki, 1972; Abrams et al, 1981) and 
laboratory animals (Dory et al, 1981; Dory and Roheim, 1981). However, the data
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obtained from these studies look conflicting. Sandhoefer et al (1966) suggested that 
the synthesis of plasma TG by hyperthyroid patients was reduced compared with the 
euthyroid subjects. Contrary to this observation, the report of Nikkila and Kekki 
(1972) indicating that the transport of TG per unit time (i.e. production rate) was 
elevated in the hyperthyroid, but was not altered in hypothyroid patients.
Alterations in thyroid status result in changes in plasma concentrations of 
cholesterol. Hypothyroidism is often associated with hypercholesterolemia, both in 
man and animal species and hyperthyroidism with hypocholesterolemia (Abrams and 
Gmndy, 1981). Hypercholesterolemia associated with hypothyroidism is due partly 
to increased plasma LDL and partly to increased HDL cholesterol concentrations. 
The increase in LDL cholesterol has been shown to be secondary to reduced plasma 
clearance of LDL (Gross et al, 1987). Hyperthyroidism, by contrast, reveals reduced 
LDL cholesterol levels (Abrams and Grundy, 1981). Conflicting data were reported 
for plasma high density lipoprotein (HDL) in hyperthyroidism. Lithell et al (1981) 
found no change of plasma HDL-cholesterol level in hyperthyroid patients, whereas 
according to Abrams and Grundy (1981) it was lowered.
From the above review, it is clear that the relationship between thyroid status 
and lipid disposition is far from clear and requires further studies.
In the present study, the effects of short term and long term administration of 
T3  and/or T4  antiserum on serum T3 , T4  and TSH levels as well as on basal glucose, 
cholesterol and triglyceride concentrations have been investigated. The study was 
also extended to the histological examination of various tissues from animal which 
had received long-term treatment with thyroid antisera.
4.2 MATERIALS AND METHODS
4.2.1 Experimental Procedures
Animals
Adult male rats of the Wistar strain weighing 120-170g (supplied by the 
Experimental Biology Unit, University of Surrey, Guildford) were maintained under 
controlled conditions of temperature (21°C ± 2), lighting (lights on from 8.00 to
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17.00 hours) and free access to food and water (standard laboratory chow and tap 
water). Rats were housed, six to a cage, under these conditions for at least one 
week prior to use.
Antisera
Sheep anti-Tg serum (510) Batch No. 15.11.84 with a titre of 1:10000 and
sheep anti-T^ serum Batch No. HP/S/1046 with a titre of 1:2000 were used
throughout these studies. Serum from non-immunized sheep (NSS) was used as a 
control. All reagents used were partially purified by an ammonium sulphate
precipitation as described before (Section 2.2.8.2). Characterisation of the antibodies 
has been previously described in detail in Section 3.2.1.2.
Experiments
Rats were divided into five groups, each group containing six animals. All 
experiments were performed between 10.00 and 17.00 hours.
4.2.1.1 Short-term Administration of Antibodies
In the first series of experiments, five groups of rats were injected
intraperitonreally (ip) with: Group (A) 0.5ml Tg antibodies (Tg-Ab), Group (B) 0.5ml 
T4  antibodies (T4 ~Ab), Group (C) 0.5ml of normal sheep serum (NSS) as a control 
for Groups A and B, Group (D) combination of Tg-Ab (0.5ml) and T4 -Ab (0.5ml) 
and Group (E) 1.0ml NSS as a control for Group D.
Individual 0.5ml blood samples were collected from the tail vein 30 minutes 
prior to injection and then at V2 » 1, 2, 4, 6  hour post-injection on the first day and 
at 11.00 hours daily on days 2-5. Blood was collected into polyethylene microfuge 
tubes and serum obtained after centrifugation for 2 minutes at approximately 900g 
using a microfuge (Type B, Beckman Ltd., High Wycombe) was stored at -20°C 
until assay.
4.2.1.2 Long-term Administration of Antibodies
In the second series of experiments, animals received one weekly ip injection 
of the antibodies as in the Short-term study for a period of six weeks.
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Blood samples (0.5ml) were collected one day before every injection from 
the tail vein. One week after the last injection (i.e. after 42 days of treatment), the 
animals were given Sodium Pentobarbitone (Iml/kg body weight; Sagatal, 6 Gmg/ml, 
May and Baker Ltd., England) and blood samples were collected by cardiac
puncture. Serum was separated by centrifugation and stored frozen at -20°C until
assay. The brain, pituitaries, thyroid, liver, kidneys and pancreas were removed and 
fixed in 1 0 % neutral buffered formalin for at least one week before processing.
4.2.2 Analytical Procedures
To avoid interassay variation, semm samples from animals of the one
experiment were analyzed in the same run.
4.2.2.1 Tg and T4  Antibodies Concentrations Following Administration of
Antibodies
Serum samples obtained at different time intervals after ip administration of 
(1) Tg antibodies, (2) T4  antibodies, or (3) Tg and T4  antibodies were serially diluted 
as follows: (1) 1:5, 1;10, 1:50 and 1:100 (2) 1:2, 1:4, 1:8 and 1:16 (3) 1:5, 1:10, 
1:50 and 1:100. They were assessed for titre and percentage binding of unbound 
antibodies by incubating lOOjil of diluted samples with 1 0 0 |xl of either ^^ I^-Tg or 
^^ I^-T4 . Reagent preparations and assay procedure were described previously in 
detail in Sections 3.2.1.1 and 3.2.1.2.
4.2.2.2 Measurement of Tg and T4  in Rat Serum
Serum samples collected at various times after administration of antibodies or 
NSS were analyzed in duplicate by double-antibody radioimmunoassays. Because of 
the interference of infused antibodies with the radioimmunoassays, serum samples 
withdrawn from rats treated with antibodies were first extracted by an acid/ethanol 
method (Section 3.2.3). The extracts were then assayed by procedures developed for 
extracted serum samples (Section 3.2.3). Serum samples from control rats were 
treated similarly.
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4.2.2.3 Measurement of TSH in Rat Serum
Rat TSH levels in unextracted serum were measured by double-antibody 
radioimmunoassay using the reagents provided by the NIADDK. Details of the 
reagents and procedure were described previously in Section 3.2.5. 
Radioimmunoassay developed for smaller serum volume (100|il) was used and the 
results were expressed in terms of the NIADDK standard preparation.
4.2.2.4 Measurement of Glucose, Cholesterol and Triglycerides in Rat Serum
Serum concentrations of glucose, cholesterol and triglyceride were determined 
using the Cobas Bio Analyzer and reagent kits supplied by Roche. All samples 
were analyzed in duplicate and quality controls were included in every run. Details 
of the methods were described in Section 3.2.6.
4.2.3 Statistical Analysis
All results were expressed as mean ± SEM. Statistical differences in the 
results were determined using a two tailed student’s t test for paired data. A value 
of P<0.05 was considered significant.
4.2.4 Processing and Sectioning of Tissues
Paraffin Section Technique: This was carried out according to the routine 
histological procedure. Tissue was fixed, dehydrated in graded alcohols, cleared in 
xylol, chloroform or other solvents which is miscible with both alcohol and wax and 
finally embedded in paraffin wax.
A piece of tissue, 2-3mm in thickness, was cut fi*om each sample and placed 
in a metal processing container. The containers were placed in a tissue basket 
which was then fitted to the Histokinette automatic tissue processor (British 
American Optical Co. Ltd., Slough). Tissues were transferred automatically from 
one beaker to the next on a two hour schedule through increasing concentrations of 
alcohol (70%, 85% and 95%), then into absolute alcohol, followed by clearing in 
toluene and finally impregnation with paraffin wax.
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After this process the tissue containers were transferred to a third wax bath 
from which the tissue was blocked out. Sections were cut from the blocks at a 
thickness of 5|i using a LKB Historange, Sweden. They were then mounted on 
slides and placed initially on a drying hotplate and then left in an incubator at a 
temperature of 37°C overnight to dry.
. Sections were stained with haematoxylin and eosin (BDH) as follows: 
Sections were dewaxed through Xylene (3 minutes) and a series of ethanols graded 
100%, 70% and 50% to water. Sections were then stained in Ehrlich’s acid 
haematoxylin (15 minutes), blued in tap water (5 minutes), differentiated in 1% acid 
alcohol (1% hydrochloric acid in 70% alcohol) for 5 seconds and returned to tap 
water (15 minutes). After 1-2 minutes in tap water, sections were examined under a 
low power microscope to ensure that they were sufficiently differentiated. They 
were then counterstained in 1 % aqueous eosin for 2  minutes, briefly differentiated in 
tap water (30 seconds), dehydrated through increasing concentrations of alcohol, 
cleared in xylene and mounted directly under coverslip using DPX (BDH).
4.3 RESULTS
4.3.1 T3  and T4  Antibodies Concentrations Following Intraperitoneal
Administration of Antibodies
In the first series of experiments, rats were treated with a single dose (0.5ml) 
of Tg and/or T4  antibodies. Maximum binding to was observed within 30
minutes in groups treated with Tg-Ab (A and D) by which time percentage binding 
to was 100% (Fig. 4.1). T3  antibody titre in the serum of recipient animals
was approximately 1:50 throughout the time of study.
In groups B and D, T4  antibodies were present in excess at aU time points
fi-om 60 minutes onward in which the percentage binding to ^^^I-T4  was 1 0 0 % of
total counts (Fig. 4.2). T4  antibody titre remained at around 1:10 throughout the
period of study. In the second series of experiment, rats received injections of Tg 
and/or T4  antibodies at weekly intervals for six weeks; this resulted in the presence 
of excess antibodies throughout the study. Serum samples collected seven days after 
every injection showed a binding capacity of 70% to ^^ I^-Tg and/or ^^I-T4
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Fig.4.1 Serum anti-Tg levels following administration
o f a single dose of Tg antibodies.
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Fig.4.2 Serum anti-T^ levels following administration
of a single dose of antibodies.
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(Figs. 4.3-4.5). The T3  and T4  antibody titre were approximately 1:50 and 1:10 
respectively.
4.3.2 Measurement of T3  and T4  in Rat Serum
Tables 4.1 and 4.2 show the serum concentrations of thyroid hormones in the 
Tg-Ab, T^-Ab and combined Tg-Ab and T^-Ab treated animals as compared to 
control rats. Mean changes in serum T3 and T4  in all animals are plotted over 96 
hours in Figs. 4.6-4.8 Tg and T4  concentrations did not change during the 96 hour 
study period in control rats (Groups C and E). Administration of Tg-Ab (Group A) 
resulted in a gradual rise in serum Tg from basal levels of 1.38 ± 0.12nmol/L to 
peak values of 7.87 ± 0.71nmol/L, mean ± SEM, at 48 hours (P<0.(X)1). Semm T4  
levels rose rapidly from 56.1 ± 1.2nmol/L to 91.2 ± 8.4nmol/L by 6  hours 
(P<0.001), followed by a retum, over 72 hours to 56.1 ± 3.0nmol/L, which were 
close to the values found in the control animals (60.9 ± 2.8nmol/L).
Administration of T4 -Ab (Group B) resulted in a gradual increase in serum 
T4  levels attaining a peak at 24 hours (88.0 ± 6.1nmol/L, P<0.01) compared with 
control animals (57.2 ± 6.2nmol/L). Thereafter, serum concentrations of T4  
decreased gradually to control levels 72 hours later (64.5 ± 4.5nmol/L vs 58.2 ± 
3.0nmol/L). The increase in serum T4  levels was correlated with a rise in serum Tg 
concentrations. One hour after injection of T4 -Ab, serum concentrations of Tg were 
significantly increased (3.65 ± 0.65nmol/L, P<0.05) compared with controls (1.3 ± 
0.12nmol/L). Levels of Tg increased further during the next 24 hours (24 hour :
12.4 ± 0.37nmol/L, P<0.001) and returned to control levels 96 hours later.
The ip injection of 0.5ml Tg-Ab and 0.5ml T4 ~Ab (Group D) caused a 
marked increase in serum Tg and T4  levels. A prompt elevation in serum T4  levels 
was apparent within 30 minutes (97.5 ± 4.7nmol/L, P<0.001), compared with 
concentrations at zero time (60.0 ± 4.2nmol/L). The T4  values peaked at 24 hours 
after administration of antibodies (176 ± 9.4nmol/L, P<0.001). This increase in 
serum T4  levels then followed by an abrupt decline. Serum Tg concentrations rose 
progressively from 1.3 ± O.lnmol/L before antibodies administration to 24.18 ± 
l.lnmol/L (P<0.001) 6  hours later and remained significantly elevated during the 
remainder of this study compared with control animals.
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Fig.4.3 Serum anti-Tg levels following long term
administration of Tg antibodies.
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Fig.4.4 Serum anti-T^ levels following long term
administration of antibodies.
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Fig.4.5 Serum anti-Tg and anti-T^ levels after long 
term  administration of Tg and T 4  polyclonal antibodies.
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In rats treated with weekly injections of 0.5 or 1.0ml NSS, concentrations of 
serum T3  and T4  showed no significant change (Tables 4.3 and 4.4). Although high 
levels of circulating T3  and/or T4  antibodies were sustained throughout the time 
period of this study (Figs. 4.3-4.5), long-term administration of T3  and/or T4  
antibodies did not cause any measurable disturbance in serum T3  and T4  
concentrations in any of the experimental groups A, B and D (Figs. 4.9-4.11).
4.3.3 Measurement of TSH in Rat Serum
The concentration of serum TSH (Table 4.5) did not change during the 96 
hour study period after treating the rats with a single dose of T3  and/or T4  
antibodies, compared with those of NSS-treated control rats (Fig. 4.12).
Similarly, weekly injections of T3  and/or T4  antibodies, did not alter basal 
serum TSH levels [43.8jiU/ml (n = 6 )] (Fig. 4.13). As was the case with single 
dose treatment, serum TSH concentrations remained at basal levels throughout the 
study (Table 4.6).
4.3.4 Measurements of Glucose, Cholesterol and Triglycerides in Rat Serum
The serum glucose, cholesterol and triglyceride levels in rats treated with a 
single dose of antibodies are summarised in Tables 4.7, 4.8 and 4.9. Results 
obtained are also shown in Figs. 4.14-4.16. Administration of NSS caused no 
significant changes in serum glucose, cholesterol and triglyceride concentrations 
throughout the duration of the experiment.
T3 -Ab treated rats (Group A): The ip injection of 0.5ml T3  antibodies caused 
a marked increase in serum glucose levels. Serum glucose levels increased within 
one hour of antibodies injection from 4.47 ± 0.21mmol/L to 5.41 ± 0.38mmol/L 
(P<0.05) and remained significantly elevated for 96 hours. Concentrations of serum 
cholesterol did not change during the 96 hours study period compared with control 
animals, values ranging from 1.42 ± 0.05mmol/L to 1.65 ± 0.07mmol/L compared 
with 1.37 ± 0.06mmol/L to 1.56 ± 0.09mmol/L. Concentrations of triglycerides, on 
the other hand, were significantly lower than those in control rats, reaching a nadir 
between 6  hours and 24 hours (P<0.05).
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T4 ~Ab treated rats (Group B): The levels of glucose in serum following 
T^-Ab administration were significantly higher than those after NSS treatment. This 
increase was observed within 1 hour of antibodies administration (5.78 ± 
0.17mmol/L, P<0.05) and high levels were sustained throughout the study. The ip 
injection of T^-Ab caused a significant decrease in triglyceride levels but no 
significant change in serum cholesterol was observed. Serum triglyceride levels 
decreased within 1  hour of antibodies injection, and remained significantly low for 
the next 96 hours (P<0.05).
T3 - and T^-Ab treated rats (Group D): In this study, injection of T3  and T4  
antibodies together caused a significant increase in semm glucose levels compared 
with control levels (Group B). Glucose concentrations increased 4 hours after 
antibodies administration (5.59 ± 0.23mmol/L, P<0.05) and remained elevated for 96 
hours. In comparison with control animals, serum cholesterol levels did not change 
during the 96 hours study period, whereas serum triglyceride levels decreased 30 
minutes after administration of antibodies from 1.36 ± 0.14mmol/L to 1.0 ± 
0.08mmol/L (P<0.05). The decline in semm triglyceride concentrations was 
observed until 72 hours after treatment.
In rats treated with weekly injections of 0.5ml of T3  and/or T4  antibodies, 
glucose, cholesterol and triglyceride concentrations in semm did not differ from 
those in control rats (Tables 4.10, 4.11 and 4.12). Results are also shown in Figs. 
4.17-4.19. The mean semm glucose concentration in aU groups (A, B, C, D and E), 
before antibodies treatment, ranged between 4.47 ± 0.21mmol/L to 5.0 ± O.13mmol/L 
compared with 4.3 ± O.23mmol/L - 5.2 ± 0.23mmol/L after antibodies treatment. 
Compared with the control values (1.29 ± 1.3mmol/L - 1.52 ± 0.09mmol/L), semm 
cholesterol levels in aU experimental groups ranged between 1.28 ± 0.09mmol/L and 
1.59 ± 0.12mmol/L. Semm triglyceride levels in antibody-treated rats ranged 
between 1.22 ± 0.05mmol/L and 1.55 ± 0.09mmol/L in comparison with 1.19 ± 
0.03mmol/L and 1.53 ± 0.09mmol/L found in the NSS treated rats.
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4.3.5 Histological Examination of Tissues after Treatment with Thyroid
Hormone Antibodies
At dissection, all organs removed from and/or T4  antibodies treated rats, 
showed normal appearance in comparison with control animals. Microscopic 
examination of sections showed no abnormalities and no morphological changes. 
Sections of the thyroids of the T3 - and T^-Ab treated animals showed no signs of 
greater thyroid activity compared with those of NSS treated rats (Figs. 4.20-4.24). 
Sections of the pituituries of antibody treated animals as well as NSS treated rats are 
shown in Figs. 4.25-4.29.
4.4 DISCUSSION
This study was designed to evaluate the effect, in vivo, of the administration 
of T3  and/or T4  antibodies, on serum concentrations of some selected serum 
constituents. To our knowledge, this approach has not been previously used.
The quantity of antibodies used in the present study appear to be adequate 
for producing complete neutralization of endogenous hormones. The total binding 
capacity of T3  antibodies administered (0.5mi/rat) as determined by Scatchard 
analysis was about 63nmol which is up to 2500 times the total T3  concentration in 
the rat serum while 0.5ml of T4  antibodies (approximately 25nmol) estimated by 
Scatchard analysis is 20 times larger than the total T4  concentration in the rat serum. 
The serum concentrations of total T3  and T4  in the rats as determined in the present 
study were 1.27 ± 0.4nmol/L and 59.9 ± 4.8nmol/L respectively (Mean ± SD (n = 
20».
T3  is the most active form of the thyroid hormones (Oppenheimer et al, 
1987), and specific saturable high affinity binding sites for T3  has been found in the 
cells of the liver, anterior pituitary, kidney and heart; all known target sites of 
thyroid hormone action. Studies of T3  binding to intact rat hepatocyte nuclei in 
vitro by Samuels and Tsai (1974), Surks et al (1975) and DeGroot and Torresani 
(1975) have yielded an equilibrium dissociation constant (K^) of 2.1 x 10'^° mol/L, 
5 X ICfio mol/L, and 1.8 x 9'^ nol/L, respectively. Latham et al (1976) have studied 
solubilized T3  binding activity from rat liver nuclei and found a comparable
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Fig. 4.20. Thyroid after long-term treatment with T3 antibodies.
Haematoxylin and eosin staining. Magnification x 250.
Fig. 4.21. Thyroid after long-term treatment with T4  antibodies. 
Haematoxylin and eosin staining. Magnification x 250.
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Fig 4.22. Thyroid after long-term treatment with Tg and T4 antibodies.
Haematoxylin and eosin staining. Magnification x 250.
Fig. 4.23. Thyroid after long-term treatment with NSS (0.5ml dose). 
Haematoxylin and eosin staining. Magnification x 250.
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Fig. 2.24. Thyroid after long-term treatment with NSS (1.0ml dose).
Haematoxylin and eosin staining. Magnification x 250.
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Fig. 4.25. Anterior pituitary after long-term treatment with T3  antibodies. 
Haematoxylin and eosin staining. Magnification x 400.
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Fig. 4.26. Anterior pituitary after long-term treatment with T4 antibodies.
Haematoxylin and eosin staining. Magnification x 400.
»
Fig. 4.27. Anterior pituitary after long-term treatment with T3  and T 4  
antibodies. Haematoxylin and eosin staining. Magnification x 400.
#
# ' -
tÿ -  /r*
180
Fig. 4.28. Anterior pituitary after long-term treatment with NSS (0.5ml dose).
Haematoxylin and eosin staining. Magnification x 400.
Fig. 4.29. Anterior pituitary after long-term treatment with NSS (1.0ml dose). 
Haematoxylin and eosin staining. Magnification x 400.
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Kj, 1 X 10'^° mol/L. This Tg binding affinity is comparable to data from previous 
more limited rat heart studies. Tsai and Chen (1976) found high affinity Tg binding 
to a crude preparation of intact rat heart nuclei (K^ = 0.9 x lO'^^mol/L). Ladenson 
et al (1986) reported high affinity, limited capacity binding site for Tg in myocardial 
nuclear extract (Kj = 4.2 ± 1.0 x lO'^^mol/L). Furthermore, they observed that Tg 
binding capacity was increased in hypothyroidism, but there was no reduction of 
binding capacity in hyperthyroidism. Bernal et al (1978) on the other hand, found 
no difference in the Tg binding capacity of intact liver nuclei between normal and 
hypothyroid rats.
The binding affinity of the Tg antibodies used in the present study was 
calculated to be 8.0 x 10'\^mol/L. This is much higher than the affinity constants 
reported for hepatic and cardiac Tg receptor in the rat. This would favour the 
binding of circulating hormones to antibodies rather than to the target organ receptor.
In the first series of experiments, rats were injected intraperitoneally with a 
single dose of sheep T3  and/or T4  antibodies and blood samples were collected at 
various time intervals. Prior to hormone measurements, serum samples collected 
from the immunoneutralized animals were subjected to acid/ethanol extraction in 
order to eliminate the neutralizing antibodies present and thus its interference in the 
T3  and T4  radioimmunoassays. Since the resulting extracted serum contained both 
the antibody-bound and the free (not bound to antibody) hormones, any protein 
binding and neutralization of endogenous thyroid hormone which might have taken 
place after the administration of T3  and/or T4  antibodies could not be demonstrated.
In the present study, the in vivo administration of T3  antibodies (Group A) 
resulted in a gradual rise in the T3  and T4  serum concentrations. The elevation in 
serum T3  levels (within 60 minutes) may probably be due to increased peripheral 
conversion of T4  to T3  (Fig. 4.30). Monodeiodination of T4  to T3  in peripheral 
tissues is well documented (Van Doom et al, 1983; Emerson et al, 1989). Unlike 
T4  which is secreted only by the thyroid gland, up to about 80% of total T 3  
production is derived from monodeiodination of T4 to T3. Studies in man and in 
rats have shown that T4  to T3  conversion is carried out to varying degrees by all 
tissues. Liver and kidney, however, play a major role in T4  deiodination because of 
their size and high 5’-deiodinase activity (Chopra, 1977; Kaplan and Utiger, 1978).
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Fig. 430. The possible effect of T3  antibodies administration (intraperitoneally) 
on the pituitary-thyroid axis. T3  antibodies bind T3  resulting in: 1 ) decrease in 
T3  levels 2) increased T4  to T3  conversion in peripheral tissues 3) increased T4  
secretion by the thyroid gland 4) normal free hormone levels and thus TSH.
Pituitary
Free T3 and T4
Thyroid
Liver
T3 + T3Ab
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The T3  produced within these tissues reenters the circulation and become available to 
all organs, accounting for about two-thirds of the plasma T3 . The effect of altered 
thyroid status on the local conversion of T4  to T3  has been the subject of many 
investigations. Previous work using several rat tissues including liver, kidney and 
heart has shown that T4  5 ’-deiodinase activity is decreased in hypothyroidism and 
increased in hyperthyroidism (Kaplan and Utiger, 1978; Van Doom et al, 1983). 
Studies describing the effects of T3 -induced hyperthyroidism have shown a clear 
increase in monodeiodination of T4  to T3  in liver, kidney and heart tissues, whereas 
the effects of T4 -induced hyperthyroidism on iodothyronine metabolism are 
inconsistent. Some have documented a significant increase in hepatic deiodination of 
T4  to T3  in T4 ~treated rats (Kaplan and Utiger, 1978), while other workers found 
only modest and inconsistent, statistically not significant, increase in hepatic 
conversion of T4  to T3  in hyperthyroidism (Hufner and Knopfle, 1976). Similarly, 
both clear and minimal increases have been described in T4  to T3  monodeiodination 
in the kidney (Kaplan and Utiger, 1978). Several studies have examined the effect 
of hypothyroidism on T4  to T3  conversion in liver and kidney (Kaplan and Utiger, 
1978; Smallbridge et al, 1982). All agree that hypothyroidism is associated with a 
diminution in metabolism of T4  to T3  in liver and kidney. In the liver of 
hypothyroid rat, a very small proportion of the T3  was derived from locally 
produced T3  which resulted in decreased T3  concentration in the liver. Opposite 
changes were observed in liver tissues from hyperthyroid rats. The results of these 
studies suggest that the liver has an important function in the regulation of the 
circulating T3  concentration. In view of these studies, our results suggest that the 
increased T3  concentrations in T3 -Ab treated rats is probably due to an increase in 
T4  to T3  conversion followed by an increase in T4  secretion by the gland (Fig. 
4.30). There are several indirect evidence to support this proposed mechanism. 
First, serum T4  concentrations lag behind those of T3 ; if T3  was secreted by the 
gland, one would expect an increase in the T3  levels only. Moreover, if T4  was not 
being converted to T3 , a rapid decline in T3  concentrations would be expected since 
the half-life of T3  is about one-fourth that of T4  (Sekadde et al, 1974).
Similarly, the administration of T4 -Ab (Group B) resulted in a rapid increase 
in serum T3  and T4  concentrations. However, the increase in T3  levels was higher 
in rats treated with T4 -Ab than in those treated with T3 -Ab. The results of the 
present study suggest that the elevation of T3  levels in rats treated with T4 -Ab might
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be due to increased T3  secretion by the gland rather than T4  to T3  conversion, since 
the increase in T4  secretion is probably used to compensate the neutralized hormone 
(T4 ) (Fig. 4.31). Under normal conditions, a small proportion (10-15%) of total 
daily T3  production is derived from direct secretion from the thyroid gland, however, 
several studies in which animals were actively immunized against T3  or T4  have 
shown that the thyroid gland selectively produce either more T3  or more T4  
according to their need (Nieschlag et al, 1973; Herrmann et al, 1975; Joseph et al, 
1987). Other workers have also reported a disproportionately greater increase of T3  
than of T4  in hyperthyroidism (Woeber et al, 1970; Nicoloff et al, 1972; Larsen, 
1973).
The administration of a combination of T3 - and T4 -Ab (Group D) produced 
qualitatively similar but clearly larger changes in serum T3  and T4  concentrations in 
the rats. The increase in serum T4  levels occurred within 30 minutes of antibodies 
administration whereas a significant rise in serum T3  concentrations was observed at 
one hour. These findings suggest that such an enormous increase in the 
concentration of thyroid hormones in the blood is presumably due to the 
hyperactivity of the gland (Fig. 4.32). T4  to T3  conversion in peripheral tissues may 
have also contributed to the elevation in serum T3  concentrations as T3  levels lagged 
behind those for T4 .
Treatment with T3  and/or T4  antibodies also led to a significant increase in 
the basal glucose level. These results are consistent with previous findings 
(Mckenzie et al, 1987), that thyrotoxicosis is associated with hyperglycaemia. In 
fact, it has been reported that endogenous glucose production is dependent on the 
thyroid state being increased in hyperthyroidism and unchanged or reduced in 
hypothyroidism (Muller and Seitz, 1981). Several previous studies reported reduced 
hepatic glycogen content in the presence of excess thyroid hormone. Furthermore, 
perfused liver or hepatocytes isolated from hyperthyroid rats showed a maximal rate 
of glyconeogenesis fi'om different precursor molecules, whereas hypothyroidism 
revealed a reduced in vitro glucose production rate. The results of the present study 
indicate that there might be a direct correlation between the serum T3  and the 
increase in serum glucose concentrations. In animals treated with T3- or T4-Ab, 
serum T3  levels rose within one hour of antibodies administration, so did serum 
glucose which increased within 30-60 minutes. These results suggest that serum
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Fig. 431. The possible effect of T4  antibodies administration (intraperitoneally) 
on the pituitary-thyroid axis. T4  antibodies bind T4  resulting in: 1 ) a decrease 
in T4  levels 2) reduced T4  to T3  conversion in peripheral tissues 3) increased T4  
and T3  secretion by the thyroid gland 4) normal free hormone levels and thus 
TSH.
Free T3 and T4
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T4 +T4Ab
186
Fig. 432. The possible effect of T3  and T4  antibodies administration 
(intraperitoneally) on the pituitary-thyroid axis. T3  and T4  antibodies bind
thyroid hormones resulting in: 1 ) a decrease in thyroid hormone levels 
2) increased T3  and T4  secretion by the thyroid gland 3) increased T3  levels due 
to T4  to T3  conversion in peripheral tissues 4) normal free hormone levels and 
thus TSH.
Free T3 and T4
Thyroid
Pituitary
T4+T4Ab
T3 +T3Ab
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glucose levels might be directly affected by T3  concentrations. However, in spite of 
the rapid increase in serum T3  (within one hour), a delayed rise in serum glucose 
levels was observed in animals treated with both T3 - and T^-Ab. In view of these 
findings, further studies regarding the possible direct influence of serum T3  levels on 
glucose concentrations could be of great value in understanding the effect of thyroid 
hormone on intermediate metabolism.
Although T3  and/or T4  antibodies treatment produced a significant increase in 
serum glucose level, no significant change in serum cholesterol concentrations was 
observed in any of the experimental groups. Furthermore, the severity of 
hyperthyroidism does not appear relevant, since no correlation was found between 
serum cholesterol level and the very high thyroid hormone values observed in Group 
D. This is inconsistent with previous reports (Müller and Seitz, 1984b) 
demonstrating that hypocholesterolemia is generally associated with hyperthyroidism 
in man and experimental animals. A recent study, however, has shown that there is 
a striking positive correlation between serum cholesterol and TSH concentrations and 
that a clinically appreciable alterations in semm cholesterol concentrations only 
occurs in hypothyroid patients with a semm TSH in excess of 40mU/L (Elder et al, 
1990). In the present study, despite high circulating levels of T3  and T4 , not only 
were semm TSH levels found to be normal but total cholesterol levels were not 
changed, thereby possibly indicating a direct action of TSH on cholesterol 
disposition which does not involve the thyroid hormones.
Triglyceride levels, on the other hand, were decreased in all experimental 
groups in comparison with control values. Previous smdies in man and experimental 
animals have shown that the effects of thyroid status on semm TO concentrations is 
extremely variable being increased, decreased or unchanged in hypo- and 
hyperthyroid state. Several reports, however, have shown that excess thyroid 
hormone was accompanied by reduced TO and VLDL TO levels, diminished output 
and/or secretion of TO, increased TG clearance rate and stimulated ketogenesis 
(Müller and Seitz, 1984b; Heimberg et al, 1985). The results of the present study 
strongly support this view especially that decreased triglyceride levels were observed 
in all experimental groups. The findings of the present study also suggest that there 
might be a strong correlation between the increase in semm T4  levels and 
triglyceride concentrations in semm. In rats treated with T3 - and T4 -Ab, the increase
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in serum T4  levels (within 30 minutes) was associated with decreased triglyceride 
values (within 30 minutes). Furthermore, the delayed increase in serum T4  levels (at 
6  hours) observed in rats treated with Tg-Ab was associated with delayed decrease in 
serum triglyceride concentrations (at 2 hours). However, in animals treated with 
T4 -Ab, serum T4  levels rose 2  hours after antibodies treatment whereas triglyceride 
levels were significantly decreased 30 minutes after antibodies administration. 
Further experiments are therefore required in order to illustrate the possible direct 
effect of serum T4  on triglyceride levels.
In spite of high circulating levels of thyroid hormone antibodies maintained 
throughout the time period of this study as well as increased total T3  and T4  serum 
concentrations in all experimental groups (A, B and D), semm TSH levels did not 
change during the 96 hours study. This was not expected, since the gland had to 
work rather strenuously so as to replace the thyroid hormone neutralized by the 
antibody administered. We had expected the thyroid hormone secretion to be 
counteracted by antibody binding leading to a higher TSH production which in mm 
would have stimulated the thyroid gland to secrete more thyroid hormone.
This was not the case in the present study as semm TSH concentrations in 
antibodies-treated animals remained at basal levels throughout the study ranging from 
35.9 ± 2.0|iU/ml to 44.3 ± 2.7p,U/ml compared with values of 34.5 ± 1.3|iU/ml to
43.5 ± 2.3jiU/ml in control rats. According to the concept of negative feedback 
control, TSH secretion is regulated by the free (unbound) thyroid hormones. 
Although, more than 99% of the circulating T3  and T4  are bound to various proteins, 
it is only the free hormones in plasma that are physiologically active and thus affect 
TSH secretion. On the other hand, in a variety of smdies the local conversion of T4  
to T3  in the anterior pimitary gland was found to be important for the negative 
feedback for TSH secretion (Larsen et al, 1981; Van Doom et al, 1983). In their 
elegant study, Larsen et al (1981) have shown that about one half of intrapimitary 
T3  comes from circulating free T3 , while the other half is derived from local T4  
monodeiodination and that it is this T3  which is responsible for the saturation of 
80% of the nuclear receptors in the pimitary. Previous studies have shown that T4  
to T3  conversion is increased in pituitaries from hypothyroid rats and decreased in 
pituitaries from hyperthyroid rats. Furthermore, T4  5 '-monodeiodinase activity in 
anterior pimitary homogenates was increased in hypothyroidism and decreased in
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hyperthyroidism (Van Doom, 1983). In agreement with these reports, several 
investigators have shown that acute or chronic administration of thyroid hormones 
was associated with decreased semm TSH and increased pimitary levels reflecting an 
acute inhibition of TSH release (Jones et al, 1988; Emerson et al, 1989). Joseph et 
al (1987), on the other hand, have shown in their studies that active 
immunoneutralization with thyroid hormones was associated not only with elevated 
total and free hormone levels, particularly the hormone against which the animal was 
immunized, but also with significant increase in semm TSH concentrations. These 
results agreed with the studies of Nieschlag et al (1972) and Herrmann et al (1975) 
which were done in similar conditions. Their studies suggest that the concept, that 
free hormone concentrations in semm govem the metabolic states of the individual is 
doubtful especially when there is extensive changes in plasma protein binding and 
when intracellular hormone binding represent the major determinant of hormone 
metabolism.
The results of the present smdy suggest that the presence of excess thyroid 
hormone antibodies in the sera of animals treated with Tg and/or T 4  antibodies might 
be involved in the thyroid hormone transport, behaving in this respect like an 
increase in TBG levels. The thyroid hormone antibodies would therefore bind T3 , 
T4  or both while keeping the free hormone levels normal and thus TSH. A recent 
smdy in patients with circulating endogenous antibodies against T4  and/or T3  have 
shown that thyroid hormone autoantibodies contribute to semm binding in vivo 
(Copping and By field, 1989). The results of their study have shown that 
autoantibodies are capable of the transport of thyroid hormones in vivo in the 
presence of thyroxine binding proteins. Their in vivo binding to thyroid hormones 
however, is dependent on their affinity and binding capacity and therefore their 
ability to compete with thyroxine binding protein. The affinity of the T3  and T4  
antibodies used in the present study (8.0 x lO'^^mol/L and 1.0 x lO'^^mol/L) 
respectively exceeded those values of thyroxine binding proteins for T 3  and T 4  
reported in the literature (~10*^mol/L - lO'^mol/L) (Gershengom et al, 1980b). In 
view of Codding and Byfield report, the properties of these antibodies would 
probably allow them to distort the normal equilibrium between the thyroid hormones 
and their thyroxine binding proteins and therefore play a major role in the transport 
of thyroid hormones in vivo. However further studies including the measurement of 
free hormones, thyroxine binding proteins and the distribution of thyroid hormones
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amongst their binding proteins and thyroid hormone antibodies are needed to confirm 
this view.
The result of our study also suggests that the elevation in total T4  and T3  
levels may be associated with an increase in the concentration of thyroxine binding 
proteins in plasma resulting in normal levels free hormone and thus TSH. The 
elevation in total T4  and T3  levels, on the other hand, may be associated with high 
free hormone levels and normal thyroxine binding protein in spite of the normal 
TSH concentration and thereby suggesting some disturbance in their pituitary-thyroid 
axis. Association of elevated serum levels of total T4  and T3  with normal TSH 
values have been described in patients suffering from thyroid hormone resistance 
syndrome. Resistance to thyroid hormones has been reported in a small number of 
families (Brooks et al, 1981; Cooper et al, 1982). In these patients, a clear 
elevation in the concentrations of semm total and free T4  and T3  is accompanied by 
normal serum TBG and TBPA concentrations.
It is apparent from the preceding discussion that the knowledge of serum free 
hormone, thyroxine binding proteins and the distribution of thyroid hormones 
between their binding proteins (TBG, TBPA and albumin) and thyroid hormone 
antibodies might have helped the understanding of the endocrine consequences of 
thyroid hormone immunoneutralization. However, because of the constraints of, for
example, limited sample volumes, these analyses were not carried out in the present
study. Nevertheless the findings of the present study are in good agreement with 
those observed in patients with thyroid hormones autoantibodies. In both of these 
situations, high levels of circulating thyroid hormones antibodies were present.
In the second series of experiments, long-term administration of T3- and/or 
T4 -Ab resulted in no significant differences in serum hormone levels or in basal 
glucose, cholesterol and triglyceride concentrations between control groups and T3  
and/or T4  antibodies treated groups. In addition, the microscopic examination of 
sections obtained from the thyroid glands of the experimental animals (Groups A, B 
and D), have not shown any abnormalities in comparison with sections obtained
from the glands of NSS treated animals.
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The normal values of serum hormone levels as well as glucose, cholesterol 
and triglyceride concentrations observed in all experimental groups following 
long-term treatment with thyroid hormone antibodies were as expected. This is 
because the results of the acute study showed a gradual decrease in these parameters 
starting 24-48 hours after antibodies administration. The results obtained from the 
histological examination of the thyroid glands of Ab-treated animals showed no signs 
of hyperfunction and hypertrophy of the glands. These findings are in agreement 
with the normal TSH levels observed in all experimental groups. It is well 
established that chronic elevation of plasma TSH induce hyperplasia and hypertrophy 
of thyroid follicular cells. Several elegant studies have clarified the histological 
changes induced by TSH (Ericson and Johansson, 1977; Connors et al, 1988). 
When administered rapidly, TSH causes dramatic morphologic alterations in the 
thyroid cell, these are associated with enhanced secretion of thyroid hormones. 
Active immunization against thyroid hormones also caused increased TSH secretion 
followed by characteristic morphological changes (Nieschlag et al, 1972; Herrmann 
et al, 1975; Joseph et al, 1987). The findings of the present study are in agreement 
with these results, since normal TSH levels were associated with no histological 
changes in thyroid glands.
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CHAPTER FIVE 
FINAL DISCUSSION AND CONCLUSIONS
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The introduction of monoclonal antibody by Kohler and Milstein in 1975 
offered the advantage of providing unlimited amount of monospecific antibodies with 
consistent activity. Although these benefits stimulated a great deal of scientific and 
clinical research, the hybridoma technology still suffered from several technical 
obstacles. These include the low efficiency of the fusion process, the tedious 
procedure of screening thousands of hybrid clones in order to find useful antibodies, 
hybrid instability, storage and recovery problems and the difficulty of generating 
interspecies monoclonal antibodies. In spite of these major difficulties, the many 
advantages of this technique combined with its wide application make it an 
important tool for research.
The mouse system the first to be employed for the production of monoclonal 
antibodies (Kohler and Milstein, 1975), has been successfully used for the 
developing of the majority of hybridomas described to date. Several investigators, 
however, have shown that Balb/c mice respond poorly when immunized with some 
immunogens resulting in the production of low-affinity monoclonal antibodies 
(Nussbaum et al, 1985; Raybould and Takahashi, 1988; Zuckier et al, 1989).
The production of murine monoclonal antibodies to thyroid hormones has 
been previously described in two separate studies for the purpose of providing 
improved reagents for immunoassay techniques. In the first study (Wang et al, 
1981) Tg and T4  monoclonal antibodies produced offered no advantages over existing 
polyclonal sera whereas the second study described the production of relatively high 
avidity T4  antibody (Mpoko et al, 1985).
In this study, the main aim of producing murine monoclonal antibodies to 
thyroid hormone was to provide specific antibodies with high-affinities that can be 
used safely for passive immunoneutralization study in the rat. Administration of 
large quantities of foreign immunoglobulins into the circulation of the rat may elicit 
a host immune response against the foreign proteins that counteract the antibody 
effect. Passive immunoneutralization requires the use of antibody with high-affinity 
in order to prevent the endogenous factor meant to be neutralized from interacting 
with its target receptors. For this puipose, murine monoclonal antibodies to thyroid 
hormones were produced by fusing spleen cells from Balb/c mice immunized with 
either Tg or T4  conjugates with the murine myeloma cell line Sp2. Following the
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successful culture and cloning of hybridomas, several cell lines producing specific 
antibodies to Tg and T4  were established. These antibodies were highly specific but 
had relatively low titres and association constants as well as low binding capacity.
In general, all murine monoclonal antibodies produced against thyroid 
hormones so far have relatively low avidity. This suggests that Balb/c mice are 
poor responders to thyroid hormones. Other species such as sheep and rabbit, on 
the other hand, have been successfully used to produce high-affinity polyclonal 
antisera (Ratcliffe et al, 1974; Seth et al, 1975). Nevertheless, the use of such 
species for the production of monoclonal antibodies remains very difficult because of 
the non-availability of suitable fusion partners.
On the basis of the characterization and the in vitro binding studies, the Tg 
and T4  monoclonal antibodies produced in the present study were not used for the 
passive immunoneutralization studies because of their poor affinities. Sheep Tg and 
T4  polyclonal antibodies were then characterised and in vitro binding study was 
performed. These antibodies showed satisfactory specificity, affinity and binding 
capacity and seemed to be adequate for use in passive immunoneutralization study. 
The effect of a single dose injection of Tg and/or T4  polycolonal antibodies on 
selected blood components including serum Tg, T4 , TSH, glucose, cholesterol and 
triglyceride was investigated. It is important to note that an acid/ethanol extraction 
process was carried out on all samples obtained from animals treated with Tg and/or 
T4  antibodies. This step is important so as to remove the administered antibodies 
and thus their interference with Tg and T4  radioimmunoassays.
The results of this study have shown that thyroid hormone levels were 
elevated in all experimental groups which received thyroid hormone antibodies. The 
increase in serum Tg levels observed in animals treated with T4  antibodies were 
higher than those obtained from animals treated with Tg antibodies whereas the 
increase in both thyroid hormones was much higher in animals that received both Tg 
and T4  antibodies. Unexpectedly, semm TSH levels did not change in any of the 
groups and remained at basal levels.
Previous observations have shown a stimulatory effect of excess thyroid 
hormones on T4  to Tg conversion in several rat tissues including liver, kidney and
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heart (Samuels and Tsai, 1979; Surks et al, 1975; DeGroot and Torresani, 1975; 
Ladenson et al, 1986). The findings of the present study suggest that treatment with 
Tg-Ab resulted in increased T4  to Tg conversion in peripheral tissues followed by an 
increase in T4  secretion. The increase in serum Tg levels in T4 -Ab treated animals, 
on the other hand, would probably be due to increased thyroidal secretion of Tg as 
the T4  secreted in this situation is presumably used to replace the neutralized 
hormone. The enormous increase in the concentration of thyroid hormones in semm 
following the administration of a combination of Tg and T4  antibodies suggest that 
such an increase result from hyperactivity of the thyroid gland itself as well as T4  to 
Tg conversion.
Administration of Tg and/or T4  antibodies also resulted in elevated basal 
glucose levels. These results are consistent with previous studies demonstrating 
increased glucose concentrations in the presence of excess thyroid hormones (Miiller 
and Seitz, 1984a; McKenzie et al, 1987). Semm triglyceride levels were also 
affected in this study, being decreased in all groups treated with Tg and/or T4  
antibodies. In agreement with these findings, several investigators have reported 
decreased semm concentration of triglyceride under hyperthyroid conditions (Miiller 
and Seitz, 1984b; Heimberg et al, 1985). The findings of the present study also 
suggested that there might be a direct correlation between semm Tg and glucose 
levels while semm T4  concentrations may have a direct effect on triglyceride levels 
in semm. Although the majority of investigators observed that hyperthyroidism is 
associated with hypocholesterolemia, total cholesterol concentrations did not change 
in the present study in spite of high circulating levels of thyroid hormones. A 
recent study, however, reported a significant correlation between semm TSH and 
cholesterol levels in patients with suspected hypothyroidism (Elder et al, 1990). The 
normal values of semm TSH and cholesterol levels found in the present study 
support these findings.
The unchanged levels of semm TSH in all experimental groups could 
possibly be because of normal levels of semm free Tg and T4 . In general, the 
maintenance of normal semm TSH concentration depends on several factors mainly 
the negative feedback control by thyroid hormone and the tropic action of 
thyrotrophin releasing hormone (TRH) secreted by the hypothalamus. The dominant 
negative regulation of the semm thyroid hormones is exerted via their active
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fraction, the free (unbound) hormones. The concentration of free thyroid hormone in 
serum are in equilibrium with the protein-bound thyroid hormones. The T 4 - and 
Tg-binding proteins in blood have a very major influence on thyroid hormone 
metabolism. The normal TSH levels observed in the present study could possible be 
ascribed to the presence of excess thyroid hormone antibodies which would probably 
bind Tg, T4  or both while keeping free hormone levels normal. Previous studies on 
patients with thyroid hormone autoantibodies have shown that autoantibodies play an 
important role in serum transport (Copping and Byfield, 1989).
Long-term effect of thyroid hormone antibodies on serum levels of Tg, T4 , 
TSH, glucose, cholesterol and triglyceride was also investigated. In this study high 
circulating levels of Tg and/or T4  antibodies were maintained by weekly injections 
with the antibodies. Blood samples were collected seven days after each injection 
and analysis of serum was performed. The results of these analysis showed that 
there was no significant changes in any of the parameters measured. These findings 
indicate that the neutralizing effect of the antibodies administered was gradually 
removed from the circulation and therefore normal conditions were restored. Finally 
the effect of chronic treatment with thyroid hormone antibodies on several rat tissues 
including brain, pituitaries, thyroid, liver, kidneys and pancreas was also studied. 
The microscopic examination of the sections did not show any histological changes 
or abnormalities. Signs of greater thyroid activity such as hypertrophy and 
hyperplasia were not observed. These results support previous finding in which 
morphologic and histologic changes in the thyroid occurred under the effect of high 
circulating levels of TSH.
Future Work
This study provided valuable information about the use of the mouse system 
for the production of monoclonal antibodies to thyroid hormones. Additional work 
is required to further evaluate this system, for example, the immunization schedule 
including the route, duration and the amount of the immunizing antigen. On the 
basis of the findings from the present study, development of sheep-mouse fusion 
partners and thereby production of ovine monoclonal antibodies to thyroid hormones 
could be undertaken.
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The outcome of the present immunoneutralization studies provides a useful 
framework for further research in this interesting field. A more detailed 
investigation is needed to define clearly the functional status of the 
hypothalamus-pituitary-thyroid axis after acute and chronic immunoneutralization 
treatment. Moreover, the levels of "free" thyroid hormones and thyroxine binding 
proteins and the distribution of thyroid hormone amongst plasma proteins and thyroid 
hormone antibodies have also to be determined in these circumstances. Such an 
experimental model would then allow studies of the precise roles of Tg and T^ in 
intermediary metabolism and contribute to the understanding of autoimmune thyroid 
diseases.
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